<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<w:document xmlns:wpc="http://schemas.microsoft.com/office/word/2010/wordprocessingCanvas" xmlns:mo="http://schemas.microsoft.com/office/mac/office/2008/main" xmlns:mc="http://schemas.openxmlformats.org/markup-compatibility/2006" xmlns:mv="urn:schemas-microsoft-com:mac:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:r="http://schemas.openxmlformats.org/officeDocument/2006/relationships" xmlns:m="http://schemas.openxmlformats.org/officeDocument/2006/math" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:wp14="http://schemas.microsoft.com/office/word/2010/wordprocessingDrawing" xmlns:wp="http://schemas.openxmlformats.org/drawingml/2006/wordprocessingDrawing" xmlns:w10="urn:schemas-microsoft-com:office:word" xmlns:w="http://schemas.openxmlformats.org/wordprocessingml/2006/main" xmlns:w14="http://schemas.microsoft.com/office/word/2010/wordml" xmlns:wpg="http://schemas.microsoft.com/office/word/2010/wordprocessingGroup" xmlns:wpi="http://schemas.microsoft.com/office/word/2010/wordprocessingInk" xmlns:wne="http://schemas.microsoft.com/office/word/2006/wordml" xmlns:wps="http://schemas.microsoft.com/office/word/2010/wordprocessingShape" mc:Ignorable="w14 wp14"><w:body><w:p w14:paraId="162A6207" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="72FF67E1" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="4B410B90" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="2FAE27AE" w14:textId="17110494" w:rsidR="00934C34" w:rsidRDefault="007E299D" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t xml:space="preserve">CRISPR/Cas9 mutagenesis invalidates a </w:t></w:r><w:r w:rsidR="00211B99"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t>candidate</w:t></w:r><w:r w:rsidR="004F14FF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00211B99"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t>drug target undergoing</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t xml:space="preserve"> clinical trials</w:t></w:r><w:r w:rsidR="002D5E40"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t xml:space="preserve"> in </w:t></w:r><w:r w:rsidR="00C370F6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr><w:t>cancer</w:t></w:r></w:p><w:p w14:paraId="3A2E6F49" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr></w:pPr></w:p><w:p w14:paraId="5A9ADFE3" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr></w:pPr></w:p><w:p w14:paraId="31C73A83" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr></w:pPr></w:p><w:p w14:paraId="372158EA" w14:textId="77777777" w:rsidR="009E50A5" w:rsidRDefault="009E50A5" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/></w:rPr></w:pPr></w:p><w:p w14:paraId="7D807979" w14:textId="79D136F3" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Ann Lin</w:t></w:r><w:r w:rsidR="00FB3067" w:rsidRPr="00FB3067"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>†</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>1</w:t></w:r><w:r w:rsidR="00BA04C3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>,2</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, Chris</w:t></w:r><w:r w:rsidR="00D74580"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>topher J.</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Giuliano</w:t></w:r><w:r w:rsidR="00FB3067" w:rsidRPr="00FB3067"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>†</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>1</w:t></w:r><w:r w:rsidR="00BA04C3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>,2</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, Nicole M. Sayles</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>1</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="007210D9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="005611C3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and </w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Jason M.</w:t></w:r><w:r w:rsidR="00BA04C3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Sheltzer</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>*</w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>1</w:t></w:r></w:p><w:p w14:paraId="44C10733" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="3C3E0D43" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="338FA619" w14:textId="0324D58E" w:rsidR="00934C34" w:rsidRDefault="009E50A5" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:softHyphen/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:softHyphen/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:softHyphen/></w:r></w:p><w:p w14:paraId="28E3CFFF" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="482A85A1" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t xml:space="preserve">1 </w:t></w:r><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724</w:t></w:r></w:p><w:p w14:paraId="62738E58" w14:textId="77777777" w:rsidR="00BA04C3" w:rsidRDefault="00BA04C3" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="6C3F3DEF" w14:textId="77777777" w:rsidR="00C84AB3" w:rsidRDefault="00C84AB3" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="0628AA14" w14:textId="6940CA27" w:rsidR="00BA04C3" w:rsidRPr="00BA04C3" w:rsidRDefault="00BA04C3" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00BA04C3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>2</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Stony Brook University, </w:t></w:r><w:r w:rsidR="00C84AB3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Stony Brook, NY 11794</w:t></w:r></w:p><w:p w14:paraId="249B25B1" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="3B8B5A75" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="500EF602" w14:textId="2FF691AE" w:rsidR="00FB3067" w:rsidRDefault="00FB3067" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00B2146E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>†</w:t></w:r><w:r w:rsidR="00B2146E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Equal contribution</w:t></w:r></w:p><w:p w14:paraId="702AAB32" w14:textId="77777777" w:rsidR="00B2146E" w:rsidRPr="00B2146E" w:rsidRDefault="00B2146E" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="6F01C3F3" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="6C1A141E" w14:textId="5834BE66" w:rsidR="00934C34" w:rsidRPr="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>* To whom correspondence may be addressed. E-mail: sheltzer@cshl.edu</w:t></w:r></w:p><w:p w14:paraId="46AF24FB" w14:textId="77777777" w:rsidR="00934C34" w:rsidRPr="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="2E210A90" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:jc w:val="center"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="449F12B3" w14:textId="77777777" w:rsidR="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:jc w:val="center"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="03FFEC77" w14:textId="2268EB8B" w:rsidR="00934C34" w:rsidRPr="00934C34" w:rsidRDefault="00934C34" w:rsidP="00934C34"><w:pPr><w:jc w:val="center"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00934C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br w:type="page"/></w:r></w:p><w:p w14:paraId="399A64DB" w14:textId="77777777" w:rsidR="00B93122" w:rsidRDefault="00B93122" w:rsidP="00B93122"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:lastRenderedPageBreak/><w:t>Abstract</w:t></w:r></w:p><w:p w14:paraId="41E9BFDC" w14:textId="31BA5D92" w:rsidR="00836EAA" w:rsidRDefault="00D05879" w:rsidP="00836EAA"><w:pPr><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">The Maternal Embryonic Leucine Zipper Kinase </w:t></w:r><w:r w:rsidR="00A839F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK</w:t></w:r><w:r w:rsidR="00A839F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> has been </w:t></w:r><w:r w:rsidR="004F27A3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>reported to be</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> a genetic dependency in </w:t></w:r><w:r w:rsidR="00164E66"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">several </w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancer</w:t></w:r><w:r w:rsidR="00164E66"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> types</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  MELK RNAi and small-molecule inhibitors of MELK block the </w:t></w:r><w:r w:rsidR="0004274A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>proliferation</w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of </w:t></w:r><w:r w:rsidR="00164E66"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>various cancer cell lines</w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and </w:t></w:r><w:r w:rsidR="00164E66"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK knockdown has</w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> been </w:t></w:r><w:r w:rsidR="004F27A3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>described as</w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> particularly effective against the</w:t></w:r><w:r w:rsidR="009065D4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> highly-aggressive</w:t></w:r><w:r w:rsidR="006C7C98"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> basal/</w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>triple-negative subtype of breast cancer.</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Based on these </w:t></w:r><w:r w:rsidR="006D4B27"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">preclinical </w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">results, the MELK inhibitor OTS167 is currently being tested as a novel chemotherapy agent in </w:t></w:r><w:r w:rsidR="00084C31"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>several</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> clinical trials.  Here, we report that mutage</w:t></w:r><w:r w:rsidR="00132E84"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nizing MELK with CRISPR/Cas9 has</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> no effect on the fitness of basal breast cancer cell lines or cell lines from </w:t></w:r><w:r w:rsidR="00DD3D78"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>six</w:t></w:r><w:r w:rsidR="00BA22B8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">other cancer types.  </w:t></w:r><w:r w:rsidR="004C3BA2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cells that harbor null mutations in MELK exhibit wild-type doubling times, </w:t></w:r><w:r w:rsidR="005E2ECA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cytokinesis</w:t></w:r><w:r w:rsidR="004C3BA2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and </w:t></w:r><w:r w:rsidR="005B378B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>anchorage-independent growth</w:t></w:r><w:r w:rsidR="004C3BA2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00464A72"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Furthermore, </w:t></w:r><w:r w:rsidR="00612FD0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK-knockout lines</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> remain sensitive to OTS167, suggesting that this drug blocks </w:t></w:r><w:r w:rsidR="00D833F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell division</w:t></w:r><w:r w:rsidR="00836EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> through an off-target mechanism.  In total, our results undermine the rationale for a series of current clinical trials and provide an experimental approach for the use of CRISPR/Cas9 in preclinical target validation that can be broadly applied.          </w:t></w:r></w:p><w:p w14:paraId="52A5F646" w14:textId="2FE6BCE7" w:rsidR="00930445" w:rsidRDefault="00930445" w:rsidP="00D05879"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="5C0A0B90" w14:textId="77777777" w:rsidR="00930445" w:rsidRDefault="00930445"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br w:type="page"/></w:r></w:p><w:p w14:paraId="6D653C29" w14:textId="696E8A82" w:rsidR="00B42FE1" w:rsidRPr="00B42FE1" w:rsidRDefault="00B42FE1" w:rsidP="00B42FE1"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Introduction</w:t></w:r></w:p><w:p w14:paraId="10AD17DA" w14:textId="68AC1D15" w:rsidR="009A2CB4" w:rsidRDefault="00816A14" w:rsidP="00816A14"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Tumors of the breast can be divided into five distinct subtypes based on characteristic gene expression </w:t></w:r><w:r w:rsidR="009B3237"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>patterns</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  These breast cancer subtypes are referred to as </w:t></w:r><w:r w:rsidR="00736248"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Luminal A, Luminal B, Her2-enrich</w:t></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ed, normal-like, and basal </w:t></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2ara1bjank","properties":{"formattedCitation":"(1)","plainCitation":"(1)"},"citationItems":[{"id":218,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/EZ8NVJ38"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/EZ8NVJ38"],"itemData":{"id":218,"type":"article-journal","title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","container-title":"Proceedings of the National Academy of Sciences","page":"10869-10874","volume":"98","issue":"19","source":"www.pnas.org","abstract":"The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.","DOI":"10.1073/pnas.191367098","ISSN":"0027-8424, 1091-6490","note":"PMID: 11553815","journalAbbreviation":"PNAS","language":"en","author":[{"family":"Sørlie","given":"Therese"},{"family":"Perou","given":"Charles M."},{"family":"Tibshirani","given":"Robert"},{"family":"Aas","given":"Turid"},{"family":"Geisler","given":"Stephanie"},{"family":"Johnsen","given":"Hilde"},{"family":"Hastie","given":"Trevor"},{"family":"Eisen","given":"Michael B."},{"family":"Rijn","given":"Matt","dropping-particle":"van de"},{"family":"Jeffrey","given":"Stefanie S."},{"family":"Thorsen","given":"Thor"},{"family":"Quist","given":"Hanne"},{"family":"Matese","given":"John C."},{"family":"Brown","given":"Patrick O."},{"family":"Botstein","given":"David"},{"family":"Lønning","given":"Per Eystein"},{"family":"Børresen-Dale","given":"Anne-Lise"}],"issued":{"date-parts":[["2001",9,11]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(1)</w:t></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00736248"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00235B4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Basal breast cancers (BBC</w:t></w:r><w:r w:rsidR="003E7D0A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00E6380E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) comprise </w:t></w:r><w:r w:rsidR="00100F73"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>~</w:t></w:r><w:r w:rsidR="00235B4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">15% </w:t></w:r><w:r w:rsidR="007554E3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>of all diagnosed breast cancers and</w:t></w:r><w:r w:rsidR="00235B4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> express genes typically found in</w:t></w:r><w:r w:rsidR="007554E3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the basal/myoepithelial layer of the mammary gland</w:t></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"r1A6H9J8","properties":{"formattedCitation":"(2, 3)","plainCitation":"(2, 3)"},"citationItems":[{"id":222,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/45X2AQ52"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/45X2AQ52"],"itemData":{"id":222,"type":"article-journal","title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","container-title":"Modern Pathology","page":"157-167","volume":"24","issue":"2","source":"www.nature.com","abstract":"Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphological features and clinical behaviors. Although morphology is often associated with the pattern of molecular aberrations in breast cancers, it is also clear that tumors of the same histological type show remarkably different clinical behavior. This is particularly true for ‘basal-like cancer’, which is an entity defined using gene expression analysis. The purpose of this article was to review the current state of knowledge of basal-like breast cancers, to discuss the relationship between basal-like and triple-negative breast cancers, and to clarify practical implications of these diagnoses for pathologists and oncologists.","DOI":"10.1038/modpathol.2010.200","ISSN":"0893-3952","shortTitle":"Basal-like and triple-negative breast cancers","journalAbbreviation":"Mod Pathol","language":"en","author":[{"family":"Badve","given":"Sunil"},{"family":"Dabbs","given":"David J."},{"family":"Schnitt","given":"Stuart J."},{"family":"Baehner","given":"Frederick L."},{"family":"Decker","given":"Thomas"},{"family":"Eusebi","given":"Vincenzo"},{"family":"Fox","given":"Stephen B."},{"family":"Ichihara","given":"Shu"},{"family":"Jacquemier","given":"Jocelyne"},{"family":"Lakhani","given":"Sunil R."},{"family":"Palacios","given":"José"},{"family":"Rakha","given":"Emad A."},{"family":"Richardson","given":"Andrea L."},{"family":"Schmitt","given":"Fernando C."},{"family":"Tan","given":"Puay-Hoon"},{"family":"Tse","given":"Gary M."},{"family":"Weigelt","given":"Britta"},{"family":"Ellis","given":"Ian O."},{"family":"Reis-Filho","given":"Jorge S."}],"issued":{"date-parts":[["2011",2]]}}},{"id":224,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/M2US68V2"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/M2US68V2"],"itemData":{"id":224,"type":"article-journal","title":"Basal-Like Breast Cancer: A Critical Review","container-title":"Journal of Clinical Oncology","page":"2568-2581","volume":"26","issue":"15","source":"jco.ascopubs.org","abstract":"Recent gene expression profiling of breast cancer has identified specific subtypes with clinical, biologic, and therapeutic implications. The basal-like group of tumors is characterized by an expression signature similar to that of the basal/myoepithelial cells of the breast and is reported to have transcriptomic characteristics similar to those of tumors arising in BRCA1 germline mutation carriers. They are associated with aggressive behavior and poor prognosis, and typically do not express hormone receptors or HER-2 (“triple-negative” phenotype). Therefore, patients with basal-like cancers are unlikely to benefit from currently available targeted systemic therapy. Although basal-like tumors are characterized by distinctive morphologic, genetic, immunophenotypic, and clinical features, neither an accepted consensus on routine clinical identification and definition of this aggressive subtype of breast cancer nor a way of systematically classifying this complex group of tumors has been described. Different definitions are, therefore, likely to produce variable and contradictory results that may hamper consistent identification and development of treatment strategies for these tumors. In this review, we discuss definition, heterogeneity, morphologic spectrum, relation to BRCA1, and clinical significance of this important class of breast cancer.","DOI":"10.1200/JCO.2007.13.1748","ISSN":"0732-183X, 1527-7755","note":"PMID: 18487574","shortTitle":"Basal-Like Breast Cancer","journalAbbreviation":"JCO","language":"en","author":[{"family":"Rakha","given":"Emad A."},{"family":"Reis-Filho","given":"Jorge S."},{"family":"Ellis","given":"Ian O."}],"issued":{"date-parts":[["2008",5,20]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(2, 3)</w:t></w:r><w:r w:rsidR="00185966"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="007554E3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00C84D77"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  BBC</w:t></w:r><w:r w:rsidR="00E81F84"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00C84D77"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="002423D3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>are most frequentl</w:t></w:r><w:r w:rsidR="001A540E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>y diagnosed in younger patients</w:t></w:r><w:r w:rsidR="002423D3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and present with </w:t></w:r><w:r w:rsidR="000E240D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>advanced</w:t></w:r><w:r w:rsidR="002423D3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> histologic grade</w:t></w:r><w:r w:rsidR="0007429F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="00A21AEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>central</w:t></w:r><w:r w:rsidR="0007429F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> necrosis,</w:t></w:r><w:r w:rsidR="00A21AEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and</w:t></w:r><w:r w:rsidR="00293549"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="000E240D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>high mitotic activity.</w:t></w:r><w:r w:rsidR="002423D3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Additionally, ~7</w:t></w:r><w:r w:rsidR="00364DA9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">0% of basal breast cancers </w:t></w:r><w:r w:rsidR="00C83597"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">fail to </w:t></w:r><w:r w:rsidR="00293549"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>express</w:t></w:r><w:r w:rsidR="00364DA9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the estrogen receptor (ER), the progesterone receptor (PR</w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">), or </w:t></w:r><w:r w:rsidR="00364DA9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">the </w:t></w:r><w:r w:rsidR="00364DA9" w:rsidRPr="00A56B45"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>human epidermal growth factor receptor 2</w:t></w:r><w:r w:rsidR="00364DA9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (HER2)</w:t></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1r158ahtr7","properties":{"formattedCitation":"(2)","plainCitation":"(2)"},"citationItems":[{"id":222,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/45X2AQ52"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/45X2AQ52"],"itemData":{"id":222,"type":"article-journal","title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","container-title":"Modern Pathology","page":"157-167","volume":"24","issue":"2","source":"www.nature.com","abstract":"Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphological features and clinical behaviors. Although morphology is often associated with the pattern of molecular aberrations in breast cancers, it is also clear that tumors of the same histological type show remarkably different clinical behavior. This is particularly true for ‘basal-like cancer’, which is an entity defined using gene expression analysis. The purpose of this article was to review the current state of knowledge of basal-like breast cancers, to discuss the relationship between basal-like and triple-negative breast cancers, and to clarify practical implications of these diagnoses for pathologists and oncologists.","DOI":"10.1038/modpathol.2010.200","ISSN":"0893-3952","shortTitle":"Basal-like and triple-negative breast cancers","journalAbbreviation":"Mod Pathol","language":"en","author":[{"family":"Badve","given":"Sunil"},{"family":"Dabbs","given":"David J."},{"family":"Schnitt","given":"Stuart J."},{"family":"Baehner","given":"Frederick L."},{"family":"Decker","given":"Thomas"},{"family":"Eusebi","given":"Vincenzo"},{"family":"Fox","given":"Stephen B."},{"family":"Ichihara","given":"Shu"},{"family":"Jacquemier","given":"Jocelyne"},{"family":"Lakhani","given":"Sunil R."},{"family":"Palacios","given":"José"},{"family":"Rakha","given":"Emad A."},{"family":"Richardson","given":"Andrea L."},{"family":"Schmitt","given":"Fernando C."},{"family":"Tan","given":"Puay-Hoon"},{"family":"Tse","given":"Gary M."},{"family":"Weigelt","given":"Britta"},{"family":"Ellis","given":"Ian O."},{"family":"Reis-Filho","given":"Jorge S."}],"issued":{"date-parts":[["2011",2]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(2)</w:t></w:r><w:r w:rsidR="004F78AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00364DA9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Tumors that </w:t></w:r><w:r w:rsidR="00CA7320"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>lack expression of</w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> ER, PR, or HER2 are referred to as “triple-ne</w:t></w:r><w:r w:rsidR="00A9039C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">gative” breast cancers, and </w:t></w:r><w:r w:rsidR="00592EEE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>are irresponsive</w:t></w:r><w:r w:rsidR="00A9039C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">to </w:t></w:r><w:r w:rsidR="00EC0EC8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>hormonal or anti-HER2</w:t></w:r><w:r w:rsidR="000B7EB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>therapies that have proven effective against receptor-positive cancers.</w:t></w:r><w:r w:rsidR="00A9039C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Due </w:t></w:r><w:r w:rsidR="00482385"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">to their resistance to targeted therapies as well as </w:t></w:r><w:r w:rsidR="009B5022"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">their </w:t></w:r><w:r w:rsidR="00DE1FE8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>rapid rate of cell division</w:t></w:r><w:r w:rsidR="009B5022"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="003228F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> basal breast </w:t></w:r><w:r w:rsidR="00B45E69"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancer</w:t></w:r><w:r w:rsidR="00682CCD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00B45E69"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> currently </w:t></w:r><w:r w:rsidR="00682CCD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>have</w:t></w:r><w:r w:rsidR="00B45E69"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the worst prognosis </w:t></w:r><w:r w:rsidR="001A4107"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">of any </w:t></w:r><w:r w:rsidR="00E67B15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">breast </w:t></w:r><w:r w:rsidR="001A4107"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cancer subtype.  </w:t></w:r><w:r w:rsidR="000B7EB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Thus,</w:t></w:r><w:r w:rsidR="00F924E4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> there is an urgent </w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">need to develop </w:t></w:r><w:r w:rsidR="000B7EB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">new </w:t></w:r><w:r w:rsidR="009A2CB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>therapies</w:t></w:r><w:r w:rsidR="000B7EB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that are effective against triple-negative or b</w:t></w:r><w:r w:rsidR="004E6DC8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>asal-type tumors</w:t></w:r><w:r w:rsidR="000B7EB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r></w:p><w:p w14:paraId="165E80F3" w14:textId="24217297" w:rsidR="00C52D34" w:rsidRPr="00AD2B19" w:rsidRDefault="00C52D34" w:rsidP="00C52D34"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">In recent years, significant progress has been made in the treatment of certain malignancies </w:t></w:r><w:r w:rsidR="001B0949"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>by targeting</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer cell “addictions”</w:t></w:r><w:r w:rsidR="001B0949"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, or </w:t></w:r><w:r w:rsidR="00B72D2E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">genetic </w:t></w:r><w:r w:rsidR="001B0949"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>dependencies</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that encode proteins required for the growth of specific cancer types </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1pq9ags0ua","properties":{"formattedCitation":"(4)","plainCitation":"(4)"},"citationItems":[{"id":139,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8SUP26GI"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8SUP26GI"],"itemData":{"id":139,"type":"article-journal","title":"Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction","container-title":"Cell","page":"823-837","volume":"136","issue":"5","source":"ScienceDirect","abstract":"Cancer is a complex collection of distinct genetic diseases united by common hallmarks. Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis. We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells. In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets. Finally, we discuss the path ahead to therapeutic discovery and provide theoretical considerations for combining orthogonal cancer therapies.","DOI":"10.1016/j.cell.2009.02.024","ISSN":"0092-8674","shortTitle":"Principles of Cancer Therapy","journalAbbreviation":"Cell","author":[{"family":"Luo","given":"Ji"},{"family":"Solimini","given":"Nicole L."},{"family":"Elledge","given":"Stephen J."}],"issued":{"date-parts":[["2009",3,6]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(4)</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  Drugs that block the function of a cancer dependency – like the antibody Herceptin in Her2+ breast cancer – can trigger apoptosis and durable tumor regression</w:t></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"a544e77k5","properties":{"formattedCitation":"(5)","plainCitation":"(5)"},"citationItems":[{"id":386,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/R3UG6WCV"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/R3UG6WCV"],"itemData":{"id":386,"type":"article-journal","title":"Addiction to Oncogenes--the Achilles Heal of Cancer","container-title":"Science","page":"63-64","volume":"297","issue":"5578","source":"science.sciencemag.org","abstract":"A series of recent studies are providing tantalizing hints of new therapeutic approaches for combating cancer. In his Perspective, [Weinstein][1] discusses new work ([ Jain et al .][2]) demonstrating that even brief inactivation of an oncogene can permanently reverse the malignant phenotype of some types of tumor.\n\n [1]: http://www.sciencemag.org/cgi/content/full/297/5578/63\n [2]: http://www.sciencemag.org/cgi/content/short/297/5578/102","DOI":"10.1126/science.1073096","ISSN":"0036-8075, 1095-9203","note":"PMID: 12098689","language":"en","author":[{"family":"Weinstein","given":"I. Bernard"}],"issued":{"date-parts":[["2002",7,5]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(5)</w:t></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  Cancer cell </w:t></w:r><w:r w:rsidR="006F618F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">addictions are often </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">investigated through the use of different transgenic technologies to disrupt </w:t></w:r><w:r w:rsidR="00A43FBC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the expression of a specified gene</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. Two of the most popular methodologies are RNA interference, which </w:t></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>destabilizes a</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> targeted transcript, and CRISPR mutagenesis, which utilizes the nuclease Cas9 to induce frameshift mutations at a </w:t></w:r><w:r w:rsidR="00920381"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>targeted</w:t></w:r><w:r w:rsidR="006F618F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> locus.  While CRISPR-mediated genetic engineering has </w:t></w:r><w:r w:rsidR="00164A6A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>been</w:t></w:r><w:r w:rsidR="006F618F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> widely adopted since its discovery in 2013, </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">RNA interference </w:t></w:r><w:r w:rsidR="006F618F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">remains popular </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>due</w:t></w:r><w:r w:rsidR="006F618F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> its ability to </w:t></w:r><w:r w:rsidR="005B378B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>deplete</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> multiple isoforms of a protein, its reversibility, and its </w:t></w:r><w:r w:rsidR="00CA6DF6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">relative </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>insensitivity to gene copy number</w:t></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"gi1lf6la8","properties":{"formattedCitation":"(6)","plainCitation":"(6)"},"citationItems":[{"id":383,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/3W7GCNSG"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/3W7GCNSG"],"itemData":{"id":383,"type":"article-journal","title":"Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR","container-title":"Molecular Cell","page":"575-585","volume":"58","issue":"4","source":"ScienceDirect","abstract":"The most widely used approach for defining gene function is to reduce or completely disrupt its normal expression. For over a decade, RNAi has ruled the lab, offering a magic bullet to disrupt gene expression in many organisms. However, new biotechnological tools—specifically CRISPR-based technologies—have become available and are squeezing out RNAi dominance in mammalian cell studies. These seemingly competing technologies leave research investigators with the question: “Which technology should I use in my experiment?” This review offers a practical resource to compare and contrast these technologies, guiding the investigator when and where to use this fantastic array of powerful tools.","DOI":"10.1016/j.molcel.2015.04.028","ISSN":"1097-2765","shortTitle":"Choosing the Right Tool for the Job","journalAbbreviation":"Molecular Cell","author":[{"family":"Boettcher","given":"Michael"},{"family":"McManus","given":"Michael T."}],"issued":{"date-parts":[["2015",5,21]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(6)</w:t></w:r><w:r w:rsidR="007E33F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  Moreover, the partial loss-of-function phenotype generated by RNAi may more accurately recapitulate the effects of drug treatment than the complete loss-of-function phenotype generated by a Cas9-induced </w:t></w:r><w:r w:rsidR="00771825"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>frameshift</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> mutation.</w:t></w:r><w:r w:rsidR="00D136C7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Nonetheless, RNAi constructs </w:t></w:r><w:r w:rsidR="007A6163"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>exhibit</w:t></w:r><w:r w:rsidR="00D136C7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> limited specificity, and off-target knockdowns</w:t></w:r><w:r w:rsidR="00164A6A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> are an inherent and widespread</w:t></w:r><w:r w:rsidR="00D136C7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> problem in RNAi experiments</w:t></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"gp7e0t28q","properties":{"formattedCitation":"{\\rtf (7\\uc0\\u8211{}9)}","plainCitation":"(7–9)"},"citationItems":[{"id":409,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/WKJFUJC3"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/WKJFUJC3"],"itemData":{"id":409,"type":"article-journal","title":"Expression profiling reveals off-target gene regulation by RNAi","container-title":"Nature Biotechnology","page":"635-637","volume":"21","issue":"6","source":"www.nature.com","abstract":"RNA interference is thought to require near-identity between the small interfering RNA (siRNA) and its cognate mRNA. Here, we used gene expression profiling to characterize the specificity of gene silencing by siRNAs in cultured human cells. Transcript profiles revealed siRNA-specific rather than target-specific signatures, including direct silencing of nontargeted genes containing as few as eleven contiguous nucleotides of identity to the siRNA. These results demonstrate that siRNAs may cross-react with targets of limited sequence similarity.","DOI":"10.1038/nbt831","ISSN":"1087-0156","journalAbbreviation":"Nat Biotech","language":"en","author":[{"family":"Jackson","given":"Aimee L."},{"family":"Bartz","given":"Steven R."},{"family":"Schelter","given":"Janell"},{"family":"Kobayashi","given":"Sumire V."},{"family":"Burchard","given":"Julja"},{"family":"Mao","given":"Mao"},{"family":"Li","given":"Bin"},{"family":"Cavet","given":"Guy"},{"family":"Linsley","given":"Peter S."}],"issued":{"date-parts":[["2003",6]]}}},{"id":412,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/PS46XDW8"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/PS46XDW8"],"itemData":{"id":412,"type":"article-journal","title":"Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity","container-title":"RNA","page":"1179-1187","volume":"12","issue":"7","source":"rnajournal.cshlp.org","abstract":"Transfected siRNAs and miRNAs regulate numerous transcripts that have only limited complementarity to the active strand of the RNA duplex. This process reflects natural target regulation by miRNAs, but is an unintended (“off-target”) consequence of siRNA-mediated silencing. Here we demonstrate that this unintended off-target silencing is widespread, and occurs in a manner reminiscent of target silencing by miRNAs. A high proportion of unintended transcripts silenced by siRNAs showed 3' UTR sequence complementarity to the seed region of the siRNA. Base mismatches within the siRNA seed region reduced the set of original off-target transcripts but generated new sets of silenced transcripts with sequence complementarity to the mismatched seed sequence. An inducible shRNA silenced a subset of transcripts that were silenced by an siRNA of the same sequence, demonstrating that unintended silencing is sequence mediated and is independent of delivery method. In all cases, off-target transcript silencing was accompanied by loss of the corresponding protein and occurred with dependence on siRNA concentration similar to that of silencing of the target transcript. Thus, short stretches of sequence complementarity to the siRNA or shRNA seed region are key to the silencing of unintended transcripts.","DOI":"10.1261/rna.25706","ISSN":"1355-8382, 1469-9001","note":"PMID: 16682560","journalAbbreviation":"RNA","language":"en","author":[{"family":"Jackson","given":"Aimee L."},{"family":"Burchard","given":"Julja"},{"family":"Schelter","given":"Janell"},{"family":"Chau","given":"B. Nelson"},{"family":"Cleary","given":"Michele"},{"family":"Lim","given":"Lee"},{"family":"Linsley","given":"Peter S."}],"issued":{"date-parts":[["2006",7,1]]}}},{"id":416,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZWCS4QPF"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZWCS4QPF"],"itemData":{"id":416,"type":"article-journal","title":"Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA","container-title":"Pharmaceutical Research","page":"2996-3015","volume":"28","issue":"12","source":"link.springer.com","abstract":"ABSTRACTRNA interference (RNAi) strategies include double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA). As this is a highly specific technique, efforts have been made to utilize RNAi towards potential knock down of disease-causing genes in a targeted fashion. RNAi has the potential to selectively inhibit gene expression by degrading or blocking the translation of the target mRNA. However, delivering these RNAs to specific cells presents a significant challenge. Some of these challenges result from the necessity of traversing the circulatory system while avoiding kidney filtration, degradation by endonucleases, aggregation with serum proteins, and uptake by phagocytes. Further, non-specific delivery may result in side-effects, including the activation of immune response. We discuss the challenges in the systemic delivery to target cells, cellular uptake, endosomal release and intracellular transport of RNAi drugs and recent progress in overcoming these barriers. We also discuss approaches that increase the specificity and metabolic stability and reduce the off-target effects of RNAi strategy.","DOI":"10.1007/s11095-011-0608-1","ISSN":"0724-8741, 1573-904X","journalAbbreviation":"Pharm Res","language":"en","author":[{"family":"Singh","given":"Saurabh"},{"family":"Narang","given":"Ajit S."},{"family":"Mahato","given":"Ram I."}],"issued":{"date-parts":[["2011",12,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00C207E1" w:rsidRPr="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/></w:rPr><w:t>(7–9)</w:t></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00D136C7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="50D97C84" w14:textId="3DB562B9" w:rsidR="00BB31F5" w:rsidRDefault="00DC0A47" w:rsidP="009A2CB4"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>The Maternal Embryonic Leucine Zipper K</w:t></w:r><w:r w:rsidR="00574E50"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">inase </w:t></w:r><w:r w:rsidR="001443A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(</w:t></w:r><w:r w:rsidR="00574E50"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK</w:t></w:r><w:r w:rsidR="001443A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00D876E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="004D576E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">has received substantial attention as a </w:t></w:r><w:r w:rsidR="006F08AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">potential cancer cell addiction and </w:t></w:r><w:r w:rsidR="004D576E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">promising </w:t></w:r><w:r w:rsidR="00F06CC9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">target for drug development. </w:t></w:r><w:r w:rsidR="00521BD4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00DA1A64"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK was first identified as </w:t></w:r><w:r w:rsidR="00751531"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">an </w:t></w:r><w:r w:rsidR="00F53171"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>AMPK family membe</w:t></w:r><w:r w:rsidR="009E4211"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">r expressed in the mouse pre-implantation embryo </w:t></w:r><w:r w:rsidR="00CD5582"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"222cg7aj9n","properties":{"formattedCitation":"(10)","plainCitation":"(10)"},"citationItems":[{"id":203,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/7U2GZMZ6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/7U2GZMZ6"],"itemData":{"id":203,"type":"article-journal","title":"New member of the Snf1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo","container-title":"Molecular Reproduction and Development","page":"148-156","volume":"47","issue":"2","source":"Wiley Online Library","abstract":"The initial phase of mammalian preimplantation development is directed by stored maternal mRNAs and their encoded proteins, yet most of the molecules controlling this process have not been described. We have used differential display analysis of cDNA libraries prepared from unfertilized eggs and preimplantation embryos to isolate three maternal cDNAs that represent novel genes exhibiting different patterns of expression during this developmental period. One of these, Melk, encodes a protein with a kinase catalytic domain and a leucine zipper motif, a new member of the Snf1/AMPK family of kinases. This gene product may play a role in the signal transduction events in the egg and early embryo. Mol. Reprod. Dev. 47:148–156, 1997. © 1997 Wiley-Liss, Inc.","DOI":"10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M","ISSN":"1098-2795","journalAbbreviation":"Mol. Reprod. Dev.","language":"en","author":[{"family":"Heyer","given":"Babette S."},{"family":"Warsowe","given":"Jennie"},{"family":"Solter","given":"Davor"},{"family":"Knowles","given":"Barbara B."},{"family":"Ackerman","given":"Susan L."}],"issued":{"date-parts":[["1997",6,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00CD5582"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(10)</w:t></w:r><w:r w:rsidR="00CD5582"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00035F5A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and </w:t></w:r><w:r w:rsidR="000E240D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>has since</w:t></w:r><w:r w:rsidR="00035F5A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> been implicated in</w:t></w:r><w:r w:rsidR="00A367A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> several cellular processes, including </w:t></w:r><w:r w:rsidR="00AB63AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>apoptosis</w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"j944ns5nr","properties":{"formattedCitation":"(11)","plainCitation":"(11)"},"citationItems":[{"id":206,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/7B8IQIPC"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/7B8IQIPC"],"itemData":{"id":206,"type":"article-journal","title":"Murine Protein Serine/Threonine Kinase 38 Activates Apoptosis Signal-regulating Kinase 1 via Thr838 Phosphorylation","container-title":"Journal of Biological Chemistry","page":"34541-34553","volume":"283","issue":"50","source":"www.jbc.org","abstract":"Murine protein serine/threonine kinase 38 (MPK38) is a member of the AMP-activated protein kinase-related serine/threonine kinase family that plays an important role in various cellular processes, including cell cycle, signaling pathways, and self-renewal of stem cells. Here we demonstrate a functional association between MPK38 and apoptosis signal-regulating kinase 1 (ASK1). The physical association between MPK38 and ASK1 was mediated through their carboxyl-terminal regulatory domains and was increased by H2O2 or tumor necrosis factor α treatment. The use of kinase-dead MPK38 and ASK1 mutants revealed that MPK38-ASK1 complex formation was dependent on the activities of both kinases. Ectopic expression of wild-type MPK38, but not kinase-dead MPK38, stimulated ASK1 activity by Thr838 phosphorylation and enhanced ASK1-mediated signaling to both JNK and p38 kinases. However, the phosphorylation of MKK6 and p38 by MPK38 was not detectable. In addition, MPK38-mediated ASK1 activation was induced through the increased interaction between ASK1 and its substrate MKK3. MPK38 also stimulated H2O2-mediated apoptosis by enhancing the ASK1 activity through Thr838 phosphorylation. These results suggest that MPK38 physically interacts with ASK1 in vivo and acts as a positive upstream regulator of ASK1.","DOI":"10.1074/jbc.M807219200","ISSN":"0021-9258, 1083-351X","note":"PMID: 18948261","journalAbbreviation":"J. Biol. Chem.","language":"en","author":[{"family":"Jung","given":"Haiyoung"},{"family":"Seong","given":"Hyun-A."},{"family":"Ha","given":"Hyunjung"}],"issued":{"date-parts":[["2008",12,12]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(11)</w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00AB63AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, splicing</w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2fdeseu86a","properties":{"formattedCitation":"(12)","plainCitation":"(12)"},"citationItems":[{"id":210,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/Z3PXTAJG"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/Z3PXTAJG"],"itemData":{"id":210,"type":"article-journal","title":"Inhibition of Spliceosome Assembly by the Cell Cycle-regulated Protein Kinase MELK and Involvement of Splicing Factor NIPP1","container-title":"Journal of Biological Chemistry","page":"8642-8647","volume":"279","issue":"10","source":"www.jbc.org","abstract":"NIPP1 is a ubiquitous nuclear protein that is required for spliceosome assembly. We report here that the phosphothreonine-binding Forkhead-associated domain of NIPP1 interacts with the cell cycle-regulated protein Ser/Thr kinase MELK (maternal embryonic leucine zipper kinase). The NIPP1-MELK interaction was critically dependent on the phosphorylaton of Thr-478 of MELK and was increased in lysates from mitotically arrested cells. Recombinant MELK was a potent inhibitor of an early step of spliceosome assembly in nuclear extracts. This splicing defect was also seen with a kinase-dead mutant but was absent after mutation (T478A) of the NIPP1 binding site of MELK, indicating a mediatory role for NIPP1. Our data suggest that MELK has a role in the cell cycle-regulated control of pre-mRNA splicing.","DOI":"10.1074/jbc.M311466200","ISSN":"0021-9258, 1083-351X","note":"PMID: 14699119","journalAbbreviation":"J. Biol. Chem.","language":"en","author":[{"family":"Vulsteke","given":"Veerle"},{"family":"Beullens","given":"Monique"},{"family":"Boudrez","given":"An"},{"family":"Keppens","given":"Stefaan"},{"family":"Eynde","given":"Aleyde Van"},{"family":"Rider","given":"Mark H."},{"family":"Stalmans","given":"Willy"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2004",3,5]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(12)</w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00AB63AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008C790F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and </w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">neurogenesis </w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"obnulkb8t","properties":{"formattedCitation":"(13)","plainCitation":"(13)"},"citationItems":[{"id":214,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/AJXPMUNU"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/AJXPMUNU"],"itemData":{"id":214,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation","container-title":"The Journal of Cell Biology","page":"413-427","volume":"170","issue":"3","source":"PubMed","abstract":"Maternal embryonic leucine zipper kinase (MELK) was previously identified in a screen for genes enriched in neural progenitors. Here, we demonstrate expression of MELK by progenitors in developing and adult brain and that MELK serves as a marker for self-renewing multipotent neural progenitors (MNPs) in cultures derived from the developing forebrain and in transgenic mice. Overexpression of MELK enhances (whereas knockdown diminishes) the ability to generate neurospheres from MNPs, indicating a function in self-renewal. MELK down-regulation disrupts the production of neurogenic MNP from glial fibrillary acidic protein (GFAP)-positive progenitors in vitro. MELK expression in MNP is cell cycle regulated and inhibition of MELK expression down-regulates the expression of B-myb, which is shown to also mediate MNP proliferation. These findings indicate that MELK is necessary for proliferation of embryonic and postnatal MNP and suggest that it regulates the transition from GFAP-expressing progenitors to rapid amplifying progenitors in the postnatal brain.","DOI":"10.1083/jcb.200412115","ISSN":"0021-9525","note":"PMID: 16061694\nPMCID: PMC2171475","journalAbbreviation":"J. Cell Biol.","language":"eng","author":[{"family":"Nakano","given":"Ichiro"},{"family":"Paucar","given":"Andres A."},{"family":"Bajpai","given":"Ruchi"},{"family":"Dougherty","given":"Joseph D."},{"family":"Zewail","given":"Amani"},{"family":"Kelly","given":"Theresa K."},{"family":"Kim","given":"Kevin J."},{"family":"Ou","given":"Jing"},{"family":"Groszer","given":"Matthias"},{"family":"Imura","given":"Tetsuya"},{"family":"Freije","given":"William A."},{"family":"Nelson","given":"Stanley F."},{"family":"Sofroniew","given":"Michael V."},{"family":"Wu","given":"Hong"},{"family":"Liu","given":"Xin"},{"family":"Terskikh","given":"Alexey V."},{"family":"Geschwind","given":"Daniel H."},{"family":"Kornblum","given":"Harley I."}],"issued":{"date-parts":[["2005",8,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(13)</w:t></w:r><w:r w:rsidR="006C68AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00AB63AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="002C78D3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK is also over-expressed</w:t></w:r><w:r w:rsidR="00A17C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in </w:t></w:r><w:r w:rsidR="00392F3F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>most types of solid</w:t></w:r><w:r w:rsidR="00A17C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> tumor</w:t></w:r><w:r w:rsidR="00392F3F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00DA1A64"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, including </w:t></w:r><w:r w:rsidR="00A17C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">breast, colon, </w:t></w:r><w:r w:rsidR="0001531E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">liver, lung, </w:t></w:r><w:r w:rsidR="001C5F0C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">melanoma, </w:t></w:r><w:r w:rsidR="0001531E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and ovarian cancer</w:t></w:r><w:r w:rsidR="00BB6E33"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00BB6E33"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"40tndu09f","properties":{"formattedCitation":"(14)","plainCitation":"(14)"},"citationItems":[{"id":130,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"itemData":{"id":130,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers","container-title":"Cancer Research","page":"9751-9761","volume":"65","issue":"21","source":"cancerres.aacrjournals.org","abstract":"To identify genes that could serve as targets for novel cancer therapeutics, we used a bioinformatic analysis of microarray data comparing gene expression between normal and tumor-derived primary human tissues. From this approach, we have found that maternal embryonic leucine zipper kinase (Melk), a member of the AMP serine/threonine kinase family, exhibits multiple features consistent with the potential utility of this gene as an anticancer target. An oligonucleotide microarray analysis of multiple human tumor samples and cell lines suggests that Melk expression is frequently elevated in cancer relative to normal tissues, a pattern confirmed by quantitative reverse transcription-PCR and Western blotting of selected primary tumor samples. In situ hybridization localized Melk expression to malignant epithelial cells in 96%, 23%, and 13% of colorectal, lung, and ovarian tissue tumor samples, respectively. Expression of this gene is also elevated in spontaneous tumors derived from the ApcMin and Apc1638N murine models of intestinal tumorigenesis. To begin addressing whether Melk is relevant for tumorigenesis, RNA interference–mediated silencing within human and murine tumor cell lines was done. We show that Melk knockdown decreases proliferation and anchorage-independent growth in vitro as well as tumor growth in a xenograft model. Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial.","DOI":"10.1158/0008-5472.CAN-04-4531","ISSN":"0008-5472, 1538-7445","note":"PMID: 16266996","journalAbbreviation":"Cancer Res","language":"en","author":[{"family":"Gray","given":"Daniel"},{"family":"Jubb","given":"Adrian M."},{"family":"Hogue","given":"Deborah"},{"family":"Dowd","given":"Patrick"},{"family":"Kljavin","given":"Noelyn"},{"family":"Yi","given":"Sothy"},{"family":"Bai","given":"Wei"},{"family":"Frantz","given":"Gretchen"},{"family":"Zhang","given":"Zemin"},{"family":"Koeppen","given":"Hartmut"},{"family":"Sauvage","given":"Frederic J.","dropping-particle":"de"},{"family":"Davis","given":"David P."}],"issued":{"date-parts":[["2005",11,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00BB6E33"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00C207E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(14)</w:t></w:r><w:r w:rsidR="00BB6E33"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00A17C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00F061AD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Furthermore,</w:t></w:r><w:r w:rsidR="003E571F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="007A6163"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>many</w:t></w:r><w:r w:rsidR="00466CAD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> publications </w:t></w:r><w:r w:rsidR="001D3692"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>have reported</w:t></w:r><w:r w:rsidR="00A164C8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that </w:t></w:r><w:r w:rsidR="0001531E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">knocking down MELK using </w:t></w:r><w:r w:rsidR="00F061AD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">RNAi </w:t></w:r><w:r w:rsidR="003E571F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>inhibited</w:t></w:r><w:r w:rsidR="00F061AD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the proliferation of </w:t></w:r><w:r w:rsidR="0001531E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cell lines derived from these cancer types </w:t></w:r><w:r w:rsidR="00466CAD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"9y9biH1Z","properties":{"formattedCitation":"{\\rtf (14\\uc0\\u8211{}27)}","plainCitation":"(14–27)"},"citationItems":[{"id":148,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/3I8BINHZ"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/3I8BINHZ"],"itemData":{"id":148,"type":"article-journal","title":"Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family","container-title":"Breast Cancer Research","page":"R17","volume":"9","source":"BioMed Central","abstract":"Cancer therapies directed at specific molecular targets in signaling pathways of cancer cells, such as tamoxifen, aromatase inhibitors and trastuzumab, have proven useful for treatment of advanced breast cancers. However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects. These side effects as well as drug resistance make it necessary to search for novel molecular targets for drugs on the basis of well-characterized mechanisms of action.","DOI":"10.1186/bcr1650","ISSN":"1465-542X","journalAbbreviation":"Breast Cancer Research","author":[{"family":"Lin","given":"Meng-Lay"},{"family":"Park","given":"Jae-Hyun"},{"family":"Nishidate","given":"Toshihiko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Katagiri","given":"Toyomasa"}],"issued":{"date-parts":[["2007"]]}}},{"id":130,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"itemData":{"id":130,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers","container-title":"Cancer Research","page":"9751-9761","volume":"65","issue":"21","source":"cancerres.aacrjournals.org","abstract":"To identify genes that could serve as targets for novel cancer therapeutics, we used a bioinformatic analysis of microarray data comparing gene expression between normal and tumor-derived primary human tissues. From this approach, we have found that maternal embryonic leucine zipper kinase (Melk), a member of the AMP serine/threonine kinase family, exhibits multiple features consistent with the potential utility of this gene as an anticancer target. An oligonucleotide microarray analysis of multiple human tumor samples and cell lines suggests that Melk expression is frequently elevated in cancer relative to normal tissues, a pattern confirmed by quantitative reverse transcription-PCR and Western blotting of selected primary tumor samples. In situ hybridization localized Melk expression to malignant epithelial cells in 96%, 23%, and 13% of colorectal, lung, and ovarian tissue tumor samples, respectively. Expression of this gene is also elevated in spontaneous tumors derived from the ApcMin and Apc1638N murine models of intestinal tumorigenesis. To begin addressing whether Melk is relevant for tumorigenesis, RNA interference–mediated silencing within human and murine tumor cell lines was done. We show that Melk knockdown decreases proliferation and anchorage-independent growth in vitro as well as tumor growth in a xenograft model. Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial.","DOI":"10.1158/0008-5472.CAN-04-4531","ISSN":"0008-5472, 1538-7445","note":"PMID: 16266996","journalAbbreviation":"Cancer Res","language":"en","author":[{"family":"Gray","given":"Daniel"},{"family":"Jubb","given":"Adrian M."},{"family":"Hogue","given":"Deborah"},{"family":"Dowd","given":"Patrick"},{"family":"Kljavin","given":"Noelyn"},{"family":"Yi","given":"Sothy"},{"family":"Bai","given":"Wei"},{"family":"Frantz","given":"Gretchen"},{"family":"Zhang","given":"Zemin"},{"family":"Koeppen","given":"Hartmut"},{"family":"Sauvage","given":"Frederic J.","dropping-particle":"de"},{"family":"Davis","given":"David P."}],"issued":{"date-parts":[["2005",11,1]]}}},{"id":246,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8TD4CXJC"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8TD4CXJC"],"itemData":{"id":246,"type":"article-journal","title":"The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer","container-title":"Journal of Molecular Medicine","page":"237-248","volume":"91","issue":"2","source":"link.springer.com","abstract":"Loss of cell cycle control is a prerequisite for cancer onset and progression. In prostate cancer, increased activity of cell cycle genes has been associated with prognostic parameters such as biochemical relapse and survival. The identification of novel oncogenic and druggable targets in patient subgroups with poor prognosis may help to develop targeted therapy approaches. We analyzed prostate cancer and corresponding benign tissues (n = 98) using microarrays. The comparison of high- and low-grade tumors (Gleason score ≥ 4 + 3 vs. ≤ 3 + 4) revealed 144 differentially expressed genes (p &lt; 0.05). Out of these, 15 genes were involved in the cell cycle process. The gene maternal embryonic leucine zipper kinase (MELK) was identified to be highly correlated with cell cycle genes like UBE2C, TOP2A, CCNB2, and AURKB. Increased MELK gene expression in high-risk prostate cancer was validated by qPCR in an independent patient cohort (p &lt; 0.005, n = 79). Immunohistochemistry analysis using a tissue microarray (n = 94) revealed increased MELK protein expression in prostate cancer tissues of high Gleason scores. RNAi-based inhibition of MELK in PC3 and LNCaP cells suggested putative function in chromatin modification, embryonic development and cell migration. The concerted inhibition of MELK and other cell cycle targets by the antibiotic siomycin A strongly impaired cell viability of prostate cancer cells, and may point to a novel therapy approach for a subset of high-risk prostate cancer patients.","DOI":"10.1007/s00109-012-0949-1","ISSN":"0946-2716, 1432-1440","journalAbbreviation":"J Mol Med","language":"en","author":[{"family":"Kuner","given":"Ruprecht"},{"family":"Fälth","given":"Maria"},{"family":"Pressinotti","given":"Nicole Chui"},{"family":"Brase","given":"Jan C."},{"family":"Puig","given":"Sabrina Balaguer"},{"family":"Metzger","given":"Jennifer"},{"family":"Gade","given":"Stephan"},{"family":"Schäfer","given":"Georg"},{"family":"Bartsch","given":"Georg"},{"family":"Steiner","given":"Eberhard"},{"family":"Klocker","given":"Helmut"},{"family":"Sültmann","given":"Holger"}],"issued":{"date-parts":[["2012",9,4]]}}},{"id":249,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VGT75BTE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VGT75BTE"],"itemData":{"id":249,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway","container-title":"Molecular Cancer","page":"100","volume":"13","source":"BioMed Central","abstract":"Elevated MELK expression is featured in multiple tumors and correlated with tumorigenesis and tumor development. This study is aimed to investigate the mechanisms of MELK-mediated development of gastric cancer.","DOI":"10.1186/1476-4598-13-100","ISSN":"1476-4598","journalAbbreviation":"Molecular Cancer","author":[{"family":"Du","given":"Tao"},{"family":"Qu","given":"Ying"},{"family":"Li","given":"Jianfang"},{"family":"Li","given":"Hao"},{"family":"Su","given":"Liping"},{"family":"Zhou","given":"Quan"},{"family":"Yan","given":"Min"},{"family":"Li","given":"Chen"},{"family":"Zhu","given":"Zhenggang"},{"family":"Liu","given":"Bingya"}],"issued":{"date-parts":[["2014"]]}}},{"id":253,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/XIPMB23Q"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/XIPMB23Q"],"itemData":{"id":253,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells","container-title":"Journal of Biological Chemistry","page":"24200-24212","volume":"288","issue":"33","source":"www.jbc.org","abstract":"Maternal embryonic leucine zipper kinase (MELK) belongs to the subfamily of AMP-activated Ser/Thr protein kinases. The expression of MELK is very high in glioblastoma-type brain tumors, but it is not clear how this contributes to tumor growth. Here we show that the siRNA-mediated loss of MELK in U87 MG glioblastoma cells causes a G1/S phase cell cycle arrest accompanied by cell death or a senescence-like phenotype that can be rescued by the expression of siRNA-resistant MELK. This cell cycle arrest is mediated by an increased expression of p21WAF1/CIP1, an inhibitor of cyclin-dependent kinases, and is associated with the hypophosphorylation of the retinoblastoma protein and the down-regulation of E2F target genes. The increased expression of p21 can be explained by the consecutive activation of ATM (ataxia telangiectasia mutated), Chk2, and p53. Intriguingly, the activation of p53 in MELK-deficient cells is not due to an increased stability of p53 but stems from the loss of MDMX (mouse double minute-X), an inhibitor of p53 transactivation. The activation of the ATM-Chk2 pathway in MELK-deficient cells is associated with the accumulation of DNA double-strand breaks during replication, as demonstrated by the appearance of γH2AX foci. Replication stress in these cells is also illustrated by an increased number of stalled replication forks and a reduced fork progression speed. Our data indicate that glioblastoma cells have elevated MELK protein levels to better cope with replication stress during unperturbed S phase. Hence, MELK inhibitors hold great potential for the treatment of glioblastomas as such or in combination with DNA-damaging therapies.","DOI":"10.1074/jbc.M113.471433","ISSN":"0021-9258, 1083-351X","note":"PMID: 23836907","journalAbbreviation":"J. Biol. Chem.","language":"en","author":[{"family":"Kig","given":"Cenk"},{"family":"Beullens","given":"Monique"},{"family":"Beke","given":"Lijs"},{"family":"Eynde","given":"Aleyde Van"},{"family":"Linders","given":"Johannes T."},{"family":"Brehmer","given":"Dirk"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2013",8,16]]}}},{"id":257,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/N49HJAQS"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/N49HJAQS"],"itemData":{"id":257,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer","container-title":"Clinical Cancer Research","page":"clincanres.2711.2015","source":"clincancerres.aacrjournals.org","abstract":"Purpose: While effective targeted therapies exist for estrogen receptor-positive and HER2-positive breast cancer, no such effective therapies exist for triple-negative breast cancer (TNBC), thus it is clear that additional targets for radiosensitization and treatment are critically needed. Experimental Design: Expression microarrays, qRT-PCR, and western blotting were used to assess MELK RNA and protein expression levels. Clonogenic survival assays were used to quantitate the radiosensitivity of cell lines at baseline and after MELK inhibition. The effect of MELK knockdown on DNA damage repair kinetics was determined using γH2AX staining. The in vivo effect of MELK knockdown on radiosensitivity was performed using mouse xenograft models. Kaplan-Meier analysis was used to estimate local control and survival information and a Cox proportional hazards model was constructed to identify potential factors impacting local recurrence-free survival. Results: : MELK expression is significantly elevated in breast cancer tissues compared to normal tissue as well as in TNBC compared to non-TNBC. MELK RNA and protein expression is significantly correlated with radioresistance in breast cancer cell lines. Inhibition of MELK (genetically and pharmacologically) induces radiation sensitivity in vitro and significantly delayed tumor growth in vivo in multiple models. Kaplan-Meier survival and multivariable analyses identify increasing MELK expression as being the strongest predictor of radioresistance and increased local recurrence in multiple independent datasets. Conclusions: Here, we identify MELK as a potential biomarker of radioresistance and target for radiosensitization in TNBC. Our results support the rationale for developing clinical strategies to inhibit MELK as a novel target in TNBC.","DOI":"10.1158/1078-0432.CCR-15-2711","ISSN":"1078-0432, 1557-3265","note":"PMID: 27225691","journalAbbreviation":"Clin Cancer Res","language":"en","author":[{"family":"Speers","given":"Corey"},{"family":"Zhao","given":"Shuang G."},{"family":"Kothari","given":"Vishal"},{"family":"Santola","given":"Alyssa"},{"family":"Liu","given":"Meilan"},{"family":"Wilder-Romans","given":"Kari"},{"family":"Evans","given":"Joseph R."},{"family":"Batra","given":"Nidhi"},{"family":"Bartelink","given":"Harry"},{"family":"Hayes","given":"Daniel F."},{"family":"Lawrence","given":"Theodore S."},{"family":"Brown","given":"Powel H."},{"family":"Pierce","given":"Lori J."},{"family":"Feng","given":"Felix Y."}],"issued":{"date-parts":[["2016",1,1]]}}},{"id":261,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZP8MMW8X"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZP8MMW8X"],"itemData":{"id":261,"type":"article-journal","title":"Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia","container-title":"Oncotarget","page":"12371-12382","volume":"5","issue":"23","source":"PubMed","abstract":"Maternal embryonic leucine-zipper kinase (MELK), which was reported to be frequently up-regulated in various types of solid cancer, plays critical roles in formation and maintenance of cancer stem cells. However, little is known about the relevance of this kinase in hematologic malignancies. Here we report characterization of possible roles of MELK in acute myeloid leukemia (AML). MELK is expressed in AML cell lines and AML blasts with higher levels in less differentiated cells. MELK is frequently upregulated in AML with complex karyotypes and is associated with worse clinical outcome. MELK knockdown resulted in growth inhibition and apoptosis of leukemic cells. Hence, we investigated the potent anti-leukemia activity of OTS167, a small molecule MELK kinase inhibitor, in AML, and found that the compound induced cell differentiation and apoptosis as well as decreased migration of AML cells. MELK expression was positively correlated with the expression of FOXM1 as well as its downstream target genes. Furthermore, MELK inhibition resulted in downregulation of FOXM1 activity and the expression of its downstream targets. Taken together, and given that OTS167 is undergoing a phase I clinical trial in solid cancer, our study warrants clinical evaluation of this compound as a novel targeted therapy for AML patients.","DOI":"10.18632/oncotarget.2642","ISSN":"1949-2553","note":"PMID: 25365263\nPMCID: PMC4323011","journalAbbreviation":"Oncotarget","language":"eng","author":[{"family":"Alachkar","given":"Houda"},{"family":"Mutonga","given":"Martin B. G."},{"family":"Metzeler","given":"Klaus H."},{"family":"Fulton","given":"Noreen"},{"family":"Malnassy","given":"Gregory"},{"family":"Herold","given":"Tobias"},{"family":"Spiekermann","given":"Karsten"},{"family":"Bohlander","given":"Stefan K."},{"family":"Hiddemann","given":"Wolfgang"},{"family":"Matsuo","given":"Yo"},{"family":"Stock","given":"Wendy"},{"family":"Nakamura","given":"Yusuke"}],"issued":{"date-parts":[["2014",12,15]]}}},{"id":263,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/9J5KWJUC"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/9J5KWJUC"],"itemData":{"id":263,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas","container-title":"International Journal of Cancer","page":"807-815","volume":"122","issue":"4","source":"Wiley Online Library","abstract":"We have performed cDNA microarray analyses to identify gene expression differences between highly invasive glioblastoma multiforme (GBM) and typically benign pilocytic astrocytomas (PA). Despite the significant clinical and pathological differences between the 2 tumor types, only 63 genes were found to exhibit 2-fold or greater overexpression in GBM as compared to PA. Forty percent of these genes are related to the regulation of the cell cycle and mitosis. QT-PCR validation of 6 overexpressed genes: MELK, AUKB, ASPM, PRC1, IL13RA2 and KIAA0101 confirmed at least a 5-fold increase in the average expression levels in GBM. Maternal embryonic leucine zipper kinase (MELK) exhibited the most statistically significant difference. A more detailed investigation of MELK expression was undertaken to study its oncogenic relevance. In the examination of more than 100 tumors of the central nervous system, we found progressively higher expression of MELK with astrocytoma grade and a noteworthy uniformity of high level expression in GBM. Similar level of overexpression was also observed in medulloblastoma. We found neither gene promoter hypomethylation nor amplification to be a factor in MELK expression, but were able to demonstrate that MELK knockdown in malignant astrocytoma cell lines caused a reduction in proliferation and anchorage-independent growth in in vitro assays. Our results indicate that GBM and PA differ by the expression of surprisingly few genes. Among them, MELK correlated with malignancy grade in astrocytomas and represents a therapeutic target for the management of the most frequent brain tumors in adult and children. © 2007 Wiley-Liss, Inc.","DOI":"10.1002/ijc.23189","ISSN":"1097-0215","journalAbbreviation":"Int. J. Cancer","language":"en","author":[{"family":"Marie","given":"Suely K.N."},{"family":"Okamoto","given":"Oswaldo K."},{"family":"Uno","given":"Miyuki"},{"family":"Hasegawa","given":"Ana Paula G."},{"family":"Oba-Shinjo","given":"Sueli M."},{"family":"Cohen","given":"Tzeela"},{"family":"Camargo","given":"Anamaria A."},{"family":"Kosoy","given":"Ana"},{"family":"Carlotti","given":"Carlos G."},{"family":"Toledo","given":"Silvia"},{"family":"Moreira-Filho","given":"Carlos A."},{"family":"Zago","given":"Marco A."},{"family":"Simpson","given":"Andrew J."},{"family":"Caballero","given":"Otavia L."}],"issued":{"date-parts":[["2008",2,15]]}}},{"id":266,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/5AQGH7AQ"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/5AQGH7AQ"],"itemData":{"id":266,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells","container-title":"Journal of Neuroscience Research","page":"48-60","volume":"86","issue":"1","source":"PubMed","abstract":"Emerging evidence suggests that neural stem cells and brain tumors regulate their proliferation via similar pathways. In a previous study, we demonstrated that maternal embryonic leucine zipper kinase (Melk) is highly expressed in murine neural stem cells and regulates their proliferation. Here we describe how MELK expression is correlated with pathologic grade of brain tumors, and its expression levels are significantly correlated with shorter survival, particularly in younger glioblastoma patients. In normal human astrocytes, MELK is only faintly expressed, and MELK knockdown does not significantly influence their growth, whereas Ras and Akt overexpressing astrocytes have up-regulated MELK expression, and the effect of MELK knockdown is more prominent in these transformed astrocytes. In primary cultures from human glioblastoma and medulloblastoma, MELK knockdown by siRNA results in inhibition of the proliferation and survival of these tumors. Furthermore, we show that MELK siRNA dramatically inhibits proliferation and, to some extent, survival of stem cells isolated from glioblastoma in vitro. These results demonstrate a critical role for MELK in the proliferation of brain tumors, including their stem cells, and suggest that MELK may be a compelling molecular target for treatment of high-grade brain tumors.","DOI":"10.1002/jnr.21471","ISSN":"0360-4012","note":"PMID: 17722061","journalAbbreviation":"J. Neurosci. Res.","language":"eng","author":[{"family":"Nakano","given":"Ichiro"},{"family":"Masterman-Smith","given":"Michael"},{"family":"Saigusa","given":"Kuniyasu"},{"family":"Paucar","given":"Andres A."},{"family":"Horvath","given":"Steve"},{"family":"Shoemaker","given":"Lorelei"},{"family":"Watanabe","given":"Momoko"},{"family":"Negro","given":"Alejandra"},{"family":"Bajpai","given":"Ruchi"},{"family":"Howes","given":"Amy"},{"family":"Lelievre","given":"Vincent"},{"family":"Waschek","given":"James A."},{"family":"Lazareff","given":"Jorge A."},{"family":"Freije","given":"William A."},{"family":"Liau","given":"Linda M."},{"family":"Gilbertson","given":"Richard J."},{"family":"Cloughesy","given":"Timothy F."},{"family":"Geschwind","given":"Daniel H."},{"family":"Nelson","given":"Stanley F."},{"family":"Mischel","given":"Paul S."},{"family":"Terskikh","given":"Alexey V."},{"family":"Kornblum","given":"Harley I."}],"issued":{"date-parts":[["2008",1]]}}},{"id":268,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/C8GQ4ERE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/C8GQ4ERE"],"itemData":{"id":268,"type":"article-journal","title":"MELK is Upregulated and Required in Mammary Tumor Initiating Cells In Vivo","container-title":"Cancer research","page":"8863-8873","volume":"70","issue":"21","source":"PubMed Central","abstract":"Maternal Embryonic Leucine zipper Kinase (MELK) is expressed in several developing tissues, in the adult germ line, and in adult neural progenitors. MELK expression is elevated in aggressive undifferentiated tumors correlating with poor patient outcome in human breast cancer. To investigate the role of MELK in mammary tumorigenesis in vivo we used a MELK-GFP reporter mouse, which allows prospective isolation of MELK expressing cells based on GFP fluorescence. We found that in the normal mammary gland, cells expressing high levels of MELK were enriched for proliferating cells, expressing markers of mammary progenitors. The isolation of cells with high levels of MELK in mammary tumors from MMTV-Wnt1/MELK-GFP bitransgenic mice resulted in a significant enrichment of tumorsphere formation in culture and tumor initiation after transplantation into mammary fat pads of syngeneic mice. Furthermore, using lentiviral delivery of MELK-specific shRNA and limiting dilution cell transplantations we demonstrated that MELK function is required for mammary tumorigenesis in vivo. Our findings identify MELK as potential target in breast tumor initiating cells.","DOI":"10.1158/0008-5472.CAN-10-1295","ISSN":"0008-5472","note":"PMID: 20861186\nPMCID: PMC3990264","journalAbbreviation":"Cancer Res","author":[{"family":"Hebbard","given":"Lionel"},{"family":"Maurer","given":"Jochen"},{"family":"Miller","given":"Amber"},{"family":"Lesperance","given":"Jacqueline"},{"family":"Hassell","given":"John"},{"family":"Oshima","given":"Robert G."},{"family":"Terskikh","given":"Alexey"}],"issued":{"date-parts":[["2010",11,1]]}}},{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}},{"id":419,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/F8XIDEB9"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/F8XIDEB9"],"itemData":{"id":419,"type":"article-journal","title":"Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression","container-title":"Biochemical and Biophysical Research Communications","page":"207-213","volume":"412","issue":"2","source":"ScienceDirect","abstract":"It was reported that the local recurrence would be caused by cancer stem cells acquiring chemo- and radio-resistance. Recently, one of the potential therapeutic targets for colorectal and other cancers has been identified, which is maternal embryonic leucine zipper kinase (MELK). MELK is known as an embryonic and neural stem cell marker, and associated with the cell survival, cell proliferation, and apoptosis. In this study, SNU-503, which is a rectal cancer cell line, was treated with radiation or 5-fluorouracil (5-FU), and elevation of the MELK expression level was observed. Furthermore, the cell line was pre-treated with small interfering RNA (siRNA) against MELK mRNA before treatment of radiation or 5-FU and its effects on cell cycle and proliferation were observed. We demonstrated that knockdown of MELK reduced the proliferation of cells with radiation or 5-FU treatment. In addition, MELK suppression caused changes in cell cycle. In conclusion, MELK could be associated with increased resistance of colorectal cancer cells against radiation and 5-FU.","DOI":"10.1016/j.bbrc.2011.07.060","ISSN":"0006-291X","journalAbbreviation":"Biochemical and Biophysical Research Communications","author":[{"family":"Choi","given":"Seungho"},{"family":"Ku","given":"Ja-Lok"}],"issued":{"date-parts":[["2011",8,26]]}}},{"id":422,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/DVGI7JRE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/DVGI7JRE"],"itemData":{"id":422,"type":"article-journal","title":"MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence","container-title":"Cancer Letters","page":"85-93","volume":"383","issue":"1","source":"ScienceDirect","abstract":"Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Many kinases have been found to be intimately involved in oncogenesis and the deregulation of kinase function has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. Previously, we have performed gene expression profile analysis on HCC samples and have identified a host of kinases that are remarkably overexpressed in HCC. Among these, the Maternal Embryonic Leucine Zipper Kinase (MELK) is highly overexpressed in HCC and its overexpression strongly correlates with early recurrence and poor patients' survival. Silencing MELK inhibited cell growth, invasion, stemness and tumorigenicity of HCC cells by inducing apoptosis and mitosis. We further showed that the overexpression of MELK in HCC samples strongly correlated with the cell cycle- and mitosis-related genes which are directly regulated as part of the forkhead transcription factor FoxM1-related cell division program. Together, our data establish MELK as an oncogenic kinase involved in the pathogenesis and recurrence of HCC and could provide a promising molecular target to develop therapeutic strategies for patients with advanced HCC.","DOI":"10.1016/j.canlet.2016.09.017","ISSN":"0304-3835","journalAbbreviation":"Cancer Letters","author":[{"family":"Xia","given":"Hongping"},{"family":"Kong","given":"Shik Nie"},{"family":"Chen","given":"Jianxiang"},{"family":"Shi","given":"Ming"},{"family":"Sekar","given":"Karthik"},{"family":"Seshachalam","given":"Veerabrahma Pratap"},{"family":"Rajasekaran","given":"Muthukumar"},{"family":"Goh","given":"Brian Kim Poh"},{"family":"Ooi","given":"London Lucien"},{"family":"Hui","given":"Kam M."}],"issued":{"date-parts":[["2016",12,1]]}}},{"id":425,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VW683SG8"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VW683SG8"],"itemData":{"id":425,"type":"article-journal","title":"Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner","container-title":"Stem Cells (Dayton, Ohio)","page":"870-881","volume":"31","issue":"5","source":"PubMed","abstract":"Accumulated evidence suggests that glioma stem cells (GSCs) may contribute to therapy resistance in high-grade glioma (HGG). Although recent studies have shown that the serine/threonine kinase maternal embryonic leucine-zipper kinase (MELK) is abundantly expressed in various cancers, the function and mechanism of MELK remain elusive. Here, we demonstrate that MELK depletion by shRNA diminishes the growth of GSC-derived mouse intracranial tumors in vivo, induces glial fibrillary acidic protein (+) glial differentiation of GSCs leading to decreased malignancy of the resulting tumors, and prolongs survival periods of tumor-bearing mice. Tissue microarray analysis with 91 HGG tumors demonstrates that the proportion of MELK (+) cells is a statistically significant indicator of postsurgical survival periods. Mechanistically, MELK is regulated by the c-Jun NH(2)-terminal kinase (JNK) signaling and forms a complex with the oncoprotein c-JUN in GSCs but not in normal progenitors. MELK silencing induces p53 expression, whereas p53 inhibition induces MELK expression, indicating that MELK and p53 expression are mutually exclusive. Additionally, MELK silencing-mediated GSC apoptosis is partially rescued by both pharmacological p53 inhibition and p53 gene silencing, indicating that MELK action in GSCs is p53 dependent. Furthermore, irradiation of GSCs markedly elevates MELK mRNA and protein expression both in vitro and in vivo. Clinically, recurrent HGG tumors following the failure of radiation and chemotherapy exhibit a statistically significant elevation of MELK protein compared with untreated newly diagnosed HGG tumors. Together, our data indicate that GSCs, but not normal cells, depend on JNK-driven MELK/c-JUN signaling to regulate their survival, maintain GSCs in an immature state, and facilitate tumor radioresistance in a p53-dependent manner.","DOI":"10.1002/stem.1322","ISSN":"1549-4918","note":"PMID: 23339114\nPMCID: PMC4132653","journalAbbreviation":"Stem Cells","language":"eng","author":[{"family":"Gu","given":"Chunyu"},{"family":"Banasavadi-Siddegowda","given":"Yeshavanth K."},{"family":"Joshi","given":"Kaushal"},{"family":"Nakamura","given":"Yuko"},{"family":"Kurt","given":"Habibe"},{"family":"Gupta","given":"Snehalata"},{"family":"Nakano","given":"Ichiro"}],"issued":{"date-parts":[["2013",5]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00466CAD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A" w:rsidRPr="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/></w:rPr><w:t>(14–27)</w:t></w:r><w:r w:rsidR="00466CAD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00F061AD" w:rsidRPr="004A2C4F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00AA09BE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="007A6163"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>In particular, MELK</w:t></w:r><w:r w:rsidR="008D1211"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> has been identified</w:t></w:r><w:r w:rsidR="007A6163"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> as a key driver of basal-type breast cancer</w:t></w:r><w:r w:rsidR="008D1211"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, suggesting a novel therapeutic approach to treat this </w:t></w:r><w:r w:rsidR="0060533D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">disease </w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2i7iifukpg","properties":{"formattedCitation":"(24)","plainCitation":"(24)"},"citationItems":[{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(24)</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00AA5366"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="005D4131"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>In response to the widespread reports that MELK is a cancer dependency</w:t></w:r><w:r w:rsidR="00AA09BE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="000B7B2E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>several</w:t></w:r><w:r w:rsidR="00AA09BE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> companies </w:t></w:r><w:r w:rsidR="001D3692"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">have </w:t></w:r><w:r w:rsidR="0001531E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">developed </w:t></w:r><w:r w:rsidR="000E0925"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">small molecule inhibitors of MELK that block the activity of the kinase </w:t></w:r><w:r w:rsidR="000E0925"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in vitro </w:t></w:r><w:r w:rsidR="000E0925"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and that </w:t></w:r><w:r w:rsidR="00AA5366"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>inhibit cancer cell proliferation at</w:t></w:r><w:r w:rsidR="000E0925"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> micromolar or nanomolar </w:t></w:r><w:r w:rsidR="00AA5366"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>concentrations</w:t></w:r><w:r w:rsidR="00195A3A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00195A3A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"NHLYqRv0","properties":{"formattedCitation":"{\\rtf (28\\uc0\\u8211{}32)}","plainCitation":"(28–32)"},"citationItems":[{"id":127,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZUNBM3JA"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZUNBM3JA"],"itemData":{"id":127,"type":"article-journal","title":"MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells","container-title":"Bioscience Reports","volume":"35","issue":"6","source":"PubMed Central","abstract":"Protein kinase MELK has oncogenic properties and is highly overexpressed in some tumors. In the present study, we show that a novel MELK inhibitor causes both the inhibition and degradation of MELK, culminating in replication stress and a senescence phenotype., Maternal embryonic leucine zipper kinase (MELK), a serine/threonine protein kinase, has oncogenic properties and is overexpressed in many cancer cells. The oncogenic function of MELK is attributed to its capacity to disable critical cell-cycle checkpoints and reduce replication stress. Most functional studies have relied on the use of siRNA/shRNA-mediated gene silencing. In the present study, we have explored the biological function of MELK using MELK-T1, a novel and selective small-molecule inhibitor. Strikingly, MELK-T1 triggered a rapid and proteasome-dependent degradation of the MELK protein. Treatment of MCF-7 (Michigan Cancer Foundation-7) breast adenocarcinoma cells with MELK-T1 induced the accumulation of stalled replication forks and double-strand breaks that culminated in a replicative senescence phenotype. This phenotype correlated with a rapid and long-lasting ataxia telangiectasia-mutated (ATM) activation and phosphorylation of checkpoint kinase 2 (CHK2). Furthermore, MELK-T1 induced a strong phosphorylation of p53 (cellular tumour antigen p53), a prolonged up-regulation of p21 (cyclin-dependent kinase inhibitor 1) and a down-regulation of FOXM1 (Forkhead Box M1) target genes. Our data indicate that MELK is a key stimulator of proliferation by its ability to increase the threshold for DNA-damage tolerance (DDT). Thus, targeting MELK by the inhibition of both its catalytic activity and its protein stability might sensitize tumours to DNA-damaging agents or radiation therapy by lowering the DNA-damage threshold.","URL":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643329/","DOI":"10.1042/BSR20150194","ISSN":"0144-8463","note":"PMID: 26431963\nPMCID: PMC4643329","journalAbbreviation":"Biosci Rep","author":[{"family":"Beke","given":"Lijs"},{"family":"Kig","given":"Cenk"},{"family":"Linders","given":"Joannes T. M."},{"family":"Boens","given":"Shannah"},{"family":"Boeckx","given":"An"},{"family":"Heerde","given":"Erika","non-dropping-particle":"van"},{"family":"Parade","given":"Marc"},{"family":"De Bondt","given":"An"},{"family":"Van den Wyngaert","given":"Ilse"},{"family":"Bashir","given":"Tarig"},{"family":"Ogata","given":"Souichi"},{"family":"Meerpoel","given":"Lieven"},{"family":"Van Eynde","given":"Aleyde"},{"family":"Johnson","given":"Christopher N."},{"family":"Beullens","given":"Monique"},{"family":"Brehmer","given":"Dirk"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2015",11,13]]},"accessed":{"date-parts":[["2016",10,4]]}},"locator":"1"},{"id":367,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/4B94A749"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/4B94A749"],"itemData":{"id":367,"type":"article-journal","title":"Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight","container-title":"Journal of Medicinal Chemistry","page":"4711-4723","volume":"59","issue":"10","source":"PubMed","abstract":"MELK kinase has been implicated in playing an important role in tumorigenesis. Our previous studies suggested that MELK is involved in the regulation of cell cycle and its genetic depletion leads to growth inhibition in a subset of high MELK-expressing basal-like breast cancer cell lines. Herein we describe the discovery and optimization of novel MELK inhibitors 8a and 8b that recapitulate the cellular effects observed by short hairpin ribonucleic acid (shRNA)-mediated MELK knockdown in cellular models. We also discovered a novel fluorine-induced hydrophobic collapse that locked the ligand in its bioactive conformation and led to a 20-fold gain in potency. These novel pharmacological inhibitors achieved high exposure in vivo and were well tolerated, which may allow further in vivo evaluation.","DOI":"10.1021/acs.jmedchem.6b00052","ISSN":"1520-4804","note":"PMID: 27187609","shortTitle":"Toward the Validation of Maternal Embryonic Leucine Zipper Kinase","journalAbbreviation":"J. Med. Chem.","language":"ENG","author":[{"family":"Touré","given":"B. Barry"},{"family":"Giraldes","given":"John"},{"family":"Smith","given":"Troy"},{"family":"Sprague","given":"Elizabeth R."},{"family":"Wang","given":"Yaping"},{"family":"Mathieu","given":"Simon"},{"family":"Chen","given":"Zhuoliang"},{"family":"Mishina","given":"Yuji"},{"family":"Feng","given":"Yun"},{"family":"Yan-Neale","given":"Yan"},{"family":"Shakya","given":"Subarna"},{"family":"Chen","given":"Dongshu"},{"family":"Meyer","given":"Matthew"},{"family":"Puleo","given":"David"},{"family":"Brazell","given":"J. Tres"},{"family":"Straub","given":"Christopher"},{"family":"Sage","given":"David"},{"family":"Wright","given":"Kirk"},{"family":"Yuan","given":"Yanqiu"},{"family":"Chen","given":"Xin"},{"family":"Duca","given":"Jose"},{"family":"Kim","given":"Sean"},{"family":"Tian","given":"Li"},{"family":"Martin","given":"Eric"},{"family":"Hurov","given":"Kristen"},{"family":"Shao","given":"Wenlin"}],"issued":{"date-parts":[["2016",5,26]]}}},{"id":364,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/BQC6G5QF"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/BQC6G5QF"],"itemData":{"id":364,"type":"article-journal","title":"Fragment-Based Discovery of Type I Inhibitors of Maternal Embryonic Leucine Zipper Kinase","container-title":"ACS Medicinal Chemistry Letters","page":"25-30","volume":"6","issue":"1","source":"ACS Publications","abstract":"Fragment-based drug design was successfully applied to maternal embryonic leucine zipper kinase (MELK). A low affinity (160 μM) fragment hit was identified, which bound to the hinge region with an atypical binding mode, and this was optimized using structure-based design into a low-nanomolar and cell-penetrant inhibitor, with a good selectivity profile, suitable for use as a chemical probe for elucidation of MELK biology.","DOI":"10.1021/ml5001245","journalAbbreviation":"ACS Med. Chem. Lett.","author":[{"family":"Johnson","given":"Christopher N."},{"family":"Berdini","given":"Valerio"},{"family":"Beke","given":"Lijs"},{"family":"Bonnet","given":"Pascal"},{"family":"Brehmer","given":"Dirk"},{"family":"Coyle","given":"Joseph E."},{"family":"Day","given":"Phillip J."},{"family":"Frederickson","given":"Martyn"},{"family":"Freyne","given":"Eddy J. E."},{"family":"Gilissen","given":"Ron A. H. J."},{"family":"Hamlett","given":"Christopher C. F."},{"family":"Howard","given":"Steven"},{"family":"Meerpoel","given":"Lieven"},{"family":"McMenamin","given":"Rachel"},{"family":"Patel","given":"Sahil"},{"family":"Rees","given":"David C."},{"family":"Sharff","given":"Andrew"},{"family":"Sommen","given":"François"},{"family":"Wu","given":"Tongfei"},{"family":"Linders","given":"Joannes T. M."}],"issued":{"date-parts":[["2015",1,8]]}}},{"id":361,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TFZZDJ7Z"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TFZZDJ7Z"],"itemData":{"id":361,"type":"article-journal","title":"Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase","container-title":"ACS Medicinal Chemistry Letters","page":"31-36","volume":"6","issue":"1","source":"ACS Publications","abstract":"A novel Type II kinase inhibitor chemotype has been identified for maternal embryonic leucine zipper kinase (MELK) using structure-based ligand design. The strategy involved structural characterization of an induced DFG-out pocket by protein–ligand X-ray crystallography and incorporation of a slender linkage capable of bypassing a large gate-keeper residue, thus enabling design of molecules accessing both hinge and induced pocket regions. Optimization of an initial hit led to the identification of a low-nanomolar, cell-penetrant Type II inhibitor suitable for use as a chemical probe for MELK.","DOI":"10.1021/ml5001273","journalAbbreviation":"ACS Med. Chem. Lett.","author":[{"family":"Johnson","given":"Christopher N."},{"family":"Adelinet","given":"Christophe"},{"family":"Berdini","given":"Valerio"},{"family":"Beke","given":"Lijs"},{"family":"Bonnet","given":"Pascal"},{"family":"Brehmer","given":"Dirk"},{"family":"Calo","given":"Frederick"},{"family":"Coyle","given":"Joseph E."},{"family":"Day","given":"Phillip J."},{"family":"Frederickson","given":"Martyn"},{"family":"Freyne","given":"Eddy J. E."},{"family":"Gilissen","given":"Ron A. H. J."},{"family":"Hamlett","given":"Christopher C. F."},{"family":"Howard","given":"Steven"},{"family":"Meerpoel","given":"Lieven"},{"family":"Mevellec","given":"Laurence"},{"family":"McMenamin","given":"Rachel"},{"family":"Pasquier","given":"Elisabeth"},{"family":"Patel","given":"Sahil"},{"family":"Rees","given":"David C."},{"family":"Linders","given":"Joannes T. M."}],"issued":{"date-parts":[["2015",1,8]]}}},{"id":370,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/93IT23E3"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/93IT23E3"],"itemData":{"id":370,"type":"article-journal","title":"Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer","container-title":"Oncotarget","page":"1629-1640","volume":"3","issue":"12","source":"www.impactjournals.com","abstract":"//     Suyoun Chung 1 , Hanae Suzuki 2 , Takashi Miyamoto 2 , Naofumi Takamatsu 2 , Ayako Tatsuguchi 3 , Koji Ueda 3 , Kyoko Kijima 2 , Yusuke Nakamura 1,4  and Yo Matsuo 2     1  Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA    2  OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan    3  Laboratory for Biomarker Development, RIKEN, Yokohama, Japan    4  Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan   Correspondence:   Yusuke Nakamura, email:         //      Yo Matsuo, email:         //       Keywords : oncogene, drug discovery, kinase inhibitor, cancer stem cell    Received : December 05, 2012,  Accepted : December 20, 2012,  Published : December 21, 2012    Abstract   We previously reported MELK (maternal embryonic leucine zipper kinase) as a novel therapeutic target for breast cancer. MELK was also reported to be highly upregulated in multiple types of human cancer. It was implied to play indispensable roles in cancer cell survival and indicated its involvement in the maintenance of tumor-initiating cells. We conducted a high-throughput screening of a compound library followed by structure-activity relationship studies, and successfully obtained a highly potent MELK inhibitor OTSSP167 with IC 50  of 0.41 nM. OTSSP167 inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like), which we identified as novel MELK substrates and are important for stem-cell characteristics and invasiveness. The compound suppressed mammosphere formation of breast cancer cells and exhibited significant tumor growth suppression in xenograft studies using breast, lung, prostate, and pancreas cancer cell lines in mice by both intravenous and oral administration. This MELK inhibitor should be a promising compound possibly to suppress the growth of tumor-initiating cells and be applied for treatment of a wide range of human cancer.","ISSN":"1949-2553","author":[{"family":"Chung","given":"Suyoun"},{"family":"Suzuki","given":"Hanae"},{"family":"Miyamoto","given":"Takashi"},{"family":"Takamatsu","given":"Naofumi"},{"family":"Tatsuguchi","given":"Ayako"},{"family":"Ueda","given":"Koji"},{"family":"Kijima","given":"Kyoko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Matsuo","given":"Yo"},{"family":"Chung","given":"Suyoun"},{"family":"Suzuki","given":"Hanae"},{"family":"Miyamoto","given":"Takashi"},{"family":"Takamatsu","given":"Naofumi"},{"family":"Tatsuguchi","given":"Ayako"},{"family":"Ueda","given":"Koji"},{"family":"Kijima","given":"Kyoko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Matsuo","given":"Yo"}],"issued":{"date-parts":[["2012",12,21]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00195A3A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A" w:rsidRPr="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/></w:rPr><w:t>(28–32)</w:t></w:r><w:r w:rsidR="00195A3A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="0001531E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="000A4595"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Additionally, </w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>four clinical tr</w:t></w:r><w:r w:rsidR="009C3452"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ials have been launched to test</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="001443A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">the </w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ME</w:t></w:r><w:r w:rsidR="009C3452"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>LK inhibitor OTS167</w:t></w:r><w:r w:rsidR="00341ADA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in human cancers</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (</w:t></w:r><w:r w:rsidR="000C4E29" w:rsidRPr="006E0429"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>NCT01910545</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="000C4E29" w:rsidRPr="006E0429"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>NCT02768519</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="000C4E29" w:rsidRPr="006E0429"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>NCT02795520</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and </w:t></w:r><w:r w:rsidR="000C4E29" w:rsidRPr="009938B8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>NCT02926690</w:t></w:r><w:r w:rsidR="000C4E29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">). </w:t></w:r></w:p><w:p w14:paraId="2461669D" w14:textId="25BA09B6" w:rsidR="001B2946" w:rsidRDefault="007A6563" w:rsidP="009A2CB4"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">As part of a project in our lab to characterize genes whose expression is associated with </w:t></w:r><w:r w:rsidR="008175EB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>patient prognosis in cancer</w:t></w:r><w:r w:rsidR="008C790F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00CA6CF9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"tv7m3qkdr","properties":{"formattedCitation":"(33)","plainCitation":"(33)"},"citationItems":[{"id":374,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/FTTKI86F"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/FTTKI86F"],"itemData":{"id":374,"type":"article-journal","title":"A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally-unstable cancer cells and informs clinical prognosis","container-title":"Cancer research","page":"6401-6412","volume":"73","issue":"21","source":"PubMed Central","abstract":"Aneuploidy is invariably associated with poor proliferation of primary cells, but the precise contributions of abnormal karyotypes to cancer, a disease characterized by aneuploidy and dysregulated proliferation, remain unclear. In this study, I demonstrate that the transcriptional alterations caused by aneuploidy in primary cells are also present in chromosomally-unstable cancer cell lines, but the same alterations are not common to all aneuploid cancers. Chromosomally-unstable cancer lines displayed increased glycolytic and TCA-cycle flux, also a feature of aneuploid primary cells. The biological response to aneuploidy is associated with cellular stress and slow proliferation, and a 70-gene signature derived from primary aneuploid cells was defined as a strong predictor of increased survival in several cancers. Inversely, a transcriptional signature derived from clonal aneuploidy in tumors correlated with high mitotic activity and poor prognosis. Together these findings suggested that there are two types of aneuploidy in cancer, one of which is clonal aneuploidy selected during tumor evolution and associated with robust growth, and the second of which is subclonal aneuploidy caused by chromosomal instability (CIN). Subclonal aneuploidy more closely resembles the stressed state of primary aneuploid cells, yet CIN is not benign: a subset of genes upregulated in high-CIN cancers predict aggressive disease in human patients in a proliferation-independent manner.","DOI":"10.1158/0008-5472.CAN-13-0749","ISSN":"0008-5472","note":"PMID: 24041940\nPMCID: PMC3901577","journalAbbreviation":"Cancer Res","author":[{"family":"Sheltzer","given":"Jason M."}],"issued":{"date-parts":[["2013",11,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00CA6CF9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(33)</w:t></w:r><w:r w:rsidR="00CA6CF9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="008175EB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="003B5315"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we </w:t></w:r><w:r w:rsidR="0068356E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">identified MELK as highly-expressed in deadly tumors from multiple cancer types (data not shown).  </w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We set out to use CRISPR/Cas9 to characterize the effects of MELK loss on tumorigenesis.  </w:t></w:r><w:r w:rsidR="00BA10D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Unexpectedly, </w:t></w:r><w:r w:rsidR="003A690D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we found that </w:t></w:r><w:r w:rsidR="00DA6565"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">mutating </w:t></w:r><w:r w:rsidR="004933C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK</w:t></w:r><w:r w:rsidR="003A690D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="005B3C10"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>failed</w:t></w:r><w:r w:rsidR="009E04F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to affect the growth of </w:t></w:r><w:r w:rsidR="004856A8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>every cancer cell line that we tested</w:t></w:r><w:r w:rsidR="009E04F5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00B33F31"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Furthermore, the</w:t></w:r><w:r w:rsidR="00DF37FD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK inhibitor OTS167 </w:t></w:r><w:r w:rsidR="005B3C10"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>remained</w:t></w:r><w:r w:rsidR="00DF37FD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> effective against </w:t></w:r><w:r w:rsidR="004856A8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cells</w:t></w:r><w:r w:rsidR="004933C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> with null mutations in </w:t></w:r><w:r w:rsidR="00DF37FD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK</w:t></w:r><w:r w:rsidR="00E05AAD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, suggesting </w:t></w:r><w:r w:rsidR="008B2A21"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">that </w:t></w:r><w:r w:rsidR="00E05AAD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>it</w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">s </w:t></w:r><w:r w:rsidR="00012124"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in vivo </w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">activity results from an off-target effect.  </w:t></w:r><w:r w:rsidR="00673285"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We </w:t></w:r><w:r w:rsidR="00E759B9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>propose</w:t></w:r><w:r w:rsidR="00673285"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that</w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> CRISPR represents an essential modality to confirm</w:t></w:r><w:r w:rsidR="00EB7C84"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> putative cancer dependencies</w:t></w:r><w:r w:rsidR="00620703"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and drug specificity </w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">before </w:t></w:r><w:r w:rsidR="002211D4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>preclinical</w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00E00480"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>findings are</w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00620703"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>advance</w:t></w:r><w:r w:rsidR="00E00480"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>d</w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to </w:t></w:r><w:r w:rsidR="00833055"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>human</w:t></w:r><w:r w:rsidR="00DD3140"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> trials. </w:t></w:r></w:p><w:p w14:paraId="427875C7" w14:textId="77777777" w:rsidR="00F90436" w:rsidRDefault="00F90436" w:rsidP="00CD31AF"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="3A94D3AF" w14:textId="0CA6D8E3" w:rsidR="00C165DB" w:rsidRPr="007F457A" w:rsidRDefault="00482779" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Results</w:t></w:r></w:p><w:p w14:paraId="7A89BED5" w14:textId="6E44CE56" w:rsidR="00C165DB" w:rsidRDefault="00556B29" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Mutagenizing MELK using CRISPR/Cas9</w:t></w:r></w:p><w:p w14:paraId="7BDC6D4D" w14:textId="326EC4F1" w:rsidR="009037D4" w:rsidRDefault="00C165DB" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00177847"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Over</w:t></w:r><w:r w:rsidR="00ED7A9C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> a dozen</w:t></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> previous publications </w:t></w:r><w:r w:rsidR="00064602"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>have reported</w:t></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that </w:t></w:r><w:r w:rsidR="00405451"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK is a cancer dependency, as </w:t></w:r><w:r w:rsidR="00177847"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">blocking </w:t></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK </w:t></w:r><w:r w:rsidR="00064602"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>with</w:t></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> RNAi</w:t></w:r><w:r w:rsidR="00177847"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or small molecules</w:t></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00177847"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>inhibited</w:t></w:r><w:r w:rsidR="00D875B3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the proliferation of cell lines</w:t></w:r><w:r w:rsidR="00BB3B29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> derived from multiple tumor types</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"sIhWYtlU","properties":{"formattedCitation":"{\\rtf (14\\uc0\\u8211{}27)}","plainCitation":"(14–27)"},"citationItems":[{"id":148,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/3I8BINHZ"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/3I8BINHZ"],"itemData":{"id":148,"type":"article-journal","title":"Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family","container-title":"Breast Cancer Research","page":"R17","volume":"9","source":"BioMed Central","abstract":"Cancer therapies directed at specific molecular targets in signaling pathways of cancer cells, such as tamoxifen, aromatase inhibitors and trastuzumab, have proven useful for treatment of advanced breast cancers. However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects. These side effects as well as drug resistance make it necessary to search for novel molecular targets for drugs on the basis of well-characterized mechanisms of action.","DOI":"10.1186/bcr1650","ISSN":"1465-542X","journalAbbreviation":"Breast Cancer Research","author":[{"family":"Lin","given":"Meng-Lay"},{"family":"Park","given":"Jae-Hyun"},{"family":"Nishidate","given":"Toshihiko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Katagiri","given":"Toyomasa"}],"issued":{"date-parts":[["2007"]]}}},{"id":130,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"itemData":{"id":130,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers","container-title":"Cancer Research","page":"9751-9761","volume":"65","issue":"21","source":"cancerres.aacrjournals.org","abstract":"To identify genes that could serve as targets for novel cancer therapeutics, we used a bioinformatic analysis of microarray data comparing gene expression between normal and tumor-derived primary human tissues. From this approach, we have found that maternal embryonic leucine zipper kinase (Melk), a member of the AMP serine/threonine kinase family, exhibits multiple features consistent with the potential utility of this gene as an anticancer target. An oligonucleotide microarray analysis of multiple human tumor samples and cell lines suggests that Melk expression is frequently elevated in cancer relative to normal tissues, a pattern confirmed by quantitative reverse transcription-PCR and Western blotting of selected primary tumor samples. In situ hybridization localized Melk expression to malignant epithelial cells in 96%, 23%, and 13% of colorectal, lung, and ovarian tissue tumor samples, respectively. Expression of this gene is also elevated in spontaneous tumors derived from the ApcMin and Apc1638N murine models of intestinal tumorigenesis. To begin addressing whether Melk is relevant for tumorigenesis, RNA interference–mediated silencing within human and murine tumor cell lines was done. We show that Melk knockdown decreases proliferation and anchorage-independent growth in vitro as well as tumor growth in a xenograft model. Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial.","DOI":"10.1158/0008-5472.CAN-04-4531","ISSN":"0008-5472, 1538-7445","note":"PMID: 16266996","journalAbbreviation":"Cancer Res","language":"en","author":[{"family":"Gray","given":"Daniel"},{"family":"Jubb","given":"Adrian M."},{"family":"Hogue","given":"Deborah"},{"family":"Dowd","given":"Patrick"},{"family":"Kljavin","given":"Noelyn"},{"family":"Yi","given":"Sothy"},{"family":"Bai","given":"Wei"},{"family":"Frantz","given":"Gretchen"},{"family":"Zhang","given":"Zemin"},{"family":"Koeppen","given":"Hartmut"},{"family":"Sauvage","given":"Frederic J.","dropping-particle":"de"},{"family":"Davis","given":"David P."}],"issued":{"date-parts":[["2005",11,1]]}}},{"id":246,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8TD4CXJC"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8TD4CXJC"],"itemData":{"id":246,"type":"article-journal","title":"The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer","container-title":"Journal of Molecular Medicine","page":"237-248","volume":"91","issue":"2","source":"link.springer.com","abstract":"Loss of cell cycle control is a prerequisite for cancer onset and progression. In prostate cancer, increased activity of cell cycle genes has been associated with prognostic parameters such as biochemical relapse and survival. The identification of novel oncogenic and druggable targets in patient subgroups with poor prognosis may help to develop targeted therapy approaches. We analyzed prostate cancer and corresponding benign tissues (n = 98) using microarrays. The comparison of high- and low-grade tumors (Gleason score ≥ 4 + 3 vs. ≤ 3 + 4) revealed 144 differentially expressed genes (p &lt; 0.05). Out of these, 15 genes were involved in the cell cycle process. The gene maternal embryonic leucine zipper kinase (MELK) was identified to be highly correlated with cell cycle genes like UBE2C, TOP2A, CCNB2, and AURKB. Increased MELK gene expression in high-risk prostate cancer was validated by qPCR in an independent patient cohort (p &lt; 0.005, n = 79). Immunohistochemistry analysis using a tissue microarray (n = 94) revealed increased MELK protein expression in prostate cancer tissues of high Gleason scores. RNAi-based inhibition of MELK in PC3 and LNCaP cells suggested putative function in chromatin modification, embryonic development and cell migration. The concerted inhibition of MELK and other cell cycle targets by the antibiotic siomycin A strongly impaired cell viability of prostate cancer cells, and may point to a novel therapy approach for a subset of high-risk prostate cancer patients.","DOI":"10.1007/s00109-012-0949-1","ISSN":"0946-2716, 1432-1440","journalAbbreviation":"J Mol Med","language":"en","author":[{"family":"Kuner","given":"Ruprecht"},{"family":"Fälth","given":"Maria"},{"family":"Pressinotti","given":"Nicole Chui"},{"family":"Brase","given":"Jan C."},{"family":"Puig","given":"Sabrina Balaguer"},{"family":"Metzger","given":"Jennifer"},{"family":"Gade","given":"Stephan"},{"family":"Schäfer","given":"Georg"},{"family":"Bartsch","given":"Georg"},{"family":"Steiner","given":"Eberhard"},{"family":"Klocker","given":"Helmut"},{"family":"Sültmann","given":"Holger"}],"issued":{"date-parts":[["2012",9,4]]}}},{"id":249,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VGT75BTE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VGT75BTE"],"itemData":{"id":249,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway","container-title":"Molecular Cancer","page":"100","volume":"13","source":"BioMed Central","abstract":"Elevated MELK expression is featured in multiple tumors and correlated with tumorigenesis and tumor development. This study is aimed to investigate the mechanisms of MELK-mediated development of gastric cancer.","DOI":"10.1186/1476-4598-13-100","ISSN":"1476-4598","journalAbbreviation":"Molecular Cancer","author":[{"family":"Du","given":"Tao"},{"family":"Qu","given":"Ying"},{"family":"Li","given":"Jianfang"},{"family":"Li","given":"Hao"},{"family":"Su","given":"Liping"},{"family":"Zhou","given":"Quan"},{"family":"Yan","given":"Min"},{"family":"Li","given":"Chen"},{"family":"Zhu","given":"Zhenggang"},{"family":"Liu","given":"Bingya"}],"issued":{"date-parts":[["2014"]]}}},{"id":253,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/XIPMB23Q"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/XIPMB23Q"],"itemData":{"id":253,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells","container-title":"Journal of Biological Chemistry","page":"24200-24212","volume":"288","issue":"33","source":"www.jbc.org","abstract":"Maternal embryonic leucine zipper kinase (MELK) belongs to the subfamily of AMP-activated Ser/Thr protein kinases. The expression of MELK is very high in glioblastoma-type brain tumors, but it is not clear how this contributes to tumor growth. Here we show that the siRNA-mediated loss of MELK in U87 MG glioblastoma cells causes a G1/S phase cell cycle arrest accompanied by cell death or a senescence-like phenotype that can be rescued by the expression of siRNA-resistant MELK. This cell cycle arrest is mediated by an increased expression of p21WAF1/CIP1, an inhibitor of cyclin-dependent kinases, and is associated with the hypophosphorylation of the retinoblastoma protein and the down-regulation of E2F target genes. The increased expression of p21 can be explained by the consecutive activation of ATM (ataxia telangiectasia mutated), Chk2, and p53. Intriguingly, the activation of p53 in MELK-deficient cells is not due to an increased stability of p53 but stems from the loss of MDMX (mouse double minute-X), an inhibitor of p53 transactivation. The activation of the ATM-Chk2 pathway in MELK-deficient cells is associated with the accumulation of DNA double-strand breaks during replication, as demonstrated by the appearance of γH2AX foci. Replication stress in these cells is also illustrated by an increased number of stalled replication forks and a reduced fork progression speed. Our data indicate that glioblastoma cells have elevated MELK protein levels to better cope with replication stress during unperturbed S phase. Hence, MELK inhibitors hold great potential for the treatment of glioblastomas as such or in combination with DNA-damaging therapies.","DOI":"10.1074/jbc.M113.471433","ISSN":"0021-9258, 1083-351X","note":"PMID: 23836907","journalAbbreviation":"J. Biol. Chem.","language":"en","author":[{"family":"Kig","given":"Cenk"},{"family":"Beullens","given":"Monique"},{"family":"Beke","given":"Lijs"},{"family":"Eynde","given":"Aleyde Van"},{"family":"Linders","given":"Johannes T."},{"family":"Brehmer","given":"Dirk"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2013",8,16]]}}},{"id":257,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/N49HJAQS"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/N49HJAQS"],"itemData":{"id":257,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer","container-title":"Clinical Cancer Research","page":"clincanres.2711.2015","source":"clincancerres.aacrjournals.org","abstract":"Purpose: While effective targeted therapies exist for estrogen receptor-positive and HER2-positive breast cancer, no such effective therapies exist for triple-negative breast cancer (TNBC), thus it is clear that additional targets for radiosensitization and treatment are critically needed. Experimental Design: Expression microarrays, qRT-PCR, and western blotting were used to assess MELK RNA and protein expression levels. Clonogenic survival assays were used to quantitate the radiosensitivity of cell lines at baseline and after MELK inhibition. The effect of MELK knockdown on DNA damage repair kinetics was determined using γH2AX staining. The in vivo effect of MELK knockdown on radiosensitivity was performed using mouse xenograft models. Kaplan-Meier analysis was used to estimate local control and survival information and a Cox proportional hazards model was constructed to identify potential factors impacting local recurrence-free survival. Results: : MELK expression is significantly elevated in breast cancer tissues compared to normal tissue as well as in TNBC compared to non-TNBC. MELK RNA and protein expression is significantly correlated with radioresistance in breast cancer cell lines. Inhibition of MELK (genetically and pharmacologically) induces radiation sensitivity in vitro and significantly delayed tumor growth in vivo in multiple models. Kaplan-Meier survival and multivariable analyses identify increasing MELK expression as being the strongest predictor of radioresistance and increased local recurrence in multiple independent datasets. Conclusions: Here, we identify MELK as a potential biomarker of radioresistance and target for radiosensitization in TNBC. Our results support the rationale for developing clinical strategies to inhibit MELK as a novel target in TNBC.","DOI":"10.1158/1078-0432.CCR-15-2711","ISSN":"1078-0432, 1557-3265","note":"PMID: 27225691","journalAbbreviation":"Clin Cancer Res","language":"en","author":[{"family":"Speers","given":"Corey"},{"family":"Zhao","given":"Shuang G."},{"family":"Kothari","given":"Vishal"},{"family":"Santola","given":"Alyssa"},{"family":"Liu","given":"Meilan"},{"family":"Wilder-Romans","given":"Kari"},{"family":"Evans","given":"Joseph R."},{"family":"Batra","given":"Nidhi"},{"family":"Bartelink","given":"Harry"},{"family":"Hayes","given":"Daniel F."},{"family":"Lawrence","given":"Theodore S."},{"family":"Brown","given":"Powel H."},{"family":"Pierce","given":"Lori J."},{"family":"Feng","given":"Felix Y."}],"issued":{"date-parts":[["2016",1,1]]}}},{"id":261,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZP8MMW8X"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZP8MMW8X"],"itemData":{"id":261,"type":"article-journal","title":"Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia","container-title":"Oncotarget","page":"12371-12382","volume":"5","issue":"23","source":"PubMed","abstract":"Maternal embryonic leucine-zipper kinase (MELK), which was reported to be frequently up-regulated in various types of solid cancer, plays critical roles in formation and maintenance of cancer stem cells. However, little is known about the relevance of this kinase in hematologic malignancies. Here we report characterization of possible roles of MELK in acute myeloid leukemia (AML). MELK is expressed in AML cell lines and AML blasts with higher levels in less differentiated cells. MELK is frequently upregulated in AML with complex karyotypes and is associated with worse clinical outcome. MELK knockdown resulted in growth inhibition and apoptosis of leukemic cells. Hence, we investigated the potent anti-leukemia activity of OTS167, a small molecule MELK kinase inhibitor, in AML, and found that the compound induced cell differentiation and apoptosis as well as decreased migration of AML cells. MELK expression was positively correlated with the expression of FOXM1 as well as its downstream target genes. Furthermore, MELK inhibition resulted in downregulation of FOXM1 activity and the expression of its downstream targets. Taken together, and given that OTS167 is undergoing a phase I clinical trial in solid cancer, our study warrants clinical evaluation of this compound as a novel targeted therapy for AML patients.","DOI":"10.18632/oncotarget.2642","ISSN":"1949-2553","note":"PMID: 25365263\nPMCID: PMC4323011","journalAbbreviation":"Oncotarget","language":"eng","author":[{"family":"Alachkar","given":"Houda"},{"family":"Mutonga","given":"Martin B. G."},{"family":"Metzeler","given":"Klaus H."},{"family":"Fulton","given":"Noreen"},{"family":"Malnassy","given":"Gregory"},{"family":"Herold","given":"Tobias"},{"family":"Spiekermann","given":"Karsten"},{"family":"Bohlander","given":"Stefan K."},{"family":"Hiddemann","given":"Wolfgang"},{"family":"Matsuo","given":"Yo"},{"family":"Stock","given":"Wendy"},{"family":"Nakamura","given":"Yusuke"}],"issued":{"date-parts":[["2014",12,15]]}}},{"id":263,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/9J5KWJUC"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/9J5KWJUC"],"itemData":{"id":263,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas","container-title":"International Journal of Cancer","page":"807-815","volume":"122","issue":"4","source":"Wiley Online Library","abstract":"We have performed cDNA microarray analyses to identify gene expression differences between highly invasive glioblastoma multiforme (GBM) and typically benign pilocytic astrocytomas (PA). Despite the significant clinical and pathological differences between the 2 tumor types, only 63 genes were found to exhibit 2-fold or greater overexpression in GBM as compared to PA. Forty percent of these genes are related to the regulation of the cell cycle and mitosis. QT-PCR validation of 6 overexpressed genes: MELK, AUKB, ASPM, PRC1, IL13RA2 and KIAA0101 confirmed at least a 5-fold increase in the average expression levels in GBM. Maternal embryonic leucine zipper kinase (MELK) exhibited the most statistically significant difference. A more detailed investigation of MELK expression was undertaken to study its oncogenic relevance. In the examination of more than 100 tumors of the central nervous system, we found progressively higher expression of MELK with astrocytoma grade and a noteworthy uniformity of high level expression in GBM. Similar level of overexpression was also observed in medulloblastoma. We found neither gene promoter hypomethylation nor amplification to be a factor in MELK expression, but were able to demonstrate that MELK knockdown in malignant astrocytoma cell lines caused a reduction in proliferation and anchorage-independent growth in in vitro assays. Our results indicate that GBM and PA differ by the expression of surprisingly few genes. Among them, MELK correlated with malignancy grade in astrocytomas and represents a therapeutic target for the management of the most frequent brain tumors in adult and children. © 2007 Wiley-Liss, Inc.","DOI":"10.1002/ijc.23189","ISSN":"1097-0215","journalAbbreviation":"Int. J. Cancer","language":"en","author":[{"family":"Marie","given":"Suely K.N."},{"family":"Okamoto","given":"Oswaldo K."},{"family":"Uno","given":"Miyuki"},{"family":"Hasegawa","given":"Ana Paula G."},{"family":"Oba-Shinjo","given":"Sueli M."},{"family":"Cohen","given":"Tzeela"},{"family":"Camargo","given":"Anamaria A."},{"family":"Kosoy","given":"Ana"},{"family":"Carlotti","given":"Carlos G."},{"family":"Toledo","given":"Silvia"},{"family":"Moreira-Filho","given":"Carlos A."},{"family":"Zago","given":"Marco A."},{"family":"Simpson","given":"Andrew J."},{"family":"Caballero","given":"Otavia L."}],"issued":{"date-parts":[["2008",2,15]]}}},{"id":266,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/5AQGH7AQ"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/5AQGH7AQ"],"itemData":{"id":266,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells","container-title":"Journal of Neuroscience Research","page":"48-60","volume":"86","issue":"1","source":"PubMed","abstract":"Emerging evidence suggests that neural stem cells and brain tumors regulate their proliferation via similar pathways. In a previous study, we demonstrated that maternal embryonic leucine zipper kinase (Melk) is highly expressed in murine neural stem cells and regulates their proliferation. Here we describe how MELK expression is correlated with pathologic grade of brain tumors, and its expression levels are significantly correlated with shorter survival, particularly in younger glioblastoma patients. In normal human astrocytes, MELK is only faintly expressed, and MELK knockdown does not significantly influence their growth, whereas Ras and Akt overexpressing astrocytes have up-regulated MELK expression, and the effect of MELK knockdown is more prominent in these transformed astrocytes. In primary cultures from human glioblastoma and medulloblastoma, MELK knockdown by siRNA results in inhibition of the proliferation and survival of these tumors. Furthermore, we show that MELK siRNA dramatically inhibits proliferation and, to some extent, survival of stem cells isolated from glioblastoma in vitro. These results demonstrate a critical role for MELK in the proliferation of brain tumors, including their stem cells, and suggest that MELK may be a compelling molecular target for treatment of high-grade brain tumors.","DOI":"10.1002/jnr.21471","ISSN":"0360-4012","note":"PMID: 17722061","journalAbbreviation":"J. Neurosci. Res.","language":"eng","author":[{"family":"Nakano","given":"Ichiro"},{"family":"Masterman-Smith","given":"Michael"},{"family":"Saigusa","given":"Kuniyasu"},{"family":"Paucar","given":"Andres A."},{"family":"Horvath","given":"Steve"},{"family":"Shoemaker","given":"Lorelei"},{"family":"Watanabe","given":"Momoko"},{"family":"Negro","given":"Alejandra"},{"family":"Bajpai","given":"Ruchi"},{"family":"Howes","given":"Amy"},{"family":"Lelievre","given":"Vincent"},{"family":"Waschek","given":"James A."},{"family":"Lazareff","given":"Jorge A."},{"family":"Freije","given":"William A."},{"family":"Liau","given":"Linda M."},{"family":"Gilbertson","given":"Richard J."},{"family":"Cloughesy","given":"Timothy F."},{"family":"Geschwind","given":"Daniel H."},{"family":"Nelson","given":"Stanley F."},{"family":"Mischel","given":"Paul S."},{"family":"Terskikh","given":"Alexey V."},{"family":"Kornblum","given":"Harley I."}],"issued":{"date-parts":[["2008",1]]}}},{"id":268,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/C8GQ4ERE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/C8GQ4ERE"],"itemData":{"id":268,"type":"article-journal","title":"MELK is Upregulated and Required in Mammary Tumor Initiating Cells In Vivo","container-title":"Cancer research","page":"8863-8873","volume":"70","issue":"21","source":"PubMed Central","abstract":"Maternal Embryonic Leucine zipper Kinase (MELK) is expressed in several developing tissues, in the adult germ line, and in adult neural progenitors. MELK expression is elevated in aggressive undifferentiated tumors correlating with poor patient outcome in human breast cancer. To investigate the role of MELK in mammary tumorigenesis in vivo we used a MELK-GFP reporter mouse, which allows prospective isolation of MELK expressing cells based on GFP fluorescence. We found that in the normal mammary gland, cells expressing high levels of MELK were enriched for proliferating cells, expressing markers of mammary progenitors. The isolation of cells with high levels of MELK in mammary tumors from MMTV-Wnt1/MELK-GFP bitransgenic mice resulted in a significant enrichment of tumorsphere formation in culture and tumor initiation after transplantation into mammary fat pads of syngeneic mice. Furthermore, using lentiviral delivery of MELK-specific shRNA and limiting dilution cell transplantations we demonstrated that MELK function is required for mammary tumorigenesis in vivo. Our findings identify MELK as potential target in breast tumor initiating cells.","DOI":"10.1158/0008-5472.CAN-10-1295","ISSN":"0008-5472","note":"PMID: 20861186\nPMCID: PMC3990264","journalAbbreviation":"Cancer Res","author":[{"family":"Hebbard","given":"Lionel"},{"family":"Maurer","given":"Jochen"},{"family":"Miller","given":"Amber"},{"family":"Lesperance","given":"Jacqueline"},{"family":"Hassell","given":"John"},{"family":"Oshima","given":"Robert G."},{"family":"Terskikh","given":"Alexey"}],"issued":{"date-parts":[["2010",11,1]]}}},{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}},{"id":419,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/F8XIDEB9"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/F8XIDEB9"],"itemData":{"id":419,"type":"article-journal","title":"Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression","container-title":"Biochemical and Biophysical Research Communications","page":"207-213","volume":"412","issue":"2","source":"ScienceDirect","abstract":"It was reported that the local recurrence would be caused by cancer stem cells acquiring chemo- and radio-resistance. Recently, one of the potential therapeutic targets for colorectal and other cancers has been identified, which is maternal embryonic leucine zipper kinase (MELK). MELK is known as an embryonic and neural stem cell marker, and associated with the cell survival, cell proliferation, and apoptosis. In this study, SNU-503, which is a rectal cancer cell line, was treated with radiation or 5-fluorouracil (5-FU), and elevation of the MELK expression level was observed. Furthermore, the cell line was pre-treated with small interfering RNA (siRNA) against MELK mRNA before treatment of radiation or 5-FU and its effects on cell cycle and proliferation were observed. We demonstrated that knockdown of MELK reduced the proliferation of cells with radiation or 5-FU treatment. In addition, MELK suppression caused changes in cell cycle. In conclusion, MELK could be associated with increased resistance of colorectal cancer cells against radiation and 5-FU.","DOI":"10.1016/j.bbrc.2011.07.060","ISSN":"0006-291X","journalAbbreviation":"Biochemical and Biophysical Research Communications","author":[{"family":"Choi","given":"Seungho"},{"family":"Ku","given":"Ja-Lok"}],"issued":{"date-parts":[["2011",8,26]]}}},{"id":422,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/DVGI7JRE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/DVGI7JRE"],"itemData":{"id":422,"type":"article-journal","title":"MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence","container-title":"Cancer Letters","page":"85-93","volume":"383","issue":"1","source":"ScienceDirect","abstract":"Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Many kinases have been found to be intimately involved in oncogenesis and the deregulation of kinase function has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. Previously, we have performed gene expression profile analysis on HCC samples and have identified a host of kinases that are remarkably overexpressed in HCC. Among these, the Maternal Embryonic Leucine Zipper Kinase (MELK) is highly overexpressed in HCC and its overexpression strongly correlates with early recurrence and poor patients' survival. Silencing MELK inhibited cell growth, invasion, stemness and tumorigenicity of HCC cells by inducing apoptosis and mitosis. We further showed that the overexpression of MELK in HCC samples strongly correlated with the cell cycle- and mitosis-related genes which are directly regulated as part of the forkhead transcription factor FoxM1-related cell division program. Together, our data establish MELK as an oncogenic kinase involved in the pathogenesis and recurrence of HCC and could provide a promising molecular target to develop therapeutic strategies for patients with advanced HCC.","DOI":"10.1016/j.canlet.2016.09.017","ISSN":"0304-3835","journalAbbreviation":"Cancer Letters","author":[{"family":"Xia","given":"Hongping"},{"family":"Kong","given":"Shik Nie"},{"family":"Chen","given":"Jianxiang"},{"family":"Shi","given":"Ming"},{"family":"Sekar","given":"Karthik"},{"family":"Seshachalam","given":"Veerabrahma Pratap"},{"family":"Rajasekaran","given":"Muthukumar"},{"family":"Goh","given":"Brian Kim Poh"},{"family":"Ooi","given":"London Lucien"},{"family":"Hui","given":"Kam M."}],"issued":{"date-parts":[["2016",12,1]]}}},{"id":425,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VW683SG8"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VW683SG8"],"itemData":{"id":425,"type":"article-journal","title":"Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner","container-title":"Stem Cells (Dayton, Ohio)","page":"870-881","volume":"31","issue":"5","source":"PubMed","abstract":"Accumulated evidence suggests that glioma stem cells (GSCs) may contribute to therapy resistance in high-grade glioma (HGG). Although recent studies have shown that the serine/threonine kinase maternal embryonic leucine-zipper kinase (MELK) is abundantly expressed in various cancers, the function and mechanism of MELK remain elusive. Here, we demonstrate that MELK depletion by shRNA diminishes the growth of GSC-derived mouse intracranial tumors in vivo, induces glial fibrillary acidic protein (+) glial differentiation of GSCs leading to decreased malignancy of the resulting tumors, and prolongs survival periods of tumor-bearing mice. Tissue microarray analysis with 91 HGG tumors demonstrates that the proportion of MELK (+) cells is a statistically significant indicator of postsurgical survival periods. Mechanistically, MELK is regulated by the c-Jun NH(2)-terminal kinase (JNK) signaling and forms a complex with the oncoprotein c-JUN in GSCs but not in normal progenitors. MELK silencing induces p53 expression, whereas p53 inhibition induces MELK expression, indicating that MELK and p53 expression are mutually exclusive. Additionally, MELK silencing-mediated GSC apoptosis is partially rescued by both pharmacological p53 inhibition and p53 gene silencing, indicating that MELK action in GSCs is p53 dependent. Furthermore, irradiation of GSCs markedly elevates MELK mRNA and protein expression both in vitro and in vivo. Clinically, recurrent HGG tumors following the failure of radiation and chemotherapy exhibit a statistically significant elevation of MELK protein compared with untreated newly diagnosed HGG tumors. Together, our data indicate that GSCs, but not normal cells, depend on JNK-driven MELK/c-JUN signaling to regulate their survival, maintain GSCs in an immature state, and facilitate tumor radioresistance in a p53-dependent manner.","DOI":"10.1002/stem.1322","ISSN":"1549-4918","note":"PMID: 23339114\nPMCID: PMC4132653","journalAbbreviation":"Stem Cells","language":"eng","author":[{"family":"Gu","given":"Chunyu"},{"family":"Banasavadi-Siddegowda","given":"Yeshavanth K."},{"family":"Joshi","given":"Kaushal"},{"family":"Nakamura","given":"Yuko"},{"family":"Kurt","given":"Habibe"},{"family":"Gupta","given":"Snehalata"},{"family":"Nakano","given":"Ichiro"}],"issued":{"date-parts":[["2013",5]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A" w:rsidRPr="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/></w:rPr><w:t>(14–27)</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00AC4036"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00BD7BBA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">However, several discrepancies exist in the literature on MELK.  For instance, </w:t></w:r><w:r w:rsidR="00A0113D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">various </w:t></w:r><w:r w:rsidR="00580FED"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">publications </w:t></w:r><w:r w:rsidR="00A0113D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">disagree over the cell cycle stage affected by MELK inhibition </w:t></w:r><w:r w:rsidR="00580FED"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00A0113D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"HmyEpKSo","properties":{"formattedCitation":"(17, 18, 20, 24, 28)","plainCitation":"(17, 18, 20, 24, 28)"},"citationItems":[{"id":261,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZP8MMW8X"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZP8MMW8X"],"itemData":{"id":261,"type":"article-journal","title":"Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia","container-title":"Oncotarget","page":"12371-12382","volume":"5","issue":"23","source":"PubMed","abstract":"Maternal embryonic leucine-zipper kinase (MELK), which was reported to be frequently up-regulated in various types of solid cancer, plays critical roles in formation and maintenance of cancer stem cells. However, little is known about the relevance of this kinase in hematologic malignancies. Here we report characterization of possible roles of MELK in acute myeloid leukemia (AML). MELK is expressed in AML cell lines and AML blasts with higher levels in less differentiated cells. MELK is frequently upregulated in AML with complex karyotypes and is associated with worse clinical outcome. MELK knockdown resulted in growth inhibition and apoptosis of leukemic cells. Hence, we investigated the potent anti-leukemia activity of OTS167, a small molecule MELK kinase inhibitor, in AML, and found that the compound induced cell differentiation and apoptosis as well as decreased migration of AML cells. MELK expression was positively correlated with the expression of FOXM1 as well as its downstream target genes. Furthermore, MELK inhibition resulted in downregulation of FOXM1 activity and the expression of its downstream targets. Taken together, and given that OTS167 is undergoing a phase I clinical trial in solid cancer, our study warrants clinical evaluation of this compound as a novel targeted therapy for AML patients.","DOI":"10.18632/oncotarget.2642","ISSN":"1949-2553","note":"PMID: 25365263\nPMCID: PMC4323011","journalAbbreviation":"Oncotarget","language":"eng","author":[{"family":"Alachkar","given":"Houda"},{"family":"Mutonga","given":"Martin B. G."},{"family":"Metzeler","given":"Klaus H."},{"family":"Fulton","given":"Noreen"},{"family":"Malnassy","given":"Gregory"},{"family":"Herold","given":"Tobias"},{"family":"Spiekermann","given":"Karsten"},{"family":"Bohlander","given":"Stefan K."},{"family":"Hiddemann","given":"Wolfgang"},{"family":"Matsuo","given":"Yo"},{"family":"Stock","given":"Wendy"},{"family":"Nakamura","given":"Yusuke"}],"issued":{"date-parts":[["2014",12,15]]}}},{"id":127,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZUNBM3JA"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZUNBM3JA"],"itemData":{"id":127,"type":"article-journal","title":"MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells","container-title":"Bioscience Reports","volume":"35","issue":"6","source":"PubMed Central","abstract":"Protein kinase MELK has oncogenic properties and is highly overexpressed in some tumors. In the present study, we show that a novel MELK inhibitor causes both the inhibition and degradation of MELK, culminating in replication stress and a senescence phenotype., Maternal embryonic leucine zipper kinase (MELK), a serine/threonine protein kinase, has oncogenic properties and is overexpressed in many cancer cells. The oncogenic function of MELK is attributed to its capacity to disable critical cell-cycle checkpoints and reduce replication stress. Most functional studies have relied on the use of siRNA/shRNA-mediated gene silencing. In the present study, we have explored the biological function of MELK using MELK-T1, a novel and selective small-molecule inhibitor. Strikingly, MELK-T1 triggered a rapid and proteasome-dependent degradation of the MELK protein. Treatment of MCF-7 (Michigan Cancer Foundation-7) breast adenocarcinoma cells with MELK-T1 induced the accumulation of stalled replication forks and double-strand breaks that culminated in a replicative senescence phenotype. This phenotype correlated with a rapid and long-lasting ataxia telangiectasia-mutated (ATM) activation and phosphorylation of checkpoint kinase 2 (CHK2). Furthermore, MELK-T1 induced a strong phosphorylation of p53 (cellular tumour antigen p53), a prolonged up-regulation of p21 (cyclin-dependent kinase inhibitor 1) and a down-regulation of FOXM1 (Forkhead Box M1) target genes. Our data indicate that MELK is a key stimulator of proliferation by its ability to increase the threshold for DNA-damage tolerance (DDT). Thus, targeting MELK by the inhibition of both its catalytic activity and its protein stability might sensitize tumours to DNA-damaging agents or radiation therapy by lowering the DNA-damage threshold.","URL":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643329/","DOI":"10.1042/BSR20150194","ISSN":"0144-8463","note":"PMID: 26431963\nPMCID: PMC4643329","journalAbbreviation":"Biosci Rep","author":[{"family":"Beke","given":"Lijs"},{"family":"Kig","given":"Cenk"},{"family":"Linders","given":"Joannes T. M."},{"family":"Boens","given":"Shannah"},{"family":"Boeckx","given":"An"},{"family":"Heerde","given":"Erika","non-dropping-particle":"van"},{"family":"Parade","given":"Marc"},{"family":"De Bondt","given":"An"},{"family":"Van den Wyngaert","given":"Ilse"},{"family":"Bashir","given":"Tarig"},{"family":"Ogata","given":"Souichi"},{"family":"Meerpoel","given":"Lieven"},{"family":"Van Eynde","given":"Aleyde"},{"family":"Johnson","given":"Christopher N."},{"family":"Beullens","given":"Monique"},{"family":"Brehmer","given":"Dirk"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2015",11,13]]},"accessed":{"date-parts":[["2016",10,4]]}},"locator":"1"},{"id":249,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VGT75BTE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VGT75BTE"],"itemData":{"id":249,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway","container-title":"Molecular Cancer","page":"100","volume":"13","source":"BioMed Central","abstract":"Elevated MELK expression is featured in multiple tumors and correlated with tumorigenesis and tumor development. This study is aimed to investigate the mechanisms of MELK-mediated development of gastric cancer.","DOI":"10.1186/1476-4598-13-100","ISSN":"1476-4598","journalAbbreviation":"Molecular Cancer","author":[{"family":"Du","given":"Tao"},{"family":"Qu","given":"Ying"},{"family":"Li","given":"Jianfang"},{"family":"Li","given":"Hao"},{"family":"Su","given":"Liping"},{"family":"Zhou","given":"Quan"},{"family":"Yan","given":"Min"},{"family":"Li","given":"Chen"},{"family":"Zhu","given":"Zhenggang"},{"family":"Liu","given":"Bingya"}],"issued":{"date-parts":[["2014"]]}}},{"id":253,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/XIPMB23Q"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/XIPMB23Q"],"itemData":{"id":253,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells","container-title":"Journal of Biological Chemistry","page":"24200-24212","volume":"288","issue":"33","source":"www.jbc.org","abstract":"Maternal embryonic leucine zipper kinase (MELK) belongs to the subfamily of AMP-activated Ser/Thr protein kinases. The expression of MELK is very high in glioblastoma-type brain tumors, but it is not clear how this contributes to tumor growth. Here we show that the siRNA-mediated loss of MELK in U87 MG glioblastoma cells causes a G1/S phase cell cycle arrest accompanied by cell death or a senescence-like phenotype that can be rescued by the expression of siRNA-resistant MELK. This cell cycle arrest is mediated by an increased expression of p21WAF1/CIP1, an inhibitor of cyclin-dependent kinases, and is associated with the hypophosphorylation of the retinoblastoma protein and the down-regulation of E2F target genes. The increased expression of p21 can be explained by the consecutive activation of ATM (ataxia telangiectasia mutated), Chk2, and p53. Intriguingly, the activation of p53 in MELK-deficient cells is not due to an increased stability of p53 but stems from the loss of MDMX (mouse double minute-X), an inhibitor of p53 transactivation. The activation of the ATM-Chk2 pathway in MELK-deficient cells is associated with the accumulation of DNA double-strand breaks during replication, as demonstrated by the appearance of γH2AX foci. Replication stress in these cells is also illustrated by an increased number of stalled replication forks and a reduced fork progression speed. Our data indicate that glioblastoma cells have elevated MELK protein levels to better cope with replication stress during unperturbed S phase. Hence, MELK inhibitors hold great potential for the treatment of glioblastomas as such or in combination with DNA-damaging therapies.","DOI":"10.1074/jbc.M113.471433","ISSN":"0021-9258, 1083-351X","note":"PMID: 23836907","journalAbbreviation":"J. Biol. Chem.","language":"en","author":[{"family":"Kig","given":"Cenk"},{"family":"Beullens","given":"Monique"},{"family":"Beke","given":"Lijs"},{"family":"Eynde","given":"Aleyde Van"},{"family":"Linders","given":"Johannes T."},{"family":"Brehmer","given":"Dirk"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2013",8,16]]}}},{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00580FED"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00A0113D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(17, 18, 20, 24, 28)</w:t></w:r><w:r w:rsidR="00580FED"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00BD7BBA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="00314D91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>while other publications disagree over whether receptor-positive breast cancer cell lin</w:t></w:r><w:r w:rsidR="00177847"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">es are </w:t></w:r><w:r w:rsidR="00262E14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>se</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">nsitive </w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"v5ZPoWfr","properties":{"formattedCitation":"(15, 28, 32)","plainCitation":"(15, 28, 32)"},"citationItems":[{"id":370,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/93IT23E3"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/93IT23E3"],"itemData":{"id":370,"type":"article-journal","title":"Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer","container-title":"Oncotarget","page":"1629-1640","volume":"3","issue":"12","source":"www.impactjournals.com","abstract":"//     Suyoun Chung 1 , Hanae Suzuki 2 , Takashi Miyamoto 2 , Naofumi Takamatsu 2 , Ayako Tatsuguchi 3 , Koji Ueda 3 , Kyoko Kijima 2 , Yusuke Nakamura 1,4  and Yo Matsuo 2     1  Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA    2  OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan    3  Laboratory for Biomarker Development, RIKEN, Yokohama, Japan    4  Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan   Correspondence:   Yusuke Nakamura, email:         //      Yo Matsuo, email:         //       Keywords : oncogene, drug discovery, kinase inhibitor, cancer stem cell    Received : December 05, 2012,  Accepted : December 20, 2012,  Published : December 21, 2012    Abstract   We previously reported MELK (maternal embryonic leucine zipper kinase) as a novel therapeutic target for breast cancer. MELK was also reported to be highly upregulated in multiple types of human cancer. It was implied to play indispensable roles in cancer cell survival and indicated its involvement in the maintenance of tumor-initiating cells. We conducted a high-throughput screening of a compound library followed by structure-activity relationship studies, and successfully obtained a highly potent MELK inhibitor OTSSP167 with IC 50  of 0.41 nM. OTSSP167 inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like), which we identified as novel MELK substrates and are important for stem-cell characteristics and invasiveness. The compound suppressed mammosphere formation of breast cancer cells and exhibited significant tumor growth suppression in xenograft studies using breast, lung, prostate, and pancreas cancer cell lines in mice by both intravenous and oral administration. This MELK inhibitor should be a promising compound possibly to suppress the growth of tumor-initiating cells and be applied for treatment of a wide range of human cancer.","ISSN":"1949-2553","author":[{"family":"Chung","given":"Suyoun"},{"family":"Suzuki","given":"Hanae"},{"family":"Miyamoto","given":"Takashi"},{"family":"Takamatsu","given":"Naofumi"},{"family":"Tatsuguchi","given":"Ayako"},{"family":"Ueda","given":"Koji"},{"family":"Kijima","given":"Kyoko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Matsuo","given":"Yo"},{"family":"Chung","given":"Suyoun"},{"family":"Suzuki","given":"Hanae"},{"family":"Miyamoto","given":"Takashi"},{"family":"Takamatsu","given":"Naofumi"},{"family":"Tatsuguchi","given":"Ayako"},{"family":"Ueda","given":"Koji"},{"family":"Kijima","given":"Kyoko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Matsuo","given":"Yo"}],"issued":{"date-parts":[["2012",12,21]]}}},{"id":148,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/3I8BINHZ"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/3I8BINHZ"],"itemData":{"id":148,"type":"article-journal","title":"Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family","container-title":"Breast Cancer Research","page":"R17","volume":"9","source":"BioMed Central","abstract":"Cancer therapies directed at specific molecular targets in signaling pathways of cancer cells, such as tamoxifen, aromatase inhibitors and trastuzumab, have proven useful for treatment of advanced breast cancers. However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects. These side effects as well as drug resistance make it necessary to search for novel molecular targets for drugs on the basis of well-characterized mechanisms of action.","DOI":"10.1186/bcr1650","ISSN":"1465-542X","journalAbbreviation":"Breast Cancer Research","author":[{"family":"Lin","given":"Meng-Lay"},{"family":"Park","given":"Jae-Hyun"},{"family":"Nishidate","given":"Toshihiko"},{"family":"Nakamura","given":"Yusuke"},{"family":"Katagiri","given":"Toyomasa"}],"issued":{"date-parts":[["2007"]]}}},{"id":127,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZUNBM3JA"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZUNBM3JA"],"itemData":{"id":127,"type":"article-journal","title":"MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells","container-title":"Bioscience Reports","volume":"35","issue":"6","source":"PubMed Central","abstract":"Protein kinase MELK has oncogenic properties and is highly overexpressed in some tumors. In the present study, we show that a novel MELK inhibitor causes both the inhibition and degradation of MELK, culminating in replication stress and a senescence phenotype., Maternal embryonic leucine zipper kinase (MELK), a serine/threonine protein kinase, has oncogenic properties and is overexpressed in many cancer cells. The oncogenic function of MELK is attributed to its capacity to disable critical cell-cycle checkpoints and reduce replication stress. Most functional studies have relied on the use of siRNA/shRNA-mediated gene silencing. In the present study, we have explored the biological function of MELK using MELK-T1, a novel and selective small-molecule inhibitor. Strikingly, MELK-T1 triggered a rapid and proteasome-dependent degradation of the MELK protein. Treatment of MCF-7 (Michigan Cancer Foundation-7) breast adenocarcinoma cells with MELK-T1 induced the accumulation of stalled replication forks and double-strand breaks that culminated in a replicative senescence phenotype. This phenotype correlated with a rapid and long-lasting ataxia telangiectasia-mutated (ATM) activation and phosphorylation of checkpoint kinase 2 (CHK2). Furthermore, MELK-T1 induced a strong phosphorylation of p53 (cellular tumour antigen p53), a prolonged up-regulation of p21 (cyclin-dependent kinase inhibitor 1) and a down-regulation of FOXM1 (Forkhead Box M1) target genes. Our data indicate that MELK is a key stimulator of proliferation by its ability to increase the threshold for DNA-damage tolerance (DDT). Thus, targeting MELK by the inhibition of both its catalytic activity and its protein stability might sensitize tumours to DNA-damaging agents or radiation therapy by lowering the DNA-damage threshold.","URL":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643329/","DOI":"10.1042/BSR20150194","ISSN":"0144-8463","note":"PMID: 26431963\nPMCID: PMC4643329","journalAbbreviation":"Biosci Rep","author":[{"family":"Beke","given":"Lijs"},{"family":"Kig","given":"Cenk"},{"family":"Linders","given":"Joannes T. M."},{"family":"Boens","given":"Shannah"},{"family":"Boeckx","given":"An"},{"family":"Heerde","given":"Erika","non-dropping-particle":"van"},{"family":"Parade","given":"Marc"},{"family":"De Bondt","given":"An"},{"family":"Van den Wyngaert","given":"Ilse"},{"family":"Bashir","given":"Tarig"},{"family":"Ogata","given":"Souichi"},{"family":"Meerpoel","given":"Lieven"},{"family":"Van Eynde","given":"Aleyde"},{"family":"Johnson","given":"Christopher N."},{"family":"Beullens","given":"Monique"},{"family":"Brehmer","given":"Dirk"},{"family":"Bollen","given":"Mathieu"}],"issued":{"date-parts":[["2015",11,13]]},"accessed":{"date-parts":[["2016",10,4]]}},"locator":"1"}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(15, 28, 32)</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or resistant </w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"vmod973ev","properties":{"formattedCitation":"(24)","plainCitation":"(24)"},"citationItems":[{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(24)</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00262E14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to</w:t></w:r><w:r w:rsidR="00314D91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK </w:t></w:r><w:r w:rsidR="00262E14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>inhibition</w:t></w:r><w:r w:rsidR="00314D91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="005A5AB8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">To </w:t></w:r><w:r w:rsidR="00AE1F5E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>unambiguously determine the effects of MELK loss in cancer cell lines, we applied CRISPR/Cas9 to generate frameshift mutations in the MELK coding sequence.  We</w:t></w:r><w:r w:rsidR="009E0235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00FD6235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>designed 7 guide RNA</w:t></w:r><w:r w:rsidR="00884EF2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00FD6235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (gRNA</w:t></w:r><w:r w:rsidR="00884EF2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00FD6235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) against MELK, 5 of which targe</w:t></w:r><w:r w:rsidR="00566E39"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">t the N-terminal kinase domain </w:t></w:r><w:r w:rsidR="00FD6235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and 2 of which target the C-terminal kinase-associated domain</w:t></w:r><w:r w:rsidR="00A40B4E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure </w:t></w:r><w:r w:rsidR="00C62B47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1A</w:t></w:r><w:r w:rsidR="00BE4A73"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 1</w:t></w:r><w:r w:rsidR="00A40B4E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00FD6235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="007B2642"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00FE5C40"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F355F1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Then, </w:t></w:r><w:r w:rsidR="009A2AD9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we </w:t></w:r><w:r w:rsidR="00450EB3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cloned</w:t></w:r><w:r w:rsidR="00CC1658"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> each guide RNA in</w:t></w:r><w:r w:rsidR="00450EB3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>to</w:t></w:r><w:r w:rsidR="00CC1658"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> a GFP-expressing vector</w:t></w:r><w:r w:rsidR="00F355F1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00450EB3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and transduced the guides </w:t></w:r><w:r w:rsidR="00285D62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">into </w:t></w:r><w:r w:rsidR="00F87AEF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>three</w:t></w:r><w:r w:rsidR="00223620"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Cas9-expressing</w:t></w:r><w:r w:rsidR="007F1533"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell lines</w:t></w:r><w:r w:rsidR="00285D62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>: the triple-ne</w:t></w:r><w:r w:rsidR="005362EB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>gative breast cancer cell line</w:t></w:r><w:r w:rsidR="009E0235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="005362EB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00285D62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cal51</w:t></w:r><w:r w:rsidR="00F87AEF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and MDA-MB-231</w:t></w:r><w:r w:rsidR="00A41D0E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, reported</w:t></w:r><w:r w:rsidR="008E6E11"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to be addicted to MELK expression</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"5tb5h43m5","properties":{"formattedCitation":"(24)","plainCitation":"(24)"},"citationItems":[{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(24)</w:t></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="008E6E11"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and t</w:t></w:r><w:r w:rsidR="00504310"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">he melanoma cell line A375, from a cancer type that over-expresses MELK </w:t></w:r><w:r w:rsidR="00504310"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"18bbl8euco","properties":{"formattedCitation":"(14, 34)","plainCitation":"(14, 34)"},"citationItems":[{"id":380,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/9F9HA2S9"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/9F9HA2S9"],"itemData":{"id":380,"type":"article-journal","title":"Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression","container-title":"PLoS ONE","volume":"2","issue":"7","source":"PubMed Central","abstract":"Background\nGene expression profiling has revolutionized our ability to molecularly classify primary human tumors and significantly enhanced the development of novel tumor markers and therapies; however, progress in the diagnosis and treatment of melanoma over the past 3 decades has been limited, and there is currently no approved therapy that significantly extends lifespan in patients with advanced disease. Profiling studies of melanoma to date have been inconsistent due to the heterogeneous nature of this malignancy and the limited availability of informative tissue specimens from early stages of disease.\n\nMethodology/Principle Findings\nIn order to gain an improved understanding of the molecular basis of melanoma progression, we have compared gene expression profiles from a series of melanoma cell lines representing discrete stages of malignant progression that recapitulate critical characteristics of the primary lesions from which they were derived. Here we describe the unsupervised hierarchical clustering of profiling data from melanoma cell lines and melanocytes. This clustering identifies two distinctive molecular subclasses of melanoma segregating aggressive metastatic tumor cell lines from less-aggressive primary tumor cell lines. Further analysis of expression signatures associated with melanoma progression using functional annotations categorized these transcripts into three classes of genes: 1) Upregulation of activators of cell cycle progression, DNA replication and repair (CDCA2, NCAPH, NCAPG, NCAPG2, PBK, NUSAP1, BIRC5, ESCO2, HELLS, MELK, GINS1, GINS4, RAD54L, TYMS, and DHFR), 2) Loss of genes associated with cellular adhesion and melanocyte differentiation (CDH3, CDH1, c-KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R, and OCA2), 3) Upregulation of genes associated with resistance to apoptosis (BIRC5/survivin). While these broad classes of transcripts have previously been implicated in the progression of melanoma and other malignancies, the specific genes identified within each class of transcripts are novel. In addition, the transcription factor NF-KB was specifically identified as being a potential “master regulator” of melanoma invasion since NF-KB binding sites were identified as consistent consensus sequences within promoters of progression-associated genes.\n\nConclusions/Significance\nWe conclude that tumor cell lines are a valuable resource for the early identification of gene signatures associated with malignant progression in tumors with significant heterogeneity like melanoma. We further conclude that the development of novel data reduction algorithms for analysis of microarray studies is critical to allow for optimized mining of important, clinically-relevant datasets. It is expected that subsequent validation studies in primary human tissues using such an approach will lead to more rapid translation of such studies to the identification of novel tumor biomarkers and therapeutic targets.","URL":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895889/","DOI":"10.1371/journal.pone.0000594","ISSN":"1932-6203","note":"PMID: 17611626\nPMCID: PMC1895889","journalAbbreviation":"PLoS ONE","author":[{"family":"Ryu","given":"Byungwoo"},{"family":"Kim","given":"Dave S."},{"family":"DeLuca","given":"Amena M."},{"family":"Alani","given":"Rhoda M."}],"issued":{"date-parts":[["2007",7,4]]},"accessed":{"date-parts":[["2016",10,24]]}}},{"id":130,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TXXN6U2K"],"itemData":{"id":130,"type":"article-journal","title":"Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers","container-title":"Cancer Research","page":"9751-9761","volume":"65","issue":"21","source":"cancerres.aacrjournals.org","abstract":"To identify genes that could serve as targets for novel cancer therapeutics, we used a bioinformatic analysis of microarray data comparing gene expression between normal and tumor-derived primary human tissues. From this approach, we have found that maternal embryonic leucine zipper kinase (Melk), a member of the AMP serine/threonine kinase family, exhibits multiple features consistent with the potential utility of this gene as an anticancer target. An oligonucleotide microarray analysis of multiple human tumor samples and cell lines suggests that Melk expression is frequently elevated in cancer relative to normal tissues, a pattern confirmed by quantitative reverse transcription-PCR and Western blotting of selected primary tumor samples. In situ hybridization localized Melk expression to malignant epithelial cells in 96%, 23%, and 13% of colorectal, lung, and ovarian tissue tumor samples, respectively. Expression of this gene is also elevated in spontaneous tumors derived from the ApcMin and Apc1638N murine models of intestinal tumorigenesis. To begin addressing whether Melk is relevant for tumorigenesis, RNA interference–mediated silencing within human and murine tumor cell lines was done. We show that Melk knockdown decreases proliferation and anchorage-independent growth in vitro as well as tumor growth in a xenograft model. Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial.","DOI":"10.1158/0008-5472.CAN-04-4531","ISSN":"0008-5472, 1538-7445","note":"PMID: 16266996","journalAbbreviation":"Cancer Res","language":"en","author":[{"family":"Gray","given":"Daniel"},{"family":"Jubb","given":"Adrian M."},{"family":"Hogue","given":"Deborah"},{"family":"Dowd","given":"Patrick"},{"family":"Kljavin","given":"Noelyn"},{"family":"Yi","given":"Sothy"},{"family":"Bai","given":"Wei"},{"family":"Frantz","given":"Gretchen"},{"family":"Zhang","given":"Zemin"},{"family":"Koeppen","given":"Hartmut"},{"family":"Sauvage","given":"Frederic J.","dropping-particle":"de"},{"family":"Davis","given":"David P."}],"issued":{"date-parts":[["2005",11,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00504310"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(14, 34)</w:t></w:r><w:r w:rsidR="00504310"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00285D62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00523DB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  As negative controls in </w:t></w:r><w:r w:rsidR="00147456"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>these</w:t></w:r><w:r w:rsidR="00523DB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> assay</w:t></w:r><w:r w:rsidR="00147456"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00523DB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, we also cloned and transduced three gRNA’</w:t></w:r><w:r w:rsidR="004D0E8B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s that target the non-essentia</w:t></w:r><w:r w:rsidR="006922F6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>l and</w:t></w:r><w:r w:rsidR="004D0E8B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00523DB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>non-coding Rosa26 locus</w:t></w:r><w:r w:rsidR="00110085"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (</w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 1</w:t></w:r><w:r w:rsidR="00110085"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00523DB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00285D62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="76AB0C59" w14:textId="37A6BB51" w:rsidR="00341D5F" w:rsidRDefault="009037D4" w:rsidP="00047CE4"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00C15243"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>To assess the efficacy of our</w:t></w:r><w:r w:rsidR="00F45823"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> CRISPR </w:t></w:r><w:r w:rsidR="00D6761C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>system</w:t></w:r><w:r w:rsidR="00725CBC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, we</w:t></w:r><w:r w:rsidR="00FD0BE9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A91385"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">purified </w:t></w:r><w:r w:rsidR="00A11CE0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">GFP+ populations from </w:t></w:r><w:r w:rsidR="00A91385"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell line</w:t></w:r><w:r w:rsidR="00A11CE0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00A91385"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> harboring each individual guide RNA, and then we </w:t></w:r><w:r w:rsidR="003B0A77"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">analyzed the targeted loci by Sanger sequencing.  </w:t></w:r><w:r w:rsidR="00115CBD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">TIDE </w:t></w:r><w:r w:rsidR="004D0E8B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>analysis</w:t></w:r><w:r w:rsidR="007154E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, which </w:t></w:r><w:r w:rsidR="00CE2062"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">decomposes </w:t></w:r><w:r w:rsidR="00B920B1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">raw </w:t></w:r><w:r w:rsidR="00CE2062"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">sequencing </w:t></w:r><w:r w:rsidR="00136E74"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>traces</w:t></w:r><w:r w:rsidR="00CE2062"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> into</w:t></w:r><w:r w:rsidR="007A66DC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00BB3F6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">linear </w:t></w:r><w:r w:rsidR="00461CEE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>combinations of in</w:t></w:r><w:r w:rsidR="00E24D9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>del mutations</w:t></w:r><w:r w:rsidR="00690468"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00690468"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1c4mok8ol0","properties":{"formattedCitation":"(35)","plainCitation":"(35)"},"citationItems":[{"id":152,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/H5NWVFJS"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/H5NWVFJS"],"itemData":{"id":152,"type":"article-journal","title":"Easy quantitative assessment of genome editing by sequence trace decomposition","container-title":"Nucleic Acids Research","page":"e168-e168","volume":"42","issue":"22","source":"nar.oxfordjournals.org","abstract":"The efficacy and the mutation spectrum of genome editing methods can vary substantially depending on the targeted sequence. A simple, quick assay to accurately characterize and quantify the induced mutations is therefore needed. Here we present TIDE, a method for this purpose that requires only a pair of PCR reactions and two standard capillary sequencing runs. The sequence traces are then analyzed by a specially developed decomposition algorithm that identifies the major induced mutations in the projected editing site and accurately determines their frequency in a cell population. This method is cost-effective and quick, and it provides much more detailed information than current enzyme-based assays. An interactive web tool for automated decomposition of the sequence traces is available. TIDE greatly facilitates the testing and rational design of genome editing strategies.","DOI":"10.1093/nar/gku936","ISSN":"0305-1048, 1362-4962","note":"PMID: 25300484","journalAbbreviation":"Nucl. Acids Res.","language":"en","author":[{"family":"Brinkman","given":"Eva K."},{"family":"Chen","given":"Tao"},{"family":"Amendola","given":"Mario"},{"family":"van Steensel","given":"Bas"}],"issued":{"date-parts":[["2014",12,16]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00690468"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(35)</w:t></w:r><w:r w:rsidR="00690468"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00E24D9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="00B17785"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>revealed</w:t></w:r><w:r w:rsidR="00690468"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> high cutting efficiency</w:t></w:r><w:r w:rsidR="00B4436A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> at most </w:t></w:r><w:r w:rsidR="00B17785"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">targeted loci </w:t></w:r><w:r w:rsidR="00C2756C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(Figure </w:t></w:r><w:r w:rsidR="00C62B47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">1B and </w:t></w:r><w:r w:rsidR="00AA1065"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 1-figure supplements 1-3</w:t></w:r><w:r w:rsidR="00C62B47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00C2756C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00B17785"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Across the </w:t></w:r><w:r w:rsidR="00F87AEF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>21</w:t></w:r><w:r w:rsidR="00B17785"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> samples, the median</w:t></w:r><w:r w:rsidR="00D66F8D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> level of indel formation was 80</w:t></w:r><w:r w:rsidR="00010C7E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>%</w:t></w:r><w:r w:rsidR="00B17785"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00295654"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  These values </w:t></w:r><w:r w:rsidR="00CF62E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>likely</w:t></w:r><w:r w:rsidR="00295654"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> underestimate the true mutation frequency, as TIDE analysis is not able to detect missense </w:t></w:r><w:r w:rsidR="00461CEE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>mutations</w:t></w:r><w:r w:rsidR="00295654"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008B29A5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and</w:t></w:r><w:r w:rsidR="00461CEE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> large indels </w:t></w:r><w:r w:rsidR="001B6D33"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>will</w:t></w:r><w:r w:rsidR="00295654"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> not be efficiently amplified by PCR.</w:t></w:r><w:r w:rsidR="00047CE4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="0004623D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Western blot analysis of </w:t></w:r><w:r w:rsidR="00391F4C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK </w:t></w:r><w:r w:rsidR="001051EF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>protein</w:t></w:r><w:r w:rsidR="00391F4C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> levels </w:t></w:r><w:r w:rsidR="00EA44EC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in A375, Cal51, and </w:t></w:r><w:r w:rsidR="0004623D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MDA-MB-231</w:t></w:r><w:r w:rsidR="00EA44EC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> sorted populations</w:t></w:r><w:r w:rsidR="0004623D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> further confirmed that our </w:t></w:r><w:r w:rsidR="00CF62E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>CRISPR system</w:t></w:r><w:r w:rsidR="0004623D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> effectively ablated MELK expression</w:t></w:r><w:r w:rsidR="009E0235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure </w:t></w:r><w:r w:rsidR="00C62B47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1C</w:t></w:r><w:r w:rsidR="004C2E90"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and Figure 1-figure supplement 4</w:t></w:r><w:r w:rsidR="009E0235"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="0004623D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r></w:p><w:p w14:paraId="1D425875" w14:textId="326E8178" w:rsidR="00A953B4" w:rsidRDefault="00926ABB" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We next set out to </w:t></w:r><w:r w:rsidR="00535AF2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>determine</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> whether MELK </w:t></w:r><w:r w:rsidR="00B33EE7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>was required for cancer cell fitness</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="008E17BA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  To test this, we measured cell proliferation </w:t></w:r><w:r w:rsidR="00C62C18"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">over 15 days in culture in the </w:t></w:r><w:r w:rsidR="00F87AEF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">30 independent lines of A375, </w:t></w:r><w:r w:rsidR="008E17BA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cal51</w:t></w:r><w:r w:rsidR="00F87AEF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and MDA-MB-231</w:t></w:r><w:r w:rsidR="008E17BA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that </w:t></w:r><w:r w:rsidR="00EB3259"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>we had generated</w:t></w:r><w:r w:rsidR="00C62B47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 1D-F</w:t></w:r><w:r w:rsidR="00BE4A73"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="008E17BA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00C90273"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="008A27F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Surprisingly, w</w:t></w:r><w:r w:rsidR="00DF025B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>e failed to detect any difference in proliferative capacity between the cell lines with wild-type or mutant MELK</w:t></w:r><w:r w:rsidR="00BE4A73"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="00F140F6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00ED7A9C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>For instance, in</w:t></w:r><w:r w:rsidR="003B37DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the </w:t></w:r><w:r w:rsidR="00F87AEF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>A375</w:t></w:r><w:r w:rsidR="003B37DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell line, we calculated a mean doubling time of 16.9 hours among cells transduced with Rosa26 guide RNAs, while the cell lines transduced with MELK gRNAs exhibited a mean doubling time of 16.8 hours.  </w:t></w:r><w:r w:rsidR="0094027E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK gRNA-transduced cell lines also exhibited wild-type levels of growth under anchorage-independent conditions (Figure </w:t></w:r><w:r w:rsidR="00C62B47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1G-I</w:t></w:r><w:r w:rsidR="0094027E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">).  </w:t></w:r><w:r w:rsidR="00E15E9E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">These results call into question the </w:t></w:r><w:r w:rsidR="00DE0928"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>notion</w:t></w:r><w:r w:rsidR="00E15E9E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> th</w:t></w:r><w:r w:rsidR="007955A2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>at MELK is a genetic dependency</w:t></w:r><w:r w:rsidR="00E15E9E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> either across cancer types or in triple-negative breast cancers.  </w:t></w:r><w:r w:rsidR="00DF025B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="003717DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008E17BA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="154837E1" w14:textId="77777777" w:rsidR="00A953B4" w:rsidRDefault="00A953B4" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="437950BD" w14:textId="505B6CC4" w:rsidR="008B67B6" w:rsidRDefault="008B67B6" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK is not a </w:t></w:r><w:r w:rsidR="00F60497"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">common </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancer cell dependency</w:t></w:r></w:p><w:p w14:paraId="392A3C6F" w14:textId="7154BAFE" w:rsidR="00F37EFB" w:rsidRDefault="00BF22D4" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">In order to assess whether a wider range of cancer cell lines were dependent on MELK for </w:t></w:r><w:r w:rsidR="00D824FC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>viability</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="001A356E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we </w:t></w:r><w:r w:rsidR="0037012D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">performed </w:t></w:r><w:r w:rsidR="003717DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">individual </w:t></w:r><w:r w:rsidR="0037012D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>GFP dropout experiments in 1</w:t></w:r><w:r w:rsidR="008A27F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>3</w:t></w:r><w:r w:rsidR="001F6C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Cas9-expressing</w:t></w:r><w:r w:rsidR="0037012D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer cell lines</w:t></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"11fpiggons","properties":{"formattedCitation":"(36)","plainCitation":"(36)"},"citationItems":[{"id":62,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ZBX5RPB9"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ZBX5RPB9"],"itemData":{"id":62,"type":"article-journal","title":"Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains","container-title":"Nature Biotechnology","page":"661-667","volume":"33","issue":"6","source":"www.n</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial" w:hint="eastAsia"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText>ature.com","abstract":"CRISPR-Cas9 genome editing technology holds great promise for discovering therapeutic targets in cancer and other diseases. Current screening strategies target CRISPR-Cas9</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial" w:hint="eastAsia"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText>–</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial" w:hint="eastAsia"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText>induced mutations to the 5</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial" w:hint="eastAsia"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText>′</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial" w:hint="eastAsia"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> exons of candidate genes, but th</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve">is approach often produces in-frame variants that retain functionality, which can obscure even strong genetic dependencies. Here we overcome this limitation by targeting CRISPR-Cas9 mutagenesis to exons encoding functional protein domains. This generates a higher proportion of null mutations and substantially increases the potency of negative selection. We also show that the magnitude of negative selection can be used to infer the functional importance of individual protein domains of interest. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia cells identifies six known drug targets and 19 additional dependencies. A broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting.","DOI":"10.1038/nbt.3235","ISSN":"1087-0156","journalAbbreviation":"Nat Biotech","language":"en","author":[{"family":"Shi","given":"Junwei"},{"family":"Wang","given":"Eric"},{"family":"Milazzo","given":"Joseph P."},{"family":"Wang","given":"Zihua"},{"family":"Kinney","given":"Justin B."},{"family":"Vakoc","given":"Christopher R."}],"issued":{"date-parts":[["2015",6]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(36)</w:t></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="001D7835"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="005D469F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="003E0E37"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">In these assays, </w:t></w:r><w:r w:rsidR="00036986"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancer cells are transduced with GFP-expressing guide RNA vectors at low MOI to create mixed populations of GFP+ and GFP- cells</w:t></w:r><w:r w:rsidR="006C1CC8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="001B42BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00036986"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">A guide RNA that induces mutations in a gene required for cancer cell fitness will drop out from the population, resulting in a </w:t></w:r><w:r w:rsidR="001A559D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>decreasing</w:t></w:r><w:r w:rsidR="00FF4381"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> ratio of GFP+ to </w:t></w:r><w:r w:rsidR="00036986"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">GFP- cells over </w:t></w:r><w:r w:rsidR="001A559D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>time.</w:t></w:r><w:r w:rsidR="00036986"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00F37EFB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Additionally, </w:t></w:r><w:r w:rsidR="00E4606C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we considered it possible that cells had adapted to MELK loss during the time required to sort and expand pure GFP+ cell populations to perform the </w:t></w:r><w:r w:rsidR="00CA25CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>experiments</w:t></w:r><w:r w:rsidR="00E4606C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00B273FF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>described</w:t></w:r><w:r w:rsidR="00E4606C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in Figure 1.  </w:t></w:r><w:r w:rsidR="00113ACE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>For</w:t></w:r><w:r w:rsidR="00F53724"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00B8114E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">the </w:t></w:r><w:r w:rsidR="00AE2524"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">following </w:t></w:r><w:r w:rsidR="00F53724"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>dropout assay</w:t></w:r><w:r w:rsidR="00113ACE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00F53724"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="00F37EFB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00CA25CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>we monitor</w:t></w:r><w:r w:rsidR="00B8114E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ed</w:t></w:r><w:r w:rsidR="00CA25CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> GFP levels </w:t></w:r><w:r w:rsidR="00984DFA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>directly</w:t></w:r><w:r w:rsidR="00F53724"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> following</w:t></w:r><w:r w:rsidR="00CA25CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> introdu</w:t></w:r><w:r w:rsidR="008805B8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ction of the gRNA virus</w:t></w:r><w:r w:rsidR="00CA25CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="00B8114E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> without </w:t></w:r><w:r w:rsidR="000B2DD1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>sorting or expanding cell populations</w:t></w:r><w:r w:rsidR="00B8114E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="00CA25CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008805B8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>potentially allowing us to detect</w:t></w:r><w:r w:rsidR="00113ACE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> a transient</w:t></w:r><w:r w:rsidR="00984DFA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or immediate</w:t></w:r><w:r w:rsidR="00B8114E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00DB634F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>effect of</w:t></w:r><w:r w:rsidR="00B8114E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00113ACE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK mutagenesis</w:t></w:r><w:r w:rsidR="00DB634F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> on cell fitness</w:t></w:r><w:r w:rsidR="00113ACE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r></w:p><w:p w14:paraId="7B94C5DB" w14:textId="5A3B13E9" w:rsidR="00883CD5" w:rsidRDefault="008357BE" w:rsidP="00F37EFB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>As negative controls in this experiment, we utilized three gRNA’s targeting Rosa26, and as positi</w:t></w:r><w:r w:rsidR="0052276F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ve controls </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we designed six gRNA’s targeting the </w:t></w:r><w:r w:rsidR="00A91417"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">essential </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>replication genes RPA3 and PCNA</w:t></w:r><w:r w:rsidR="0083280C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (</w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Supplementary File </w:t></w:r><w:r w:rsidR="0083280C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1)</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="0052276F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  We first transduced these gRNA’s</w:t></w:r><w:r w:rsidR="005450C2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> individually</w:t></w:r><w:r w:rsidR="0052276F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> into 7 triple-negative breast cancer cell lines (Cal51, HCC1143, HCC1937, HCC70, MDA-MB-231, MDA-MB-453, and MDA-MB-468).</w:t></w:r><w:r w:rsidR="00E776D5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Over the course of 5 passages in culture, gRNA’s </w:t></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">targeting Rosa26 </w:t></w:r><w:r w:rsidR="0071341B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">typically </w:t></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>depl</w:t></w:r><w:r w:rsidR="00743409"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">eted 1.2 to </w:t></w:r><w:r w:rsidR="0057788B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>2</w:t></w:r><w:r w:rsidR="00E776D5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-fold</w:t></w:r><w:r w:rsidR="001E7A08"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 2A</w:t></w:r><w:r w:rsidR="0083280C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00E776D5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  This </w:t></w:r><w:r w:rsidR="00B77F7F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">low </w:t></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>level of depletion may result from off-target mutagenesis</w:t></w:r><w:r w:rsidR="00DE0928"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">or from </w:t></w:r><w:r w:rsidR="00046652"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell cycle arrest caused by</w:t></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> repeated DN</w:t></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">A breaks </w:t></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"36c137mhb","properties":{"formattedCitation":"(37)","plainCitation":"(37)"},"citationItems":[{"id":274,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/92XDG8Q4"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/92XDG8Q4"],"itemData":{"id":274,"type":"article-journal","title":"Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting","container-title":"Cancer Discovery","page":"CD-16-0154","source":"cancerdiscovery.aacrjournals.org","abstract":"The CRISPR-Cas9 system enables genome editing and somatic cell genetic screens in mammalian cells. We performed genome scale loss-of-function screens in 33 cancer cell lines to identify genes essential for proliferation/survival and found a strong correlation between increased gene copy number and decreased cell viability after genome editing. Within regions of copy number gain, CRISPR-Cas9 targeting of both expressed and unexpressed genes, as well as intergenic loci, led to significantly decreased cell proliferation through induction of a G2 cell cycle arrest. By examining single guide RNAs that map to multiple genomic sites, we found that this cell response to CRISPR-Cas9 editing correlated strongly with the number of target loci. These observations indicate that genome targeting by CRISPR-Cas9 elicits a gene-independent anti-proliferative cell response. This effect has important practical implications for interpretation of CRISPR-Cas9 screening data and confounds the use of this technology for identification of essential genes in amplified regions.","DOI":"10.1158/2159-8290.CD-16-0154","ISSN":"2159-8274, 2159-8290","note":"PMID: 27260156","journalAbbreviation":"Cancer Discov","language":"en","author":[{"family":"Aguirre","given":"Andrew J."},{"family":"Meyers","given":"Robin M."},{"family":"Weir","given":"Barbara A."},{"family":"Vazquez","given":"Francisca"},{"family":"Zhang","given":"Cheng-Zhong"},{"family":"Ben-David","given":"Uri"},{"family":"Cook","given":"April"},{"family":"Ha","given":"Gavin"},{"family":"Harrington","given":"William F."},{"family":"Doshi","given":"Mihir B."},{"family":"Kost-Alimova","given":"Maria"},{"family":"Gill","given":"Stanley"},{"family":"Xu","given":"Han"},{"family":"Ali","given":"Levi D."},{"family":"Jiang","given":"Guozhi"},{"family":"Pantel","given":"Sasha"},{"family":"Lee","given":"Yenarae"},{"family":"Goodale","given":"Amy"},{"family":"Cherniack","given":"Andrew D."},{"family":"Oh","given":"Coyin"},{"family":"Kryukov","given":"Gregory"},{"family":"Cowley","given":"Glenn S."},{"family":"Garraway","given":"Levi A."},{"family":"Stegmaier","given":"Kimberly"},{"family":"Roberts","given":"Charles W."},{"family":"Golub","given":"Todd R."},{"family":"Meyerson","given":"Matthew"},{"family":"Root","given":"David E."},{"family":"Tsherniak","given":"Aviad"},{"family":"Hahn","given":"William C."}],"issued":{"date-parts":[["2016",1,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(37)</w:t></w:r><w:r w:rsidR="00100E2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00F01312"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="005A0B06"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Over the same period of time,</w:t></w:r><w:r w:rsidR="00CB0E58"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> gRNA’s targeting RPA3 and PCNA depleted </w:t></w:r><w:r w:rsidR="008523B4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>5-fold to 100-fold.</w:t></w:r><w:r w:rsidR="007479BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="001373DA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">These positive control guides exhibited varying degrees of dropout </w:t></w:r><w:r w:rsidR="00C30D98"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(</w:t></w:r><w:r w:rsidR="001373DA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>e.g., compare RPA3 g1 and RPA3 g2)</w:t></w:r><w:r w:rsidR="00F814F4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, which may result from </w:t></w:r><w:r w:rsidR="005C5325"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>variability</w:t></w:r><w:r w:rsidR="00F814F4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00C30D98"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in </w:t></w:r><w:r w:rsidR="00F814F4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cutting efficiency or from </w:t></w:r><w:r w:rsidR="00C30D98"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">functionally-important differences in the </w:t></w:r><w:r w:rsidR="00C2404B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">protein </w:t></w:r><w:r w:rsidR="0031406B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>domain</w:t></w:r><w:r w:rsidR="00765C64"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00C2404B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> targeted by </w:t></w:r><w:r w:rsidR="00765C64"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>these</w:t></w:r><w:r w:rsidR="00C2404B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> guides</w:t></w:r><w:r w:rsidR="001373DA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  However, i</w:t></w:r><w:r w:rsidR="007479BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">n every cell line tested, every </w:t></w:r><w:r w:rsidR="00FC287D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">single </w:t></w:r><w:r w:rsidR="007479BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">gRNA targeting RPA3 or PCNA dropped out to a greater </w:t></w:r><w:r w:rsidR="00716234"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">degree than every </w:t></w:r><w:r w:rsidR="00676271"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">single </w:t></w:r><w:r w:rsidR="00716234"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Rosa26 guide.  </w:t></w:r><w:r w:rsidR="00F83C6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">In </w:t></w:r><w:r w:rsidR="00EE22D0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">contrast to RPA3 and PCNA, </w:t></w:r><w:r w:rsidR="00F83C6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the 7 guides that targeted MELK</w:t></w:r><w:r w:rsidR="008E1250"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00DD7467"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">typically depleted less than </w:t></w:r><w:r w:rsidR="009F4077"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>2</w:t></w:r><w:r w:rsidR="008E1250"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-fold.</w:t></w:r><w:r w:rsidR="008E6FEC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00CB1BB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Across 7 different gRNAs </w:t></w:r><w:r w:rsidR="003E2501"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>tested in</w:t></w:r><w:r w:rsidR="00CB1BB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 7 different cell lines, we never observed a MELK guide deplete more than 2.5-fold.  </w:t></w:r><w:r w:rsidR="008E6FEC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">In 6 of the 7 cell lines, </w:t></w:r><w:r w:rsidR="00D03911"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>a</w:t></w:r><w:r w:rsidR="0025649F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Rosa26 gRNA exhibited a </w:t></w:r><w:r w:rsidR="009B3652"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>higher level of depletion than every</w:t></w:r><w:r w:rsidR="0025649F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="000D4368"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">single </w:t></w:r><w:r w:rsidR="0025649F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK gRNA</w:t></w:r><w:r w:rsidR="0083280C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (</w:t></w:r><w:r w:rsidR="001E7A08"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 2</w:t></w:r><w:r w:rsidR="0083280C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>B)</w:t></w:r><w:r w:rsidR="0025649F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="00075A1E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="009F4088"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>We conclude that the</w:t></w:r><w:r w:rsidR="00323EAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>se 7</w:t></w:r><w:r w:rsidR="009F4088"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> triple-negative breast cancer cell lines </w:t></w:r><w:r w:rsidR="00E07D92"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">are not dependent on MELK </w:t></w:r><w:r w:rsidR="005C5325"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">for cell </w:t></w:r><w:r w:rsidR="00032C3C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>fitness</w:t></w:r><w:r w:rsidR="00B66435"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="004B02ED"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="1B686DA0" w14:textId="6DDDE124" w:rsidR="00B32BD7" w:rsidRDefault="00883CD5" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/><w:t xml:space="preserve">To extend these </w:t></w:r><w:r w:rsidR="00720359"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">observations, we repeated </w:t></w:r><w:r w:rsidR="00077B99"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the GFP dropout</w:t></w:r><w:r w:rsidR="00720359"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> experiments in </w:t></w:r><w:r w:rsidR="005700A6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>6</w:t></w:r><w:r w:rsidR="00075A1E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="001F68B9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cas9-</w:t></w:r><w:r w:rsidR="009711C6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>expressing</w:t></w:r><w:r w:rsidR="00720359"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell lines</w:t></w:r><w:r w:rsidR="001905CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (A375, Cama1, HCT116, NCI-H1299, T24, </w:t></w:r><w:r w:rsidR="005D6CB8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and </w:t></w:r><w:r w:rsidR="001905CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>U118-MG)</w:t></w:r><w:r w:rsidR="00720359"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> from</w:t></w:r><w:r w:rsidR="001F68B9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> other cancer types</w:t></w:r><w:r w:rsidR="00165841"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> previously suggested to </w:t></w:r><w:r w:rsidR="00F66014"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">require </w:t></w:r><w:r w:rsidR="00165841"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK expression.</w:t></w:r><w:r w:rsidR="00061082"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00165841"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00905143"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Consistent with our observations</w:t></w:r><w:r w:rsidR="0086053F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in the triple-negative breast cancer cell</w:t></w:r><w:r w:rsidR="00BA4F32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00F15802"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="006D429A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">guides targeting Rosa26 exhibited minimal dropout over 5 passages, while guides targeting RPA3 or PCNA were depleted up to </w:t></w:r><w:r w:rsidR="00D04941"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>90</w:t></w:r><w:r w:rsidR="006D429A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-fold</w:t></w:r><w:r w:rsidR="00511A3C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure </w:t></w:r><w:r w:rsidR="00AA1065"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>2-figure supplement 1</w:t></w:r><w:r w:rsidR="00511A3C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="006D429A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="009578D3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">However, </w:t></w:r><w:r w:rsidR="00ED0739"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>0 of the 7 MELK guides exhibited significant dropout in any of the cell lines tested</w:t></w:r><w:r w:rsidR="004B4162"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (maximum dropout: 1.8</w:t></w:r><w:r w:rsidR="006135BA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-fold)</w:t></w:r><w:r w:rsidR="00ED0739"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00DD7467"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Again, guides targeting Rosa26 exhibited an equivalent or occasionally greater degree of depletion than guides targeting MELK</w:t></w:r><w:r w:rsidR="003E6496"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 2-figure supplement 1B</w:t></w:r><w:r w:rsidR="000163B0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00DD7467"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00ED0739"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00B32BD7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>In total, this data suggests that MELK is not a common cancer dependency.</w:t></w:r></w:p><w:p w14:paraId="5B848B91" w14:textId="77777777" w:rsidR="009D0513" w:rsidRDefault="009D0513" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="06EB1996" w14:textId="04415627" w:rsidR="009D0513" w:rsidRDefault="009D0513" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Unbiased RNAi and CRISPR screens fail to identify MELK as a cancer dependency</w:t></w:r></w:p><w:p w14:paraId="1DC7FCA6" w14:textId="3EC7077A" w:rsidR="007D1764" w:rsidRPr="007D1764" w:rsidRDefault="007D1764" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="008F33AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Several </w:t></w:r><w:r w:rsidR="00CC3C0A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">laboratories have conducted </w:t></w:r><w:r w:rsidR="008F33AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">genome-wide or kinase-focused screens to identify novel cancer </w:t></w:r><w:r w:rsidR="008B2E26"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>addictions</w:t></w:r><w:r w:rsidR="008F33AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="004827A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  If these </w:t></w:r><w:r w:rsidR="00581453"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>unbiased</w:t></w:r><w:r w:rsidR="004827A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> screens </w:t></w:r><w:r w:rsidR="00D22141"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>indicated</w:t></w:r><w:r w:rsidR="004827A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00E55C41"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>that</w:t></w:r><w:r w:rsidR="004827A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer cell lines required MELK expression to proliferate, then that would bolster the </w:t></w:r><w:r w:rsidR="004D22D5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>contention that MELK could be a</w:t></w:r><w:r w:rsidR="00861C7B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> therapeutic target in cancer</w:t></w:r><w:r w:rsidR="004827A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00935F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  We therefore examined data from </w:t></w:r><w:r w:rsidR="007546EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>four</w:t></w:r><w:r w:rsidR="00935F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> recent screens: a kinome-wide siRNA s</w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">creen in 117 cancer cell lines </w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2862m4hcir","properties":{"formattedCitation":"(38)","plainCitation":"(38)"},"citationItems":[{"id":278,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/7HS8TASR"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/7HS8TASR"],"itemData":{"id":278,"type":"article-journal","title":"Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines","container-title":"Cell Reports","page":"2490-2501","volume":"14","issue":"10","source":"ScienceDirect","abstract":"Summary\nOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase genetic dependencies in 117 cancer cell lines from ten cancer types. By integrating the siRNA screen data with molecular profiling data, including exome sequencing data, we show how vulnerabilities/genetic dependencies that are associated with mutations in specific cancer driver genes can be identified. By integrating additional data sets into this analysis, including protein-protein interaction data, we also demonstrate that the genetic dependencies associated with many cancer driver genes form dense connections on functional interaction networks. We demonstrate the utility of this resource by using it to predict the drug sensitivity of genetically or histologically defined subsets of tumor cell lines, including an increased sensitivity of osteosarcoma cell lines to FGFR inhibitors and SMAD4 mutant tumor cells to mitotic inhibitors.","DOI":"10.1016/j.celrep.2016.02.023","ISSN":"2211-1247","journalAbbreviation":"Cell Reports","author":[{"family":"Campbell","given":"James"},{"family":"Ryan","given":"Colm J."},{"family":"Brough","given":"Rachel"},{"family":"Bajrami","given":"Ilirjana"},{"family":"Pemberton","given":"Helen N."},{"family":"Chong","given":"Irene Y."},{"family":"Costa-Cabral","given":"Sara"},{"family":"Frankum","given":"Jessica"},{"family":"Gulati","given":"Aditi"},{"family":"Holme","given":"Harriet"},{"family":"Miller","given":"Rowan"},{"family":"Postel-Vinay","given":"Sophie"},{"family":"Rafiq","given":"Rumana"},{"family":"Wei","given":"Wenbin"},{"family":"Williamson","given":"Chris T."},{"family":"Quigley","given":"David A."},{"family":"Tym","given":"Joe"},{"family":"Al-Lazikani","given":"Bissan"},{"family":"Fenton","given":"Timothy"},{"family":"Natrajan","given":"Rachael"},{"family":"Strauss","given":"Sandra J."},{"family":"Ashworth","given":"Alan"},{"family":"Lord","given":"Christopher J."}],"issued":{"date-parts":[["2016",3,15]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(38)</w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00935F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, a genome-wide CRI</w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">SPR screen in 6 cell lines </w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1j4sjjq4cf","properties":{"formattedCitation":"(39)","plainCitation":"(39)"},"citationItems":[{"id":281,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/278T2M9U"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/278T2M9U"],"itemData":{"id":281,"type":"article-journal","title":"High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities","container-title":"Cell","page":"1515-1526","volume":"163","issue":"6","source":"www.cell.com","abstract":"The ability to perturb genes in human cells is crucial for elucidating gene function and holds great potential for finding therapeutic targets for diseases such as cancer. To extend the catalog of human core and context-dependent fitness genes, we have developed a high-complexity second-generation genome-scale CRISPR-Cas9 gRNA library and applied it to fitness screens in five human cell lines. Using an improved Bayesian analytical approach, we consistently discover 5-fold more fitness genes than were previously observed. We present a list of 1,580 human core fitness genes and describe their general properties. Moreover, we demonstrate that context-dependent fitness genes accurately recapitulate pathway-specific genetic vulnerabilities induced by known oncogenes and reveal cell-type-specific dependencies for specific receptor tyrosine kinases, even in oncogenic KRAS backgrounds. Thus, rigorous identification of human cell line fitness genes using a high-complexity CRISPR-Cas9 library affords a high-resolution view of the genetic vulnerabilities of a cell.","DOI":"10.1016/j.cell.2015.11.015","ISSN":"0092-8674, 1097-4172","note":"PMID: 26627737","journalAbbreviation":"Cell","language":"English","author":[{"family":"Hart","given":"Traver"},{"family":"Chandrashekhar","given":"Megha"},{"family":"Aregger","given":"Michael"},{"family":"Steinhart","given":"Zachary"},{"family":"Brown","given":"Kevin R."},{"family":"MacLeod","given":"Graham"},{"family":"Mis","given":"Monika"},{"family":"Zimmermann","given":"Michal"},{"family":"Fradet-Turcotte","given":"Amelie"},{"family":"Sun","given":"Song"},{"family":"Mero","given":"Patricia"},{"family":"Dirks","given":"Peter"},{"family":"Sidhu","given":"Sachdev"},{"family":"Roth","given":"Frederick P."},{"family":"Rissland","given":"Olivia S."},{"family":"Durocher","given":"Daniel"},{"family":"Angers","given":"Stephane"},{"family":"Moffat","given":"Jason"}],"issued":{"date-parts":[["2015",12,3]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(39)</w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00935F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, a genome-wide shRNA </w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">screen in 72 cancer cell lines </w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"srceb5q4o","properties":{"formattedCitation":"(40, 41)","plainCitation":"(40, 41)"},"citationItems":[{"id":288,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VDW47NXE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VDW47NXE"],"itemData":{"id":288,"type":"article-journal","title":"Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells","container-title":"Cancer Discovery","page":"172-189","volume":"2","issue":"2","source":"cancerdiscovery.aacrjournals.org","abstract":"Genomic analyses are yielding a host of new information on the multiple genetic abnormalities associated with specific types of cancer. A comprehensive description of cancer-associated genetic abnormalities can improve our ability to classify tumors into clinically relevant subgroups and, on occasion, identify mutant genes that drive the cancer phenotype (“drivers”). More often, though, the functional significance of cancer-associated mutations is difficult to discern. Genome-wide pooled short hairpin RNA (shRNA) screens enable global identification of the genes essential for cancer cell survival and proliferation, providing a “functional genomic” map of human cancer to complement genomic studies. Using a lentiviral shRNA library targeting </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Bradley Hand Bold" w:hAnsi="Bradley Hand Bold" w:cs="Bradley Hand Bold"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText>∼</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve">16,000 genes and a newly developed, dynamic scoring approach, we identified essential gene profiles in 72 breast, pancreatic, and ovarian cancer cell lines. Integrating our results with current and future genomic data should facilitate the systematic identification of drivers, unanticipated synthetic lethal relationships, and functional vulnerabilities of these tumor types.\nSignificance: This study presents a resource of genome-scale, pooled shRNA screens for 72 breast, pancreatic, and ovarian cancer cell lines that will serve as a functional complement to genomics data, facilitate construction of essential gene profiles, help uncover synthetic lethal relationships, and identify uncharacterized genetic vulnerabilities in these tumor types. Cancer Discovery; 2(2); 172–89. © 2011 AACR.\nThis article is highlighted in the In This Issue feature, p. 95.","DOI":"10.1158/2159-8290.CD-11-0224","ISSN":"2159-8274, 2159-8290","note":"PMID: 22585861","journalAbbreviation":"Cancer Discov","language":"en","author":[{"family":"Marcotte","given":"Richard"},{"family":"Brown","given":"Kevin R."},{"family":"Suarez","given":"Fernando"},{"family":"Sayad","given":"Azin"},{"family":"Karamboulas","given":"Konstantina"},{"family":"Krzyzanowski","given":"Paul M."},{"family":"Sircoulomb","given":"Fabrice"},{"family":"Medrano","given":"Mauricio"},{"family":"Fedyshyn","given":"Yaroslav"},{"family":"Koh","given":"Judice L. Y."},{"family":"Dyk","given":"Dewald","dropping-particle":"van"},{"family":"Fedyshyn","given":"Bohdana"},{"family":"Luhova","given":"Marianna"},{"family":"Brito","given":"Glauber C."},{"family":"Vizeacoumar","given":"Franco J."},{"family":"Vizeacoumar","given":"Frederick S."},{"family":"Datti","given":"Alessandro"},{"family":"Kasimer","given":"Dahlia"},{"family":"Buzina","given":"Alla"},{"family":"Mero","given":"Patricia"},{"family":"Misquitta","given":"Christine"},{"family":"Normand","given":"Josee"},{"family":"Haider","given":"Maliha"},{"family":"Ketela","given":"Troy"},{"family":"Wrana","given":"Jeffrey L."},{"family":"Rottapel","given":"Robert"},{"family":"Neel","given":"Benjamin G."},{"family":"Moffat","given":"Jason"}],"issued":{"date-parts":[["2012",2,1]]}}},{"id":285,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/WA5ZFQQP"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/WA5ZFQQP"],"itemData":{"id":285,"type":"article-journal","title":"Measuring error rates in genomic perturbation screens: gold standards for human functional genomics","container-title":"Molecular Systems Biology","page":"n/a-n/a","volume":"10","issue":"7","source":"Wiley Online Library","abstract":"Technological advancement has opened the door to systematic genetics in mammalian cells. Genome-scale loss-of-function screens can assay fitness defects induced by partial gene knockdown, using RNA interference, or complete gene knockout, using new CRISPR techniques. These screens can reveal the basic blueprint required for cellular proliferation. Moreover, comparing healthy to cancerous tissue can uncover genes that are essential only in the tumor; these genes are targets for the development of specific anticancer therapies. Unfortunately, progress in this field has been hampered by off-target effects of perturbation reagents and poorly quantified error rates in large-scale screens. To improve the quality of information derived from these screens, and to provide a framework for understanding the capabilities and limitations of CRISPR technology, we derive gold-standard reference sets of essential and nonessential genes, and provide a Bayesian classifier of gene essentiality that outperforms current methods on both RNAi and CRISPR screens. Our results indicate that CRISPR technology is more sensitive than RNAi and that both techniques have nontrivial false discovery rates that can be mitigated by rigorous analytical methods.","DOI":"10.15252/msb.20145216","ISSN":"1744-4292","shortTitle":"Measuring error rates in genomic perturbation screens","journalAbbreviation":"Mol Syst Biol","language":"en","author":[{"family":"Hart","given":"Traver"},{"family":"Brown","given":"Kevin R"},{"family":"Sircoulomb","given":"Fabrice"},{"family":"Rottapel","given":"Robert"},{"family":"Moffat","given":"Jason"}],"issued":{"date-parts":[["2014",7,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(40, 41)</w:t></w:r><w:r w:rsidR="009352E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="007546EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and a genome-wide CRISPR screen in 7 cell lines </w:t></w:r><w:r w:rsidR="007546EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2d5o8tuifp","properties":{"formattedCitation":"(42)","plainCitation":"(42)"},"citationItems":[{"id":355,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TXZAS2MW"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TXZAS2MW"],"itemData":{"id":355,"type":"article-journal","title":"A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia","container-title":"Cell Reports","page":"1193-1205","volume":"17","issue":"4","source":"www.cell.com","DOI":"10.1016/j.celrep.2016.09.079","ISSN":"2211-1247","journalAbbreviation":"Cell Reports","language":"English","author":[{"family":"Tzelepis","given":"Konstantinos"},{"family":"Koike-Yusa","given":"Hiroko"},{"family":"De Braekeleer","given":"Etienne"},{"family":"Li","given":"Yilong"},{"family":"Metzakopian","given":"Emmanouil"},{"family":"Dovey","given":"Oliver M."},{"family":"Mupo","given":"Annalisa"},{"family":"Grinkevich","given":"Vera"},{"family":"Li","given":"Meng"},{"family":"Mazan","given":"Milena"},{"family":"Gozdecka","given":"Malgorzata"},{"family":"Ohnishi","given":"Shuhei"},{"family":"Cooper","given":"Jonathan"},{"family":"Patel","given":"Miten"},{"family":"McKerrell","given":"Thomas"},{"family":"Chen","given":"Bin"},{"family":"Domingues","given":"Ana Filipa"},{"family":"Gallipoli","given":"Paolo"},{"family":"Teichmann","given":"Sarah"},{"family":"Ponstingl","given":"Hannes"},{"family":"McDermott","given":"Ultan"},{"family":"Saez-Rodriguez","given":"Julio"},{"family":"Huntly","given":"Brian J. P."},{"family":"Iorio","given":"Francesco"},{"family":"Pina","given":"Cristina"},{"family":"Vassiliou","given":"George S."},{"family":"Yusa","given":"Kosuke"}],"issued":{"date-parts":[["2016",10,18]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="007546EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(42)</w:t></w:r><w:r w:rsidR="007546EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00935F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00E579C8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="001069BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Large-scale unbiased</w:t></w:r><w:r w:rsidR="008A794C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> screens are prone to </w:t></w:r><w:r w:rsidR="001069BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">experimental artifacts, and </w:t></w:r><w:r w:rsidR="00A534CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>variations</w:t></w:r><w:r w:rsidR="001069BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in protocol, technology, or</w:t></w:r><w:r w:rsidR="008A794C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the method of </w:t></w:r><w:r w:rsidR="00086622"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>analysis</w:t></w:r><w:r w:rsidR="008A794C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> can cause different screens to </w:t></w:r><w:r w:rsidR="002C0E79"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>yield</w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> different results </w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"k4dmjju2","properties":{"formattedCitation":"(43)","plainCitation":"(43)"},"citationItems":[{"id":292,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/J59C9397"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/J59C9397"],"itemData":{"id":292,"type":"article-journal","title":"RNAi screening comes of age: improved techniques and complementary approaches","container-title":"Nature Reviews Molecular Cell Biology","page":"591-600","volume":"15","issue":"9","source":"www.nature.com","abstract":"Gene silencing through sequence-specific targeting of mRNAs by RNAi has enabled genome-wide functional screens in cultured cells and in vivo in model organisms. These screens have resulted in the identification of new cellular pathways and potential drug targets. Considerable progress has been made to improve the quality of RNAi screen data through the development of new experimental and bioinformatics approaches. The recent availability of genome-editing strategies, such as the CRISPR (clustered regularly interspaced short palindromic repeats)–Cas9 system, when combined with RNAi, could lead to further improvements in screen data quality and follow-up experiments, thus promoting our understanding of gene function and gene regulatory networks.","DOI":"10.1038/nrm3860","ISSN":"1471-0072","shortTitle":"RNAi screening comes of age","journalAbbreviation":"Nat Rev Mol Cell Biol","language":"en","author":[{"family":"Mohr","given":"Stephanie E."},{"family":"Smith","given":"Jennifer A."},{"family":"Shamu","given":"Caroline E."},{"family":"Neumüller","given":"Ralph A."},{"family":"Perrimon","given":"Norbert"}],"issued":{"date-parts":[["2014",9]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(43)</w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="008A794C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="001069BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00A637CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Nonetheless, e</w:t></w:r><w:r w:rsidR="00E579C8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ach of these screens identified </w:t></w:r><w:r w:rsidR="003057E1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>multiple</w:t></w:r><w:r w:rsidR="00E579C8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> mitotic kinases as essential</w:t></w:r><w:r w:rsidR="00A058D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A04611"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in </w:t></w:r><w:r w:rsidR="00BE68B8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>various</w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer cell lines</w:t></w:r><w:r w:rsidR="007546EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, including Aurora B, BubR1, CDK1, and Plk1</w:t></w:r><w:r w:rsidR="003A7D32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (</w:t></w:r><w:r w:rsidR="00AA1065"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 2-figure supplement 2</w:t></w:r><w:r w:rsidR="003A7D32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00A058D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="00FB15F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="0088055C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>In contrast, MELK was not iden</w:t></w:r><w:r w:rsidR="00DD7C1C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">tified as essential </w:t></w:r><w:r w:rsidR="008A3651"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>in a single experiment</w:t></w:r><w:r w:rsidR="001376B8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  These negative results include</w:t></w:r><w:r w:rsidR="00F11191"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 13 triple-negative breast cancer cell lines tested by Campbell et al. and 16 triple-negative breast cancer cell lines tested </w:t></w:r><w:r w:rsidR="0032117B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>by</w:t></w:r><w:r w:rsidR="00F11191"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the Moffatt lab</w:t></w:r><w:r w:rsidR="008A3651"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00FB15F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Several other published</w:t></w:r><w:r w:rsidR="0069367F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> pan-cancer or breast cancer-focused screens have failed to identify MELK as </w:t></w:r><w:r w:rsidR="00266CC1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">either </w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">a </w:t></w:r><w:r w:rsidR="00266CC1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">general </w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancer dependency</w:t></w:r><w:r w:rsidR="00266CC1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or a triple-negative breast cancer dependency</w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"9JpGBuo1","properties":{"formattedCitation":"{\\rtf (44\\uc0\\u8211{}46)}","plainCitation":"(44–46)"},"citationItems":[{"id":299,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/CMRSP43H"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/CMRSP43H"],"itemData":{"id":299,"type":"article-journal","title":"Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening","container-title":"Science (New York, N.Y.)","page":"617-620","volume":"319","issue":"5863","source":"PubMed Central","abstract":"By virtue of their accumulated genetic alterations, tumor cells may acquire vulnerabilities that create opportunities for therapeutic intervention. We have devised a massively parallel strategy for screening short hairpin RNA (shRNA) collections for stable loss-of-function phenotypes. We assayed from 6000 to 20,000 shRNAs simultaneously to identify genes important for the proliferation and survival of five cell lines derived from human mammary tissue. Lethal shRNAs common to these cell lines targeted many known cell-cycle regulatory networks. Cell line–specific sensitivities to suppression of protein complexes and biological pathways also emerged, and these could be validated by RNA interference (RNAi) and pharmacologically. These studies establish a practical platform for genome-scale screening of complex phenotypes in mammalian cells and demonstrate that RNAi can be used to expose genotype-specific sensitivities.","DOI":"10.1126/science.1149185","ISSN":"0036-8075","note":"PMID: 18239125\nPMCID: PMC2981861","journalAbbreviation":"Science","author":[{"family":"Silva","given":"Jose M."},{"family":"Marran","given":"Krista"},{"family":"Parker","given":"Joel S."},{"family":"Silva","given":"Javier"},{"family":"Golding","given":"Michael"},{"family":"Schlabach","given":"Michael R."},{"family":"Elledge","given":"Stephen J."},{"family":"Hannon","given":"Gregory J."},{"family":"Chang","given":"Kenneth"}],"issued":{"date-parts":[["2008",2,1]]}}},{"id":295,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/5DIRK9U6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/5DIRK9U6"],"itemData":{"id":295,"type":"article-journal","title":"Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance","container-title":"Cell","page":"293-309","volume":"164","issue":"1-2","source":"PubMed","abstract":"Large-scale genomic studies have identified multiple somatic aberrations in breast cancer, including copy number alterations and point mutations. Still, identifying causal variants and emergent vulnerabilities that arise as a consequence of genetic alterations remain major challenges. We performed whole-genome small hairpin RNA (shRNA) \"dropout screens\" on 77 breast cancer cell lines. Using a hierarchical linear regression algorithm to score our screen results and integrate them with accompanying detailed genetic and proteomic information, we identify vulnerabilities in breast cancer, including candidate \"drivers,\" and reveal general functional genomic properties of cancer cells. Comparisons of gene essentiality with drug sensitivity data suggest potential resistance mechanisms, effects of existing anti-cancer drugs, and opportunities for combination therapy. Finally, we demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer and PIK3CA mutations as a resistance determinant for BET-inhibitors.","DOI":"10.1016/j.cell.2015.11.062","ISSN":"1097-4172","note":"PMID: 26771497\nPMCID: PMC4724865","journalAbbreviation":"Cell","language":"eng","author":[{"family":"Marcotte","given":"Richard"},{"family":"Sayad","given":"Azin"},{"family":"Brown","given":"Kevin R."},{"family":"Sanchez-Garcia","given":"Felix"},{"family":"Reimand","given":"Jüri"},{"family":"Haider","given":"Maliha"},{"family":"Virtanen","given":"Carl"},{"family":"Bradner","given":"James E."},{"family":"Bader","given":"Gary D."},{"family":"Mills","given":"Gordon B."},{"family":"Pe'er","given":"Dana"},{"family":"Moffat","given":"Jason"},{"family":"Neel","given":"Benjamin G."}],"issued":{"date-parts":[["2016",1,14]]}}},{"id":297,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/85XSK77I"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/85XSK77I"],"itemData":{"id":297,"type":"article-journal","title":"Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies","container-title":"Scientific Data","page":"140035","volume":"1","source":"PubMed","abstract":"Using a genome-scale, lentivirally delivered shRNA library, we performed massively parallel pooled shRNA screens in 216 cancer cell lines to identify genes that are required for cell proliferation and/or viability. Cell line dependencies on 11,000 genes were interrogated by 5 shRNAs per gene. The proliferation effect of each shRNA in each cell line was assessed by transducing a population of 11M cells with one shRNA-virus per cell and determining the relative enrichment or depletion of each of the 54,000 shRNAs after 16 population doublings using Next Generation Sequencing. All the cell lines were screened using standardized conditions to best assess differential genetic dependencies across cell lines. When combined with genomic characterization of these cell lines, this dataset facilitates the linkage of genetic dependencies with specific cellular contexts (e.g., gene mutations or cell lineage). To enable such comparisons, we developed and provided a bioinformatics tool to identify linear and nonlinear correlations between these features.","DOI":"10.1038/sdata.2014.35","ISSN":"2052-4463","note":"PMID: 25984343\nPMCID: PMC4432652","journalAbbreviation":"Sci Data","language":"eng","author":[{"family":"Cowley","given":"Glenn S."},{"family":"Weir","given":"Barbara A."},{"family":"Vazquez","given":"Francisca"},{"family":"Tamayo","given":"Pablo"},{"family":"Scott","given":"Justine A."},{"family":"Rusin","given":"Scott"},{"family":"East-Seletsky","given":"Alexandra"},{"family":"Ali","given":"Levi D."},{"family":"Gerath","given":"William Fj"},{"family":"Pantel","given":"Sarah E."},{"family":"Lizotte","given":"Patrick H."},{"family":"Jiang","given":"Guozhi"},{"family":"Hsiao","given":"Jessica"},{"family":"Tsherniak","given":"Aviad"},{"family":"Dwinell","given":"Elizabeth"},{"family":"Aoyama","given":"Simon"},{"family":"Okamoto","given":"Michael"},{"family":"Harrington","given":"William"},{"family":"Gelfand","given":"Ellen"},{"family":"Green","given":"Thomas M."},{"family":"Tomko","given":"Mark J."},{"family":"Gopal","given":"Shuba"},{"family":"Wong","given":"Terence C."},{"family":"Wong","given":"Terrence C."},{"family":"Li","given":"Hubo"},{"family":"Howell","given":"Sara"},{"family":"Stransky","given":"Nicolas"},{"family":"Liefeld","given":"Ted"},{"family":"Jang","given":"Dongkeun"},{"family":"Bistline","given":"Jonathan"},{"family":"Hill Meyers","given":"Barbara"},{"family":"Armstrong","given":"Scott A."},{"family":"Anderson","given":"Ken C."},{"family":"Stegmaier","given":"Kimberly"},{"family":"Reich","given":"Michael"},{"family":"Pellman","given":"David"},{"family":"Boehm","given":"Jesse S."},{"family":"Mesirov","given":"Jill P."},{"family":"Golub","given":"Todd R."},{"family":"Root","given":"David E."},{"family":"Hahn","given":"William C."}],"issued":{"date-parts":[["2014"]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A" w:rsidRPr="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/></w:rPr><w:t>(44–46)</w:t></w:r><w:r w:rsidR="001F5915"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00081E77"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00C559C1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Thus, while we do not consider </w:t></w:r><w:r w:rsidR="00873D55"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>results</w:t></w:r><w:r w:rsidR="00C559C1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> from </w:t></w:r><w:r w:rsidR="00990A0C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>large-scale</w:t></w:r><w:r w:rsidR="00C559C1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> screens to be dispositive, </w:t></w:r><w:r w:rsidR="008A3661"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we believe that these </w:t></w:r><w:r w:rsidR="00C77562"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>findings</w:t></w:r><w:r w:rsidR="008A3661"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, coupled with </w:t></w:r><w:r w:rsidR="007F3DE0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">our own </w:t></w:r><w:r w:rsidR="00F75E7C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>experimental evidence</w:t></w:r><w:r w:rsidR="008A3661"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, suggest</w:t></w:r><w:r w:rsidR="005810A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that MELK </w:t></w:r><w:r w:rsidR="00051FE5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">expression </w:t></w:r><w:r w:rsidR="005810A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">is not </w:t></w:r><w:r w:rsidR="00051FE5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>required</w:t></w:r><w:r w:rsidR="005810A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> for</w:t></w:r><w:r w:rsidR="008A3661"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer cell proliferation.  </w:t></w:r><w:r w:rsidR="0069367F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00614755"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">    </w:t></w:r><w:r w:rsidR="008A3651"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="5CF6CCF3" w14:textId="77777777" w:rsidR="00B32BD7" w:rsidRDefault="00B32BD7" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="23A1FEE4" w14:textId="257F977E" w:rsidR="001E0DE1" w:rsidRDefault="00F23CAC" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">OTS167 inhibits the growth of </w:t></w:r><w:r w:rsidR="00C7187A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>receptor-positive breast cancer cell lines</w:t></w:r><w:r w:rsidR="00CB48C9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and cells that harbor mutant MELK</w:t></w:r></w:p><w:p w14:paraId="027352FD" w14:textId="11F32B11" w:rsidR="008457EB" w:rsidRDefault="001E0DE1" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00AF3CC2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">If MELK is not a cancer cell dependency, then </w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>drugs that inhibit</w:t></w:r><w:r w:rsidR="00AF3CC2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK </w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>must either</w:t></w:r><w:r w:rsidR="00667C5B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> be</w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> ineffective at </w:t></w:r><w:r w:rsidR="006E2BDF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>stopping</w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer </w:t></w:r><w:r w:rsidR="00ED5524"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cell </w:t></w:r><w:r w:rsidR="00374D15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>division</w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or they must</w:t></w:r><w:r w:rsidR="00725DA3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> also</w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00667C5B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>act on</w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00667C5B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>other cellular</w:t></w:r><w:r w:rsidR="00094D83"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> targets. </w:t></w:r><w:r w:rsidR="00E13A74"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F37365"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We </w:t></w:r><w:r w:rsidR="00E13A74"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">therefore </w:t></w:r><w:r w:rsidR="00AE3EDF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>assessed</w:t></w:r><w:r w:rsidR="00E13A74"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the efficacy of the</w:t></w:r><w:r w:rsidR="002A1121"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK inhibitor OTS167</w:t></w:r><w:r w:rsidR="00745148"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (alternately called OTSSP167)</w:t></w:r><w:r w:rsidR="002A1121"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="007E5918"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>a therapeutic agent</w:t></w:r><w:r w:rsidR="006652FB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00FF12C8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>being tested in several clinical trials.</w:t></w:r><w:r w:rsidR="002A1121"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00CA3E81"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We </w:t></w:r><w:r w:rsidR="002A56AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>treated a variety of cancer cell lines with</w:t></w:r><w:r w:rsidR="00CA3E81"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 7-point serial dilutions of </w:t></w:r><w:r w:rsidR="001C3969"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>OT</w:t></w:r><w:r w:rsidR="002A56AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>S167</w:t></w:r><w:r w:rsidR="001C3969"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and we observed that OTS167 did in fact </w:t></w:r><w:r w:rsidR="00C14E64"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>impede</w:t></w:r><w:r w:rsidR="001C3969"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell proliferation at nanomolar concentrations (mean GI50 = </w:t></w:r><w:r w:rsidR="00020AB7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>16nM</w:t></w:r><w:r w:rsidR="00F712D4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>; see below</w:t></w:r><w:r w:rsidR="001C3969"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">).  </w:t></w:r><w:r w:rsidR="00C14E64"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>As OTS167 was able to inhibit growth despite the non-essentially of MELK, we</w:t></w:r><w:r w:rsidR="00842BB1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> considered</w:t></w:r><w:r w:rsidR="00C15C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the possibility that OTS167 acted through</w:t></w:r><w:r w:rsidR="00842BB1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> an off-target </w:t></w:r><w:r w:rsidR="00D74909"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>effect</w:t></w:r><w:r w:rsidR="00842BB1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00E73B13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">To test this, we </w:t></w:r><w:r w:rsidR="00C15C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">set out to determine whether MELK expression was </w:t></w:r><w:r w:rsidR="000B7488"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">actually </w:t></w:r><w:r w:rsidR="00C15C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">required for OTS167 sensitivity.  </w:t></w:r><w:r w:rsidR="002A03A9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We </w:t></w:r><w:r w:rsidR="00E73B13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">calculated the GI50 value of OTS167 in A375, Cal51, and MDA-MB-231 cells that harbored gRNA’s </w:t></w:r><w:r w:rsidR="002A03A9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>targeting either Rosa26 or MELK, and we</w:t></w:r><w:r w:rsidR="005A4023"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> found that cell populations with wild-type or mutant MELK displayed equivalent sensitivity to </w:t></w:r><w:r w:rsidR="00667C5B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the drug</w:t></w:r><w:r w:rsidR="006F18F3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure </w:t></w:r><w:r w:rsidR="00BB5605"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>3</w:t></w:r><w:r w:rsidR="006F18F3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>).</w:t></w:r><w:r w:rsidR="007E6009"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006F18F3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00E01DFB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">For instance, </w:t></w:r><w:r w:rsidR="00DA3278"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in Cal51 cells transduced with Rosa26 gRNAs, the </w:t></w:r><w:r w:rsidR="004F250D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>GI50</w:t></w:r><w:r w:rsidR="00DA3278"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> values ranged from </w:t></w:r><w:r w:rsidR="00B56063"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>9nM</w:t></w:r><w:r w:rsidR="00DA3278"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to </w:t></w:r><w:r w:rsidR="00B56063"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>12n</w:t></w:r><w:r w:rsidR="000F0796"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>M</w:t></w:r><w:r w:rsidR="00504310"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (mean: 10nM)</w:t></w:r><w:r w:rsidR="00DA3278"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, while in Cal51 cells transduced with MELK gRNAs, the </w:t></w:r><w:r w:rsidR="004F250D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>GI50</w:t></w:r><w:r w:rsidR="00DA3278"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> values ranged from </w:t></w:r><w:r w:rsidR="00B56063"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>8nM</w:t></w:r><w:r w:rsidR="00DA3278"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to </w:t></w:r><w:r w:rsidR="00B56063"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>14nM</w:t></w:r><w:r w:rsidR="00504310"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (mean: 11nM)</w:t></w:r><w:r w:rsidR="00E01DFB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="005B73DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  As OTS167 exhibits nanomolar potency against cancer cell lines </w:t></w:r><w:r w:rsidR="00622BB3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>but</w:t></w:r><w:r w:rsidR="005B73DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> is unaf</w:t></w:r><w:r w:rsidR="007B1ED7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">fected by mutations in MELK, this suggests </w:t></w:r><w:r w:rsidR="005B73DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>that OTS167 blocks p</w:t></w:r><w:r w:rsidR="007B1ED7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>roliferation by inhibiting another target or targets</w:t></w:r><w:r w:rsidR="005B73DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="007B1ED7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="0EA0C322" w14:textId="3BFFFF5E" w:rsidR="00C621A2" w:rsidRPr="00C621A2" w:rsidRDefault="006257BD" w:rsidP="00C621A2"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/><w:t xml:space="preserve">To further explore this observation, we tested the efficacy of OTS167 against a panel of triple-negative or receptor-positive breast cancer cell lines.  </w:t></w:r><w:r w:rsidR="005959AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK is significantly up-regulated in triple-negative tumors relative to receptor-positive tumors</w:t></w:r><w:r w:rsidR="00B72836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00B72836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00B72836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2mv4p56ggr","properties":{"formattedCitation":"(24)","plainCitation":"(24)"},"citationItems":[{"id":123,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/8RBX6BP6"],"itemData":{"id":123,"type":"article-journal","title":"MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells","container-title":"eLife","page":"e01763","volume":"3","source":"elifesciences.org","abstract":"Not all cancers are the same. There are, for example, at least five types of breast cancer. Different types of cancer can have different mutations and express different genes that determine how aggressively the tumors grow and how well they respond to different therapies. By exploiting these differences, scientists have developed therapies that target specific tumor types, and these targeted therapies have proven useful against most breast cancers. One type of breast cancer, however, has proven hard to treat. Basal-like breast cancer grows rapidly and there are few treatment options for women with this type of cancer. One reason for this is that, unlike other forms of breast cancer, these cancers do not have the hormone receptors that are the targets of existing therapies. Enzymes called kinases are promising alternate targets, and many kinase-inhibiting drugs can kill tumor cells in mice. Nevertheless, it has proven difficult to develop kinase inhibitors that are safe for use in humans because these drugs can also kill normal cells. To avoid this side effect, cancer researchers have been searching for a kinase that is active in cancer cells but not in normal cells. Wang et al. tested a large collection of kinases and found that one called MELK caused tumors to grow in the mammary glands of mice. Further examination of tumor samples collected from hundreds of women in previous clinical studies revealed that MELK expression was increased in basal-like breast cancers and other breast cancer tumors that lack the usual hormone receptor targets. When Wang et al. treated tumor cells and mice with tumors with a chemical that stops MELK working, basal-like breast cancer cells stopped multiplying and died. On the other hand, tumor cells that had the usual hormone receptors continued to multiply. To see if MELK is important in healthy mice, Wang et al. genetically engineered mice to delete the MELK gene and found that these mutant mice appear normal. The next challenge will be to test if drugs that inhibit MELK can kill basal-like breast cancer cells without having the side effect of harming normal cells.","DOI":"10.7554/eLife.01763","ISSN":"2050-084X","note":"PMID: 24844244","language":"en","author":[{"family":"Wang","given":"Yubao"},{"family":"Lee","given":"Young-Mi"},{"family":"Baitsch","given":"Lukas"},{"family":"Huang","given":"Alan"},{"family":"Xiang","given":"Yi"},{"family":"Tong","given":"Haoxuan"},{"family":"Lako","given":"Ana"},{"family":"Von","given":"Thanh"},{"family":"Choi","given":"Christine"},{"family":"Lim","given":"Elgene"},{"family":"Min","given":"Junxia"},{"family":"Li","given":"Li"},{"family":"Stegmeier","given":"Frank"},{"family":"Schlegel","given":"Robert"},{"family":"Eck","given":"Michael J."},{"family":"Gray","given":"Nathanael S."},{"family":"Mitchison","given":"Timothy J."},{"family":"Zhao","given":"Jean J."}],"issued":{"date-parts":[["2014",5,20]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00B72836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00B72836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(24)</w:t></w:r><w:r w:rsidR="00B72836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="005959AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and one clinical trial (</w:t></w:r><w:r w:rsidR="00C621A2" w:rsidRPr="00C621A2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>NCT02926690</w:t></w:r><w:r w:rsidR="00C621A2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) </w:t></w:r><w:r w:rsidR="00806111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>includes</w:t></w:r><w:r w:rsidR="007A49AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> a dosage-</w:t></w:r><w:r w:rsidR="003F2686"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>escalation</w:t></w:r><w:r w:rsidR="007A49AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> study </w:t></w:r><w:r w:rsidR="00D26A1C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>of OTS167 in</w:t></w:r><w:r w:rsidR="007A49AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> patients with triple-negative </w:t></w:r><w:r w:rsidR="00667C5B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancers</w:t></w:r><w:r w:rsidR="007A49AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00806111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00D26A1C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>However,</w:t></w:r><w:r w:rsidR="00806111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> we observed no significant difference between the GI50 values of OTS167 according to receptor status</w:t></w:r><w:r w:rsidR="00BA427D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 3-figure supplement 1</w:t></w:r><w:r w:rsidR="00BB5605"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00806111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  In triple-negative breast cancer cell lines, OTS167 inhibited growth by 50% at concentrations ranging from 10nM to 42nM (mean: 19nM), while in receptor-positive breast cancer cells GI50 values ranged from 9nM to 21nM (mean: 14nM).  These results demonstrate that OTS167 is not specifically effective against triple-negative breast cancer cell lines, but instead remains remarkably potent against breast cancer cell lines that express </w:t></w:r><w:r w:rsidR="00563ED3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>hormone</w:t></w:r><w:r w:rsidR="00806111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> receptors.   </w:t></w:r><w:r w:rsidR="003F2686"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="007A49AB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00C621A2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="201B38E8" w14:textId="2B2CECE2" w:rsidR="008B67B6" w:rsidRPr="00195780" w:rsidRDefault="009F3395" w:rsidP="009F3395"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Lastly,</w:t></w:r><w:r w:rsidR="00760EF2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to confirm that OTS167 </w:t></w:r><w:r w:rsidR="00A60698"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>treatment fails to phenocopy MELK mutations,</w:t></w:r><w:r w:rsidR="00760EF2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008457EB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>we examined th</w:t></w:r><w:r w:rsidR="0033635F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">eir effects </w:t></w:r><w:r w:rsidR="008457EB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">on cell cycle progression.  </w:t></w:r><w:r w:rsidR="00BB2AB2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>We found that treatment with OTS167 blocked cytokinesis</w:t></w:r><w:r w:rsidR="004C7563"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in a dose-dependent manner</w:t></w:r><w:r w:rsidR="00BB2AB2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, resulting in populations harboring </w:t></w:r><w:r w:rsidR="00B7150E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>13%</w:t></w:r><w:r w:rsidR="00BB2AB2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to </w:t></w:r><w:r w:rsidR="00B7150E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>60%</w:t></w:r><w:r w:rsidR="00BB2AB2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> multinucleate cells. </w:t></w:r><w:r w:rsidR="002F1413"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="009E5CB2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>In contrast, cells transduced with either Ro</w:t></w:r><w:r w:rsidR="006A4946"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">sa26 or MELK gRNAs </w:t></w:r><w:r w:rsidR="0005557C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">progressed through the cell cycle without gross mitotic defects, and </w:t></w:r><w:r w:rsidR="006A4946"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">exhibited </w:t></w:r><w:r w:rsidR="0005093E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>no significant difference in the frequency o</w:t></w:r><w:r w:rsidR="00BA427D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>f multinucleate cells (Figure 3-figure supplement 2</w:t></w:r><w:r w:rsidR="0005093E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="009E5CB2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00955531"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">These results </w:t></w:r><w:r w:rsidR="00D26A1C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>demonstrate</w:t></w:r><w:r w:rsidR="00955531"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that OTS167 induces a cell cycle failure phenotype that is not recapitulated by mutagenizing MELK.  </w:t></w:r><w:r w:rsidR="005B73DF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>We</w:t></w:r><w:r w:rsidR="00F06905"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> note that this </w:t></w:r><w:r w:rsidR="00D26A1C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>observation</w:t></w:r><w:r w:rsidR="00F06905"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> is</w:t></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> consistent with a recent publication that </w:t></w:r><w:r w:rsidR="00600C99"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>reported</w:t></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006F325B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>that</w:t></w:r><w:r w:rsidR="00AD02EC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="00A70AF9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> at certain concentrations,</w:t></w:r><w:r w:rsidR="006F325B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>OTS167</w:t></w:r><w:r w:rsidR="006F325B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00D26A1C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">was capable of inhibiting </w:t></w:r><w:r w:rsidR="008B7187"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">the </w:t></w:r><w:r w:rsidR="004933E4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">mitotic kinases Aurora B, Haspin, and Bub1 </w:t></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1clcsoo0nj","properties":{"formattedCitation":"(47)","plainCitation":"(47)"},"citationItems":[{"id":157,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/G6D8TNG8"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/G6D8TNG8"],"itemData":{"id":157,"type":"article-journal","title":"OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases","container-title":"PLOS ONE","page":"e0153518","volume":"11","issue":"4","source":"PLoS Journals","abstract":"OTSSP167 was recently characterized as a potent inhibitor for maternal embryonic leucine zipper kinase (MELK) and is currently tested in Phase I clinical trials for solid tumors that have not responded to other treatment. Here we report that OTSSP167 abrogates the mitotic checkpoint at concentrations used to inhibit MELK. The abrogation is not recapitulated by RNAi mediated silencing of  MELK  in cells. Although OTSSP167 indeed inhibits MELK, it exhibits off-target activity against Aurora B kinase  in vitro  and in cells. Furthermore, OTSSP167 inhibits BUB1 and Haspin kinases, reducing phosphorylation at histones H2A T120  and H3 T3  and causing mislocalization of Aurora B and associated chromosomal passenger complex from the centromere/kinetochore. The results suggest that OTSSP167 may have additional mechanisms of action for cancer cell killing and caution the use of OTSSP167 as a MELK specific kinase inhibitor in biochemical and cellular assays.","DOI":"10.1371/journal.pone.0153518","ISSN":"1932-6203","journalAbbreviation":"PLOS ONE","author":[{"family":"Ji","given":"Wenbin"},{"family":"Arnst","given":"Christopher"},{"family":"Tipton","given":"Aaron R."},{"family":"Ii","given":"Michael E. Bekier"},{"family":"Taylor","given":"William R."},{"family":"Yen","given":"Tim J."},{"family":"Liu","given":"Song-Tao"}],"issued":{"date-parts":[["2016",4,15]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(47)</w:t></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00BB26AF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00195780"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  We conclude that the </w:t></w:r><w:r w:rsidR="00CF42A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>anti-proliferative</w:t></w:r><w:r w:rsidR="00195780"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> effects of OTS167</w:t></w:r><w:r w:rsidR="00CF42A4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00195780"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">are not a result of its inhibition of MELK.  </w:t></w:r></w:p><w:p w14:paraId="74DD97AC" w14:textId="77777777" w:rsidR="00622303" w:rsidRDefault="00622303" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="210F078F" w14:textId="77777777" w:rsidR="008A3B51" w:rsidRDefault="00622303" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Generation and characterization of</w:t></w:r><w:r w:rsidR="00E947E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK-knockou</w:t></w:r><w:r w:rsidR="008A3B51"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>t clonal cell lines</w:t></w:r></w:p><w:p w14:paraId="285740ED" w14:textId="4EED6A40" w:rsidR="00BC313B" w:rsidRDefault="008A3B51" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="001419D6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">To </w:t></w:r><w:r w:rsidR="00EA0EF5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>unambiguously</w:t></w:r><w:r w:rsidR="001419D6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> demonstrate that MELK is dispensable for the proliferation of certain cancer cell lines, we used CRISPR to generate clonal cell </w:t></w:r><w:r w:rsidR="0000069E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">lines that </w:t></w:r><w:r w:rsidR="00CA1958"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>lack MELK protein</w:t></w:r><w:r w:rsidR="001419D6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00967552"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>We transduced the MDA-MB-231 triple-negative breast cancer cell line</w:t></w:r><w:r w:rsidR="002D5753"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00967552"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">with sets of 2 guide </w:t></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">RNAs and </w:t></w:r><w:r w:rsidR="000D0560"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">then expanded </w:t></w:r><w:r w:rsidR="008B2E1B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>clonal populations</w:t></w:r><w:r w:rsidR="000D0560"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> from single cells</w:t></w:r><w:r w:rsidR="00EB08AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 4A)</w:t></w:r><w:r w:rsidR="000D0560"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Recombination between the </w:t></w:r><w:r w:rsidR="008B2E26"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">chosen </w:t></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">gRNA cut sites eliminates exon 3, which encodes residues </w:t></w:r><w:r w:rsidR="003F3655"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">that are </w:t></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>essential for ATP binding</w:t></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"h5akja961","properties":{"formattedCitation":"(48, 49)","plainCitation":"(48, 49)"},"citationItems":[{"id":427,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/ECG6R2QD"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/ECG6R2QD"],"itemData":{"id":427,"type":"article-journal","title":"Structural Basis for the Regulation of Maternal Embryonic Leucine Zipper Kinase","container-title":"PLOS ONE","page":"e70031","volume":"8","issue":"7","source":"PLoS Journals","abstract":"MELK (maternal embryonic leucine zipper kinase), which is a member of the AMPK (AMP-activated protein kinase)-related kinase family, plays important roles in diverse cellular processes and has become a promising drug target for certain cancers. However, the regulatory mechanism of MELK remains elusive. Here, we report the crystal structure of a fragment of human MELK that contains the kinase domain and ubiquitin-associated (UBA) domain. The UBA domain tightly binds to the back of the kinase domain, which may contribute to the proper conformation and activity of the kinase domain. Interestingly, the activation segment in the kinase domain displays a unique conformation that contains an intramolecular disulfide bond. The structural and biochemical analyses unravel the molecular mechanisms for the autophosphorylation/activation of MELK and the dependence of its catalytic activity on reducing agents. Thus, our results may provide the basis for designing specific MELK inhibitors for cancer treatment.","DOI":"10.1371/journal.pone.0070031","ISSN":"1932-6203","journalAbbreviation":"PLOS ONE","author":[{"family":"Cao","given":"Lu-Sha"},{"family":"Wang","given":"Jue"},{"family":"Chen","given":"Yuling"},{"family":"Deng","given":"Haiteng"},{"family":"Wang","given":"Zhi-Xin"},{"family":"Wu","given":"Jia-Wei"}],"issued":{"date-parts":[["2013",7,26]]}}},{"id":390,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/56CRMBVW"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/56CRMBVW"],"itemData":{"id":390,"type":"article-journal","title":"The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor","container-title":"Biochemical and Biophysical Research Communications","page":"7-11","volume":"447","issue":"1","source":"ScienceDirect","abstract":"Murine protein serine/threonine kinase 38 (MPK38), also known as maternal embryonic leucine zipper kinase (MELK), has been associated with various human cancers and plays an important role in the formation of cancer stem cells. OTSSP167, a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC50 of 0.41 nM and in vivo effect on various human cancer xenograft models. Here, we report the crystal structure of MPK38 (T167E), an active mutant, in complex with OTSSP167 and describe its detailed protein-inhibitor interactions. Comparison with the previous determined structure of MELK bound to the nanomolar inhibitors shows that OTSSP167 effectively fits into the active site, thus offering an opportunity for structure-based development and optimization of MELK inhibitors.","DOI":"10.1016/j.bbrc.2014.03.034","ISSN":"0006-291X","journalAbbreviation":"Biochemical and Biophysical Research Communications","author":[{"family":"Cho","given":"Yong-Soon"},{"family":"Kang","given":"YingJin"},{"family":"Kim","given":"Kuglae"},{"family":"Cha","given":"Young-je"},{"family":"Cho","given":"Hyun-Soo"}],"issued":{"date-parts":[["2014",4,25]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(48, 49)</w:t></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, as well as parts of exons 2, 4, </w:t></w:r><w:r w:rsidR="00E343F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and/</w:t></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>or 5.</w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  We used PCR to </w:t></w:r><w:r w:rsidR="003F3655"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">identify </w:t></w:r><w:r w:rsidR="009B5C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>3 independent</w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cl</w:t></w:r><w:r w:rsidR="00D10D15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ones that were homozygous for CRISPR-induced </w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>reco</w:t></w:r><w:r w:rsidR="00D10D15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>mbination</w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and then confirmed the </w:t></w:r><w:r w:rsidR="00B476AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>loss of the intervening genetic material</w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> by sequencing across the </w:t></w:r><w:r w:rsidR="00D10D15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>gRNA cut</w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> site</w:t></w:r><w:r w:rsidR="007260E2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00EB08AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 4B-C)</w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="0041599F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00852C23"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Additionally, we derived clones of Cal51 that </w:t></w:r><w:r w:rsidR="00EC0437"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>have</w:t></w:r><w:r w:rsidR="00852C23"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> been transduced with single MELK gRNAs, and then identified 3 clones that harbored indels in the MELK kinase domain</w:t></w:r><w:r w:rsidR="00613B88"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure </w:t></w:r><w:r w:rsidR="00C72E51"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>4-figure supplement 1</w:t></w:r><w:r w:rsidR="00613B88"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00852C23"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="0041599F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Western blot analysis</w:t></w:r><w:r w:rsidR="00852C23"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of the MDA-MB-231 and Cal51 clones</w:t></w:r><w:r w:rsidR="009B5C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> with two antibodies that recognize distinct regions of MELK </w:t></w:r><w:r w:rsidR="00411FAB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>further verified the complete lack</w:t></w:r><w:r w:rsidR="009B5C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of</w:t></w:r><w:r w:rsidR="00411FAB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK expression in </w:t></w:r><w:r w:rsidR="00175DB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>all six</w:t></w:r><w:r w:rsidR="00411FAB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="003507CE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>derived cell</w:t></w:r><w:r w:rsidR="003E5585"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00830BE7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">lines </w:t></w:r><w:r w:rsidR="00EB08AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(Figure 4D-E</w:t></w:r><w:r w:rsidR="00947C05"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="00C72E51"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 4-figure supplement 1</w:t></w:r><w:r w:rsidR="00EB08AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00411FAB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="000542F7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="53A45B76" w14:textId="0BDA9A79" w:rsidR="0029142E" w:rsidRDefault="00BC313B" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00175DB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>The MDA-MB-231and Cal51</w:t></w:r><w:r w:rsidR="00411FAB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK-KO clones </w:t></w:r><w:r w:rsidR="005B2AB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">exhibited robust proliferation, demonstrating that MELK is </w:t></w:r><w:r w:rsidR="002D5753"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">fully </w:t></w:r><w:r w:rsidR="005B2AB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">dispensable for the </w:t></w:r><w:r w:rsidR="00751001"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>growth</w:t></w:r><w:r w:rsidR="005B2AB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of </w:t></w:r><w:r w:rsidR="00986AEE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">these </w:t></w:r><w:r w:rsidR="005B2AB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cancer</w:t></w:r><w:r w:rsidR="008B2E1B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="005B2AB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell lines</w:t></w:r><w:r w:rsidR="00D172C2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure </w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>4F</w:t></w:r><w:r w:rsidR="00997448"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="00C72E51"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 4-figure supplement 1</w:t></w:r><w:r w:rsidR="00D172C2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="005B2AB9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">In fact, one </w:t></w:r><w:r w:rsidR="00487100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MDA-MB-</w:t></w:r><w:r w:rsidR="00175DB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">231 </w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK-KO clone e</w:t></w:r><w:r w:rsidR="00751001"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>xhibited a significantly shorter</w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> doubling time than</w:t></w:r><w:r w:rsidR="00842381"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the</w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Rosa26 gRNA-transduced cell lines, potentially due to</w:t></w:r><w:r w:rsidR="002D5753"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the presence of</w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> additional mutations that </w:t></w:r><w:r w:rsidR="00751001"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>were acquired</w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> during </w:t></w:r><w:r w:rsidR="00D172C2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>clonal expansion</w:t></w:r><w:r w:rsidR="00491E91"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00AE08C6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The MELK-KO clones</w:t></w:r><w:r w:rsidR="00AD7972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> progressed through the cell cy</w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cle without gross abnormalities and </w:t></w:r><w:r w:rsidR="00D172C2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">accumulated few </w:t></w:r><w:r w:rsidR="00AD7972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>multinucleate cells</w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00FC33BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(Figure </w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>4G</w:t></w:r><w:r w:rsidR="00997448"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="00C72E51"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 4-figure supplement 1</w:t></w:r><w:r w:rsidR="00FC33BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00D172C2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00904BA7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">OTS167 treatment of MELK-KO clones </w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>caused the formation of multinucleate cells</w:t></w:r><w:r w:rsidR="00904BA7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> demonstrating that this drug </w:t></w:r><w:r w:rsidR="008B2E26"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>blocks</w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cytokinesis </w:t></w:r><w:r w:rsidR="008B2E26"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>by inhibiting</w:t></w:r><w:r w:rsidR="00F424C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> another cellular target</w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 4H</w:t></w:r><w:r w:rsidR="00A85AC2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and Figure 4-figure supplement 1</w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  Finally, serial dilution analysis revealed that </w:t></w:r><w:r w:rsidR="00E934F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the</w:t></w:r><w:r w:rsidR="00842381"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MDA-MB-231 and Cal51</w:t></w:r><w:r w:rsidR="00E934F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK-KO clones exhibited equivalent</w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> OTS167</w:t></w:r><w:r w:rsidR="00E934F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00904BA7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>GI50 values</w:t></w:r><w:r w:rsidR="00CA1723"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00904BA7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>compared to</w:t></w:r><w:r w:rsidR="00E934F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> R</w:t></w:r><w:r w:rsidR="00CA1723"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>o</w:t></w:r><w:r w:rsidR="00470D86"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">sa26 gRNA-transduced </w:t></w:r><w:r w:rsidR="00080246"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>lines</w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Figure 4I-J</w:t></w:r><w:r w:rsidR="00487100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="00C72E51"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 4-figure supplement 1</w:t></w:r><w:r w:rsidR="00304A9D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00CA1723"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="0017224F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00BA1508"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>We conclude that MELK is not an absolute requirement for triple-negative breast cancer</w:t></w:r><w:r w:rsidR="00542340"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> proliferation</w:t></w:r><w:r w:rsidR="00BA1508"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and that OTS167 blocks growth in a MELK-independent manner.  </w:t></w:r><w:r w:rsidR="00904BA7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="649FC37B" w14:textId="63559A40" w:rsidR="00E01DFB" w:rsidRDefault="00CA1723" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00E934F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="008B2E1B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008B2E1B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="009B5C34"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00B476AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00D10D15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00D61A75"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">     </w:t></w:r><w:r w:rsidR="00055D53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">   </w:t></w:r><w:r w:rsidR="0000069E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="000D0560"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="003131F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="000D7640"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="6323A553" w14:textId="698A5B35" w:rsidR="001840C4" w:rsidRPr="001840C4" w:rsidRDefault="001840C4" w:rsidP="00C165DB"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Discussion</w:t></w:r></w:p><w:p w14:paraId="6175B93F" w14:textId="479874DE" w:rsidR="00F209B6" w:rsidRDefault="00D77B11" w:rsidP="00EF730C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/><w:t xml:space="preserve">As a mitotic kinase highly expressed in </w:t></w:r><w:r w:rsidR="00CC5FBC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>many</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cancer</w:t></w:r><w:r w:rsidR="00816B2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> types</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, MELK has been identifie</w:t></w:r><w:r w:rsidR="0049477E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>d as a promising targ</w:t></w:r><w:r w:rsidR="00D673CA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>et for therapeutic intervention</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00CC5FBC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00F9288E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">However, </w:t></w:r><w:r w:rsidR="00816B2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>through the use of CRISPR/Cas9</w:t></w:r><w:r w:rsidR="00F209B6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-mediated mutagenesis</w:t></w:r><w:r w:rsidR="00816B2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="00F9288E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">we have </w:t></w:r><w:r w:rsidR="00816B2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>demonstrated</w:t></w:r><w:r w:rsidR="00104A53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that MELK is dispensab</w:t></w:r><w:r w:rsidR="00D33ACA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">le for growth in </w:t></w:r><w:r w:rsidR="00816B2C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">13 out of 13 cancer cell lines tested, and that a MELK inhibitor currently in clinical trials blocks cell division by </w:t></w:r><w:r w:rsidR="000A40D4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">inhibiting another </w:t></w:r><w:r w:rsidR="008263C1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>target</w:t></w:r><w:r w:rsidR="00B71B33"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="003E1CB6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F209B6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00D52E58"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We believe that our results highlight </w:t></w:r><w:r w:rsidR="008D0C53"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the importance of using</w:t></w:r><w:r w:rsidR="00D52E58"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> CRISPR/Cas9 technology to </w:t></w:r><w:r w:rsidR="009210E9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">study and </w:t></w:r><w:r w:rsidR="00041DC7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>validate pre</w:t></w:r><w:r w:rsidR="00D52E58"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">clinical targets </w:t></w:r><w:r w:rsidR="00BC7B09"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>in cancer</w:t></w:r><w:r w:rsidR="00D52E58"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> drug development.</w:t></w:r><w:r w:rsidR="00296F72"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="66EE0CAD" w14:textId="4AC05E46" w:rsidR="004F70D9" w:rsidRDefault="005A7197" w:rsidP="00BC7B09"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Previous research </w:t></w:r><w:r w:rsidR="00713309"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>utilizing</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> RNA interference</w:t></w:r><w:r w:rsidR="004C2048"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to knock down MELK</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> has </w:t></w:r><w:r w:rsidR="00297186"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>indicated</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that MELK expression is required for cancer cell proliferation</w:t></w:r><w:r w:rsidR="00C11B6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>However, a</w:t></w:r><w:r w:rsidR="0031759D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> growing body of</w:t></w:r><w:r w:rsidR="00AA1041"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="004C2048"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>evidence</w:t></w:r><w:r w:rsidR="00AA1041"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> has revealed that R</w:t></w:r><w:r w:rsidR="004C4C63"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">NAi </w:t></w:r><w:r w:rsidR="002A2F7C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>is prone to pervasive off-target effects.</w:t></w:r><w:r w:rsidR="00872701"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  This problem is particularly </w:t></w:r><w:r w:rsidR="00AB10A9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>challenging</w:t></w:r><w:r w:rsidR="00872701"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> when </w:t></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">RNAi is used to study </w:t></w:r><w:r w:rsidR="006946E6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">putative cell cycle regulators, </w:t></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">as </w:t></w:r><w:r w:rsidR="003E1CB6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>multiple</w:t></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> publications have reported that the cell cycle genes </w:t></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">RAD51 </w:t></w:r><w:r w:rsidR="00703E1D" w:rsidRPr="009E2F72"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and</w:t></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MAD2 </w:t></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>are particularly sensitive to off-target RNAi inhibition</w:t></w:r><w:r w:rsidR="00521F45"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00CF220A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"d1txNDbZ","properties":{"formattedCitation":"{\\rtf (50\\uc0\\u8211{}52)}","plainCitation":"(50–52)"},"citationItems":[{"id":331,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/HAHKB4I2"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/HAHKB4I2"],"itemData":{"id":331,"type":"article-journal","title":"A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response","container-title":"Nature Cell Biology","page":"318-328","volume":"14","issue":"3","source":"www.nature.com","abstract":"Repair of DNA double-strand breaks is critical to genomic stability and the prevention of developmental disorders and cancer. A central pathway for this repair is homologous recombination (HR). Most knowledge of HR is derived from work in prokaryotic and eukaryotic model organisms. We carried out a genome-wide siRNA-based screen in human cells. Among positive regulators of HR we identified networks of DNA-damage-response and pre-mRNA-processing proteins, and among negative regulators we identified a phosphatase network. Three candidate proteins localized to DNA lesions, including RBMX, a heterogeneous nuclear ribonucleoprotein that has a role in alternative splicing. RBMX accumulated at DNA lesions through multiple domains in a poly(ADP-ribose) polymerase 1-dependent manner and promoted HR by facilitating proper BRCA2 expression. Our screen also revealed that off-target depletion of RAD51 is a common source of RNAi false positives, raising a cautionary note for siRNA screens and RNAi-based studies of HR.","DOI":"10.1038/ncb2426","ISSN":"1465-7392","journalAbbreviation":"Nat Cell Biol","language":"en","author":[{"family":"Adamson","given":"Britt"},{"family":"Smogorzewska","given":"Agata"},{"family":"Sigoillot","given":"Frederic D."},{"family":"King","given":"Randall W."},{"family":"Elledge","given":"Stephen J."}],"issued":{"date-parts":[["2012",3]]}}},{"id":339,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/HE9P3GAZ"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/HE9P3GAZ"],"itemData":{"id":339,"type":"article-journal","title":"Re-examination of siRNA specificity questions role of PICH and Tao1 in the spindle checkpoint and identifies Mad2 as a sensitive target for small RNAs","container-title":"Chromosoma","page":"149-165","volume":"119","issue":"2","source":"PubMed Central","abstract":"The DNA-dependent adenosine triphosphatase (ATPase) Plk1-interacting checkpoint helicase (PICH) has recently been implicated in spindle checkpoint (SAC) signaling (Baumann et al., Cell 128(1):101–114, ). Depletion of PICH by siRNA abolished the SAC and resulted in an apparently selective loss of Mad2 from kinetochores, suggesting a role for PICH in the regulation of the Mad1–Mad2 interaction. An apparent rescue of SAC functionality by overexpression of PICH in PICH-depleted cells initially seemed to confirm a role for PICH in the SAC. However, we have subsequently discovered that all PICH-directed siRNA oligonucleotides that abolish the SAC also reduce Mad2 mRNA and protein expression. This reduction is functionally significant, as PICH siRNA does not abolish SAC activity in a cell line that harbors a bacterial artificial chromosome driving the expression of murine Mad2. Moreover, we identified several siRNA duplexes that effectively deplete PICH but do not significantly affect SAC functionality or Mad2 abundance or localization. Finally, we discovered that the ability of overexpressed PICH to restore SAC activity in PICH-depleted cells depends on sequestration of the mitotic kinase Plk1 rather than ATPase activity of PICH, pointing to an underlying mechanism of “bypass suppression.” In support of this view, depletion or inhibition of Plk1 also rescued SAC activity in cells harboring low levels of Mad2. This observation suggests that a reduction of Plk1 activity partially compensates for reduced Mad2 levels and argues that Plk1 normally reduces the strength of SAC signaling. Collectively, our results question the role of PICH in the SAC and instead identify Mad2 as a sensitive off target for small RNA duplexes. In support of the latter conclusion, our evidence suggests that an off-target effect on Mad2 may also contribute to explain the apparent role of the Tao1 kinase in SAC signaling (Draviam et al., Nat Cell Biol 9(5):556–564, ).","DOI":"10.1007/s00412-009-0244-2","ISSN":"0009-5915","note":"PMID: 19904549\nPMCID: PMC2846388","journalAbbreviation":"Chromosoma","author":[{"family":"Hübner","given":"Nadja C."},{"family":"Wang","given":"Lily Hui-Ching"},{"family":"Kaulich","given":"Manuel"},{"family":"Descombes","given":"Patrick"},{"family":"Poser","given":"Ina"},{"family":"Nigg","given":"Erich A."}],"issued":{"date-parts":[["2010",4]]}},"locator":"2"},{"id":333,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/576QTGD3"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/576QTGD3"],"itemData":{"id":333,"type":"article-journal","title":"A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens","container-title":"Nature Methods","page":"363-366","volume":"9","issue":"4","source":"www.nature.com","abstract":"Because off-target effects hamper interpretation and validation of RNAi screen data, we developed a bioinformatics method, genome-wide enrichment of seed sequence matches (GESS), to identify candidate off-targeted transcripts in primary screening data. GESS analysis revealed a prominent off-targeted transcript in several screens, including MAD2 (MAD2L1) in a screen for genes required for the spindle assembly checkpoint. GESS analysis results can enhance the validation rate in RNAi screens.","DOI":"10.1038/nmeth.1898","ISSN":"1548-7091","journalAbbreviation":"Nat Meth","language":"en","author":[{"family":"Sigoillot","given":"Frederic D."},{"family":"Lyman","given":"Susan"},{"family":"Huckins","given":"Jeremy F."},{"family":"Adamson","given":"Britt"},{"family":"Chung","given":"Eunah"},{"family":"Quattrochi","given":"Brian"},{"family":"King","given":"Randall W."}],"issued":{"date-parts":[["2012",4]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00CF220A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="0029142E" w:rsidRPr="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/></w:rPr><w:t>(50–52)</w:t></w:r><w:r w:rsidR="00CF220A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00703E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00756C8B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  For instance, </w:t></w:r><w:r w:rsidR="00430298"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in a screen </w:t></w:r><w:r w:rsidR="00DD682D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>for genes whose depletion caused</w:t></w:r><w:r w:rsidR="00430298"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> a bypass of the spindle assembly checkpoint, </w:t></w:r><w:r w:rsidR="004D6C42"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>34 of the</w:t></w:r><w:r w:rsidR="00430298"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> top 34 candidate siRNA’s exhibited off-target </w:t></w:r><w:r w:rsidR="00A2238E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>down-regulation of</w:t></w:r><w:r w:rsidR="00430298"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Mad2 </w:t></w:r><w:r w:rsidR="00A2238E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>levels</w:t></w:r><w:r w:rsidR="004D6C42"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="004D6C42"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"qrajfgdqf","properties":{"formattedCitation":"(52)","plainCitation":"(52)"},"citationItems":[{"id":333,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/576QTGD3"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/576QTGD3"],"itemData":{"id":333,"type":"article-journal","title":"A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens","container-title":"Nature Methods","page":"363-366","volume":"9","issue":"4","source":"www.nature.com","abstract":"Because off-target effects hamper interpretation and validation of RNAi screen data, we developed a bioinformatics method, genome-wide enrichment of seed sequence matches (GESS), to identify candidate off-targeted transcripts in primary screening data. GESS analysis revealed a prominent off-targeted transcript in several screens, including MAD2 (MAD2L1) in a screen for genes required for the spindle assembly checkpoint. GESS analysis results can enhance the validation rate in RNAi screens.","DOI":"10.1038/nmeth.1898","ISSN":"1548-7091","journalAbbreviation":"Nat Meth","language":"en","author":[{"family":"Sigoillot","given":"Frederic D."},{"family":"Lyman","given":"Susan"},{"family":"Huckins","given":"Jeremy F."},{"family":"Adamson","given":"Britt"},{"family":"Chung","given":"Eunah"},{"family":"Quattrochi","given":"Brian"},{"family":"King","given":"Randall W."}],"issued":{"date-parts":[["2012",4]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="004D6C42"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(52)</w:t></w:r><w:r w:rsidR="004D6C42"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00430298"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00575873"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Moreover, the expression of MELK </w:t></w:r><w:r w:rsidR="000E1A4C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">is </w:t></w:r><w:r w:rsidR="008263C1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>strongly cell-cycle regulated: MELK levels are typically low in G0/G1, and peak in mitosis</w:t></w:r><w:r w:rsidR="00575873"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>[</w:t></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1dbing9bld","properties":{"formattedCitation":"(53)","plainCitation":"(53)"},"citationItems":[{"id":377,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/6TX4592P"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/6TX4592P"],"itemData":{"id":377,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit","container-title":"Experimental Cell Research","page":"2166-2173","volume":"316","issue":"13","source":"ScienceDirect","abstract":"MELK (maternal embryonic leucine zipper kinase) is a cell cycle dependent protein kinase involved in diverse cell processes including cell proliferation, apoptosis, cell cycle and mRNA processing. Noticeably, MELK expression is increased in cancerous tissues, upon cell transformation and in mitotically-blocked cells. The question of how MELK protein level is controlled is therefore important. Here, we show that MELK protein is restricted to proliferating cells derived from either cancer or normal tissues and that MELK protein level is severely decreased concomitantly with other cell cycle proteins in cells which exit the cell cycle. Moreover, we demonstrate in human HeLa cells and Xenopus embryos that approximately half of MELK protein is degraded upon mitotic exit whereas another half remains stable during interphase. We show that the stability of MELK protein in M-phase is dependent on its phosphorylation state.","DOI":"10.1016/j.yexcr.2010.04.019","ISSN":"0014-4827","journalAbbreviation":"Experimental Cell Research","author":[{"family":"Badouel","given":"Caroline"},{"family":"Chartrain","given":"Isabelle"},{"family":"Blot","given":"Joëlle"},{"family":"Tassan","given":"Jean-Pierre"}],"issued":{"date-parts":[["2010",8,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(53)</w:t></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and our unpublished data]</w:t></w:r><w:r w:rsidR="00507A2D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  A genetic or chemical treatment that induces a G1 arrest would therefore be predicted to down-regulate MELK, potentially confounding the analysis of knockdown efficiency.</w:t></w:r><w:r w:rsidR="000E1A4C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00935196"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">While Cas9 mutagenesis is also susceptible </w:t></w:r><w:r w:rsidR="0049125E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">to </w:t></w:r><w:r w:rsidR="00935196"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">off-target editing, </w:t></w:r><w:r w:rsidR="0049125E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">to the best of our knowledge, the off-target </w:t></w:r><w:r w:rsidR="00814731"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>loci</w:t></w:r><w:r w:rsidR="0049125E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> affected by CRISPR are </w:t></w:r><w:r w:rsidR="00A01576"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">unlikely to </w:t></w:r><w:r w:rsidR="0065081A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">substantially </w:t></w:r><w:r w:rsidR="00A01576"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">overlap </w:t></w:r><w:r w:rsidR="00D52C68"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">with </w:t></w:r><w:r w:rsidR="0049125E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">those </w:t></w:r><w:r w:rsidR="005C10A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">that are </w:t></w:r><w:r w:rsidR="0049125E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>affect</w:t></w:r><w:r w:rsidR="005C10A0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ed</w:t></w:r><w:r w:rsidR="0049125E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> by RNAi.</w:t></w:r><w:r w:rsidR="007F4211"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="009228A2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Moreover, s</w:t></w:r><w:r w:rsidR="007F4211"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">equencing the locus targeted by Cas9 can provide an unbiased readout of mutagenesis efficiency that is not sensitive to cell </w:t></w:r><w:r w:rsidR="00F713E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>state</w:t></w:r><w:r w:rsidR="007F4211"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-dependent expression variability.  Finally,</w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00EB5560"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">unlike RNAi, </w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">CRISPR can be </w:t></w:r><w:r w:rsidR="00B87C2E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">applied to generate </w:t></w:r><w:r w:rsidR="00965820"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">clonal cell lines that harbor </w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>null</w:t></w:r><w:r w:rsidR="00F713E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> mutations in a </w:t></w:r><w:r w:rsidR="00F07E6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>targeted</w:t></w:r><w:r w:rsidR="00F713E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> gene.  This technique bypasses</w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F713E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">the </w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">problems inherent in the </w:t></w:r><w:r w:rsidR="00DF1A3D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>analysis</w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of </w:t></w:r><w:r w:rsidR="00965820"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">mixed cell populations and </w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>partia</w:t></w:r><w:r w:rsidR="004F70D9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>l loss-of-function phenotypes</w:t></w:r><w:r w:rsidR="00F713E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and can provide significant insight into the genetic architecture of cancer</w:t></w:r><w:r w:rsidR="004F70D9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00EB5560"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="11F0988F" w14:textId="74847092" w:rsidR="00965820" w:rsidRDefault="00A01E3F" w:rsidP="000A33B2"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>One limita</w:t></w:r><w:r w:rsidR="004A2ED3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">tion of CRISPR mutagenesis is that, </w:t></w:r><w:r w:rsidR="002D666C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>over the time required to generate or select for a pure cell population</w:t></w:r><w:r w:rsidR="004A2ED3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, cells may engage compensatory mechanisms to buffer against the</w:t></w:r><w:r w:rsidR="000A33B2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> loss of </w:t></w:r><w:r w:rsidR="00AF61B7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>a</w:t></w:r><w:r w:rsidR="000A33B2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> targeted protein.</w:t></w:r><w:r w:rsidR="00DD3150"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="002D666C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A513CB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Thus, the analysis of </w:t></w:r><w:r w:rsidR="001F0F6A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>knockout clones</w:t></w:r><w:r w:rsidR="00A513CB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> can be complemented with </w:t></w:r><w:r w:rsidR="000A33B2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell-cell competition</w:t></w:r><w:r w:rsidR="00472F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> assays, which </w:t></w:r><w:r w:rsidR="00AF61B7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>allow</w:t></w:r><w:r w:rsidR="00472F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> less time for cells to </w:t></w:r><w:r w:rsidR="001F0F6A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>adapt to</w:t></w:r><w:r w:rsidR="00472F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00576AD2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">gene loss </w:t></w:r><w:r w:rsidR="00472F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and may reveal the presence of </w:t></w:r><w:r w:rsidR="001F0F6A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>a transient or immediate fitness defect</w:t></w:r><w:r w:rsidR="000001DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> induced by CRISPR</w:t></w:r><w:r w:rsidR="00472F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="009114D8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="009052AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>We</w:t></w:r><w:r w:rsidR="007C2D50"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> performed a total of 91 competition assays </w:t></w:r><w:r w:rsidR="009114D8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(7 MELK gRNAs </w:t></w:r><w:r w:rsidR="007C2D50"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in 13 </w:t></w:r><w:r w:rsidR="009114D8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">different </w:t></w:r><w:r w:rsidR="007C2D50"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell lines</w:t></w:r><w:r w:rsidR="00824777"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) that failed to reveal an effect of MELK loss on cell fitness</w:t></w:r><w:r w:rsidR="009052AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, further </w:t></w:r><w:r w:rsidR="00140E8C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>strengthening</w:t></w:r><w:r w:rsidR="009052AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> our conclusion</w:t></w:r><w:r w:rsidR="00801941"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> that MELK is dispensable for cancer cell proliferation. </w:t></w:r><w:r w:rsidR="009052AA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="007C2D50"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="001F0F6A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00CA085E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">    </w:t></w:r><w:r w:rsidR="00472F14"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00A513CB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00DD1A24"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00965820"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="3DDB13AB" w14:textId="3AA8C275" w:rsidR="005914FC" w:rsidRDefault="0032138D" w:rsidP="004722BD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:ind w:firstLine="720"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">CRISPR </w:t></w:r><w:r w:rsidR="00984580"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">mutagenesis </w:t></w:r><w:r w:rsidR="004060A9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">can also assist in the </w:t></w:r><w:r w:rsidR="00DF40E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">pharmacological </w:t></w:r><w:r w:rsidR="00F64907"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>study</w:t></w:r><w:r w:rsidR="00DF40E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of potential drugs</w:t></w:r><w:r w:rsidR="00984580"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  Several lines of evidence indicate that OTS167 </w:t></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>does indeed inhibit</w:t></w:r><w:r w:rsidR="00FA4148"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> MELK: f</w:t></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">or instance, a crystal structure </w:t></w:r><w:r w:rsidR="00984580"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>of OTS167 binding to the MELK kinase domain</w:t></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> has been reported </w:t></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"23scqorito","properties":{"formattedCitation":"(49)","plainCitation":"(49)"},"citationItems":[{"id":390,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/56CRMBVW"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/56CRMBVW"],"itemData":{"id":390,"type":"article-journal","title":"The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor","container-title":"Biochemical and Biophysical Research Communications","page":"7-11","volume":"447","issue":"1","source":"ScienceDirect","abstract":"Murine protein serine/threonine kinase 38 (MPK38), also known as maternal embryonic leucine zipper kinase (MELK), has been associated with various human cancers and plays an important role in the formation of cancer stem cells. OTSSP167, a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC50 of 0.41 nM and in vivo effect on various human cancer xenograft models. Here, we report the crystal structure of MPK38 (T167E), an active mutant, in complex with OTSSP167 and describe its detailed protein-inhibitor interactions. Comparison with the previous determined structure of MELK bound to the nanomolar inhibitors shows that OTSSP167 effectively fits into the active site, thus offering an opportunity for structure-based development and optimization of MELK inhibitors.","DOI":"10.1016/j.bbrc.2014.03.034","ISSN":"0006-291X","journalAbbreviation":"Biochemical and Biophysical Research Communications","author":[{"family":"Cho","given":"Yong-Soon"},{"family":"Kang","given":"YingJin"},{"family":"Kim","given":"Kuglae"},{"family":"Cha","given":"Young-je"},{"family":"Cho","given":"Hyun-Soo"}],"issued":{"date-parts":[["2014",4,25]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="0029142E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(49)</w:t></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00984580"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00CF6EB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">However, these structural and biochemical </w:t></w:r><w:r w:rsidR="00115075"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>studies</w:t></w:r><w:r w:rsidR="00CF6EB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> are unable to conclusively </w:t></w:r><w:r w:rsidR="00E0085B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>demonstrate that a phenotype</w:t></w:r><w:r w:rsidR="001A2166"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00BB237B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in a living cell </w:t></w:r><w:r w:rsidR="00E0085B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>is due to an on-target effect</w:t></w:r><w:r w:rsidR="008C735E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00AE490B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  We believe that </w:t></w:r><w:r w:rsidR="00076768"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">CRISPR </w:t></w:r><w:r w:rsidR="00AE490B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>represents a useful tool to gain gene</w:t></w:r><w:r w:rsidR="00507034"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">tic insight into this question: </w:t></w:r><w:r w:rsidR="004722BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">if </w:t></w:r><w:r w:rsidR="00AA2E05"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">a </w:t></w:r><w:r w:rsidR="004722BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>CRISPR</w:t></w:r><w:r w:rsidR="00AA2E05"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-induced null mutation</w:t></w:r><w:r w:rsidR="004722BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of a putative drug target </w:t></w:r><w:r w:rsidR="00323C22"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>fails to confer resistance</w:t></w:r><w:r w:rsidR="00F44589"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to that drug</w:t></w:r><w:r w:rsidR="0074342E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, t</w:t></w:r><w:r w:rsidR="00F44589"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">hen that </w:t></w:r><w:r w:rsidR="00507034"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>drug must act</w:t></w:r><w:r w:rsidR="0074342E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> through</w:t></w:r><w:r w:rsidR="00507034"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> alternate</w:t></w:r><w:r w:rsidR="0074342E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> targets or mechanisms.</w:t></w:r><w:r w:rsidR="00487100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00A76F15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>While the MELK-KO cell lines that we generated remain exquisitely sensitive to OTS167, a</w:t></w:r><w:r w:rsidR="00487100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">t present, we do not know how OTS167 </w:t></w:r><w:r w:rsidR="0087180B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>blocks</w:t></w:r><w:r w:rsidR="009204C5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell division</w:t></w:r><w:r w:rsidR="00487100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  One possibility, not ruled out by our studies, is that OTS167 exhibits polypharmacology</w:t></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1p6g3588nt","properties":{"formattedCitation":"(54)","plainCitation":"(54)"},"citationItems":[{"id":447,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/PTI3S8TV"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/PTI3S8TV"],"itemData":{"id":447,"type":"article-journal","title":"Targeting the cancer kinome through polypharmacology","container-title":"Nature Reviews Cancer","page":"130-137","volume":"10","issue":"2","source":"www.nature.com","abstract":"Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.","DOI":"10.1038/nrc2787","ISSN":"1474-175X","journalAbbreviation":"Nat Rev Cancer","language":"en","author":[{"family":"Knight","given":"Zachary A."},{"family":"Lin","given":"Henry"},{"family":"Shokat","given":"Kevan M."}],"issued":{"date-parts":[["2010",2]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(54)</w:t></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00487100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and kills cancer cells by inhibiting multiple kinases, potentially including MELK.</w:t></w:r><w:r w:rsidR="007D2866"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The </w:t></w:r><w:r w:rsidR="0074237C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">analysis of </w:t></w:r><w:r w:rsidR="008E639A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>drug</w:t></w:r><w:r w:rsidR="0074237C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-resistant alleles of other mitotic kinases that OTS167 has been shown to inhibit</w:t></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2i643ggobm","properties":{"formattedCitation":"(47)","plainCitation":"(47)"},"citationItems":[{"id":157,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/G6D8TNG8"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/G6D8TNG8"],"itemData":{"id":157,"type":"article-journal","title":"OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases","container-title":"PLOS ONE","page":"e0153518","volume":"11","issue":"4","source":"PLoS Journals","abstract":"OTSSP167 was recently characterized as a potent inhibitor for maternal embryonic leucine zipper kinase (MELK) and is currently tested in Phase I clinical trials for solid tumors that have not responded to other treatment. Here we report that OTSSP167 abrogates the mitotic checkpoint at concentrations used to inhibit MELK. The abrogation is not recapitulated by RNAi mediated silencing of  MELK  in cells. Although OTSSP167 indeed inhibits MELK, it exhibits off-target activity against Aurora B kinase  in vitro  and in cells. Furthermore, OTSSP167 inhibits BUB1 and Haspin kinases, reducing phosphorylation at histones H2A T120  and H3 T3  and causing mislocalization of Aurora B and associated chromosomal passenger complex from the centromere/kinetochore. The results suggest that OTSSP167 may have additional mechanisms of action for cancer cell killing and caution the use of OTSSP167 as a MELK specific kinase inhibitor in biochemical and cellular assays.","DOI":"10.1371/journal.pone.0153518","ISSN":"1932-6203","journalAbbreviation":"PLOS ONE","author":[{"family":"Ji","given":"Wenbin"},{"family":"Arnst","given":"Christopher"},{"family":"Tipton","given":"Aaron R."},{"family":"Ii","given":"Michael E. Bekier"},{"family":"Taylor","given":"William R."},{"family":"Yen","given":"Tim J."},{"family":"Liu","given":"Song-Tao"}],"issued":{"date-parts":[["2016",4,15]]}},"locator":"167"}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(47)</w:t></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="0074237C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> may shed further light on the </w:t></w:r><w:r w:rsidR="0074237C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in vivo </w:t></w:r><w:r w:rsidR="00615265"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MOA</w:t></w:r><w:r w:rsidR="0074237C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of this compound. </w:t></w:r><w:r w:rsidR="008717F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="605E4AC4" w14:textId="75758727" w:rsidR="00F209B6" w:rsidRDefault="001D6C02" w:rsidP="00F209B6"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00176033"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Our results leave open the question of </w:t></w:r><w:r w:rsidR="008614C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">what role, if any, </w:t></w:r><w:r w:rsidR="00176033"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK</w:t></w:r><w:r w:rsidR="008614C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> plays </w:t></w:r><w:r w:rsidR="00D8082D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in mammalian biology and </w:t></w:r><w:r w:rsidR="00333A13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cell cycle progression</w:t></w:r><w:r w:rsidR="00EB2C78"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00D8082D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00333A13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">While MELK is up-regulated in diverse tumor types, it is also expressed in several normal cell lineages, including embryonic cells, hematopoietic cells, and neural progenitor cells </w:t></w:r><w:r w:rsidR="00333A13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"4gL0bTXg","properties":{"formattedCitation":"(10, 13, 55)","plainCitation":"(10, 13, 55)"},"citationItems":[{"id":214,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/AJXPMUNU"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/AJXPMUNU"],"itemData":{"id":214,"type":"article-journal","title":"Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation","container-title":"The Journal of Cell Biology","page":"413-427","volume":"170","issue":"3","source":"PubMed","abstract":"Maternal embryonic leucine zipper kinase (MELK) was previously identified in a screen for genes enriched in neural progenitors. Here, we demonstrate expression of MELK by progenitors in developing and adult brain and that MELK serves as a marker for self-renewing multipotent neural progenitors (MNPs) in cultures derived from the developing forebrain and in transgenic mice. Overexpression of MELK enhances (whereas knockdown diminishes) the ability to generate neurospheres from MNPs, indicating a function in self-renewal. MELK down-regulation disrupts the production of neurogenic MNP from glial fibrillary acidic protein (GFAP)-positive progenitors in vitro. MELK expression in MNP is cell cycle regulated and inhibition of MELK expression down-regulates the expression of B-myb, which is shown to also mediate MNP proliferation. These findings indicate that MELK is necessary for proliferation of embryonic and postnatal MNP and suggest that it regulates the transition from GFAP-expressing progenitors to rapid amplifying progenitors in the postnatal brain.","DOI":"10.1083/jcb.200412115","ISSN":"0021-9525","note":"PMID: 16061694\nPMCID: PMC2171475","journalAbbreviation":"J. Cell Biol.","language":"eng","author":[{"family":"Nakano","given":"Ichiro"},{"family":"Paucar","given":"Andres A."},{"family":"Bajpai","given":"Ruchi"},{"family":"Dougherty","given":"Joseph D."},{"family":"Zewail","given":"Amani"},{"family":"Kelly","given":"Theresa K."},{"family":"Kim","given":"Kevin J."},{"family":"Ou","given":"Jing"},{"family":"Groszer","given":"Matthias"},{"family":"Imura","given":"Tetsuya"},{"family":"Freije","given":"William A."},{"family":"Nelson","given":"Stanley F."},{"family":"Sofroniew","given":"Michael V."},{"family":"Wu","given":"Hong"},{"family":"Liu","given":"Xin"},{"family":"Terskikh","given":"Alexey V."},{"family":"Geschwind","given":"Daniel H."},{"family":"Kornblum","given":"Harley I."}],"issued":{"date-parts":[["2005",8,1]]}}},{"id":203,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/7U2GZMZ6"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/7U2GZMZ6"],"itemData":{"id":203,"type":"article-journal","title":"New member of the Snf1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo","container-title":"Molecular Reproduction and Development","page":"148-156","volume":"47","issue":"2","source":"Wiley Online Library","abstract":"The initial phase of mammalian preimplantation development is directed by stored maternal mRNAs and their encoded proteins, yet most of the molecules controlling this process have not been described. We have used differential display analysis of cDNA libraries prepared from unfertilized eggs and preimplantation embryos to isolate three maternal cDNAs that represent novel genes exhibiting different patterns of expression during this developmental period. One of these, Melk, encodes a protein with a kinase catalytic domain and a leucine zipper motif, a new member of the Snf1/AMPK family of kinases. This gene product may play a role in the signal transduction events in the egg and early embryo. Mol. Reprod. Dev. 47:148–156, 1997. © 1997 Wiley-Liss, Inc.","DOI":"10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M","ISSN":"1098-2795","journalAbbreviation":"Mol. Reprod. Dev.","language":"en","author":[{"family":"Heyer","given":"Babette S."},{"family":"Warsowe","given":"Jennie"},{"family":"Solter","given":"Davor"},{"family":"Knowles","given":"Barbara B."},{"family":"Ackerman","given":"Susan L."}],"issued":{"date-parts":[["1997",6,1]]}},"locator":"38"},{"id":352,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/3JRDQ23T"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/3JRDQ23T"],"itemData":{"id":352,"type":"article-journal","title":"Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells","container-title":"Gene","page":"295-301","volume":"195","issue":"2","source":"ScienceDirect","abstract":"We have isolated a cDNA clone of a new member of protein serine/threonine kinases, MPK38, from a cDNA library constructed from the murine teratocarcinoma PCC4 cell line by the polymerase chain reaction. MPK38 was transcribed as an approx. 2.5 kb mRNA encoding for a protein of 643 amino acids. N-terminus of MPK38 contains the kinase catalytic domain which exhibits approximately 60% protein sequence identity with the SNF1 serine/threonine kinase family. The MPK38 cDNA directs the in vitro translation of two protein species of approx. 70 and approx. 50 kDa, which appear to result from an internal initiation of translation. MPK38 was predominantly expressed in thymus and spleen, but was not detectable in kidney, liver, and muscle in the adult tissues. In addition, MPK38 was apparently expressed in T lineage cells and a macrophage/monocyte cell, but was not detectable in a B cell line and an embryonic cell line. However, a low level of MPK38 transcript was detectable in a mast cell line after a longer exposure. Furthermore, MPK38 gene product showed the kinase activity which was assessed by immune complex kinase assay. Thus, MPK38 gene product seems to play an important role in signal transduction of certain lineages of hematopoietic cells.","DOI":"10.1016/S0378-1119(97)00181-9","ISSN":"0378-1119","journalAbbreviation":"Gene","author":[{"family":"Gil","given":"Minchan"},{"family":"Yang","given":"Young"},{"family":"Lee","given":"Younghoon"},{"family":"Choi","given":"Inpyo"},{"family":"Ha","given":"Hyunjung"}],"issued":{"date-parts":[["1997",8,22]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00333A13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="002F79DE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(10, 13, 55)</w:t></w:r><w:r w:rsidR="00333A13"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="006476FB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  MELK may </w:t></w:r><w:r w:rsidR="004F04A6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>be required at a certain</w:t></w:r><w:r w:rsidR="006476FB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="003F7508"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">developmental stage, </w:t></w:r><w:r w:rsidR="004F04A6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>or for a specific cell type</w:t></w:r><w:r w:rsidR="006476FB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or organismal process.  </w:t></w:r><w:r w:rsidR="00736C9A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Similarly, we cannot currently rule out the possibility that MELK plays a role in tumor</w:t></w:r><w:r w:rsidR="00DB25CF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">igenesis </w:t></w:r><w:r w:rsidR="00736C9A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in vivo </w:t></w:r><w:r w:rsidR="00736C9A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>that was not assessed in our current work.</w:t></w:r><w:r w:rsidR="00CA7BEA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00920C76"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>At a minimum</w:t></w:r><w:r w:rsidR="00FB2090"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, our results suggest that MELK is dispensable for mitotic pr</w:t></w:r><w:r w:rsidR="007E6402"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ogression in</w:t></w:r><w:r w:rsidR="00782100"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> most cancers</w:t></w:r><w:r w:rsidR="00FB2090"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="007E6402"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00692485"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A835AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK may function in an overlapping or redundant pathway </w:t></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">with other mitotic kinases, </w:t></w:r><w:r w:rsidR="00F77606"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>several of which are</w:t></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> up-regulated </w:t></w:r><w:r w:rsidR="00F77606"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">along with MELK </w:t></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in tumor cells </w:t></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"fmbcn1ffg","properties":{"formattedCitation":"(56)","plainCitation":"(56)"},"citationItems":[{"id":346,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/66K6T6UI"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/66K6T6UI"],"itemData":{"id":346,"type":"article-journal","title":"Cell cycle kinases in cancer","container-title":"Current Opinion in Genetics &amp; Development","collection-title":"Genetic and cellular mechanisms of oncogenesis","page":"60-65","volume":"17","issue":"1","source":"ScienceDirect","abstract":"Cell division in mammalian cells is driven by protein kinases that regulate progression through the various phases of the cell cycle. Cyclin-dependent kinases (Cdks) regulate cell cycle commitment, DNA synthesis and the onset of mitosis. Kinases of the Aurora, Polo and Nek families participate in the centrosome cycle and modulate spindle function. Additional kinases such as Bub1, BubR1 and Mps1 regulate the spindle assembly checkpoint. It has been well established that misregulation of Cdks is one of the most frequent alterations in human cancer. Recent evidence indicates that mutations involving mitotic kinases are also linked to tumor development. These findings suggest novel strategies to use cell cycle kinases as targets for therapeutic intervention.","DOI":"10.1016/j.gde.2006.12.008","ISSN":"0959-437X","journalAbbreviation":"Current Opinion in Genetics &amp; Development","author":[{"family":"Malumbres","given":"Marcos"},{"family":"Barbacid","given":"Mariano"}],"issued":{"date-parts":[["2007",2]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(56)</w:t></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00F0127E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00C77C9F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Synthetic lethal screens and further </w:t></w:r><w:r w:rsidR="00C77C9F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:i/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in vivo </w:t></w:r><w:r w:rsidR="00C77C9F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">investigation </w:t></w:r><w:r w:rsidR="00BC4B40"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>will</w:t></w:r><w:r w:rsidR="00C77C9F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> shed light on MELK’s </w:t></w:r><w:r w:rsidR="00832F08"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>function in development and cancer</w:t></w:r><w:r w:rsidR="00C77C9F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  Nonetheless, o</w:t></w:r><w:r w:rsidR="00F209B6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ur data suggest that specific MELK inhibitors are unlikely to be useful monoagents in cancer therapy.  </w:t></w:r></w:p><w:p w14:paraId="68F59337" w14:textId="1C6718DF" w:rsidR="00433E09" w:rsidRDefault="00F209B6" w:rsidP="00F209B6"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00433E09"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br w:type="page"/></w:r></w:p><w:p w14:paraId="6FF2024F" w14:textId="15D688BF" w:rsidR="00EF730C" w:rsidRDefault="00EF730C" w:rsidP="00EF730C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Materials and Methods</w:t></w:r></w:p><w:p w14:paraId="6248D1B7" w14:textId="437A42B6" w:rsidR="004F71D1" w:rsidRDefault="004F71D1" w:rsidP="00EF730C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Tissue </w:t></w:r><w:r w:rsidR="007E5983"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>c</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ulture</w:t></w:r></w:p><w:p w14:paraId="4D34D8F6" w14:textId="30C7B1B4" w:rsidR="00A3584C" w:rsidRPr="003E7D29" w:rsidRDefault="00A3584C" w:rsidP="00A3584C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>The identity of every human cell line utilized in this paper was authenticated using STR profiling (University of Arizona Genetics Core, Tucson).  Cell lines were also confirmed to be negative for mycoplasma contamination using the MycoAlert Detection Kit (Lonza; LT07-218).  Cell lines HCC70, HCC1937, MDA-MB-453,</w:t></w:r><w:r w:rsidR="00667A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00667A5D" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MDA-MB-468,</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and ZR-75-1 were grown in RPMI 1640 supplemented with 10% fetal bovine (FBS), 2mM glutamine, </w:t></w:r><w:r w:rsidRPr="00A3584C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1% Nonessential Amino Acids</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Life Technologies; </w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:color w:val="24262C"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>BY00148)</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:color w:val="24262C"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and </w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>100 U/ml penicillin and streptomycin.</w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00667A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">HCC1143 and </w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">NCI-H1299 </w:t></w:r><w:r w:rsidR="005A4C5E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>were</w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> grown in </w:t></w:r><w:r w:rsidR="00D90A5D" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>RPMI 1640 sup</w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>plemented with 10% FBS</w:t></w:r><w:r w:rsidR="00D90A5D" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, 2mM glutamine</w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:color w:val="24262C"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and </w:t></w:r><w:r w:rsidR="00D90A5D" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>100 U/ml penicillin and streptomycin</w:t></w:r><w:r w:rsidR="00D90A5D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  T24 was grown in McCoy’s 5A media supplemented with 10% FBS, 2mM glutamine, and 100 U/ml penicillin and streptomycin.  </w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cal51, A375, MDA-MB-231, HCT116, Cama1, </w:t></w:r><w:r w:rsidR="00C25812"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">JIMT-1, </w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and U118-MG cells were grown in DMEM supplemented with 10% FBS, 2mM glutamine, and 100 U/</w:t></w:r><w:r w:rsidR="008F446E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ml penicillin and streptomycin.  </w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>T47D cells were grown in RPMI s</w:t></w:r><w:r w:rsidR="00B70FB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">upplemented with 10% FBS, 6.94 </w:t></w:r><w:r w:rsidR="00B70FB4" w:rsidRPr="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μ</w:t></w:r><w:r w:rsidR="00BF603D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>g/ml i</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nsulin (Thermo Fisher;</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:color w:val="24262C"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> BN00226)</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, 2mM glutamine, and 100 U/ml penicillin and streptomycin.</w:t></w:r><w:r w:rsidR="00B70FB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00B70FB4" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MCF7 cells</w:t></w:r><w:r w:rsidR="00E82C08"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00B70FB4" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">were grown in DMEM supplemented with 10% FBS, </w:t></w:r><w:r w:rsidR="00B70FB4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>0.01mg/ml insulin</w:t></w:r><w:r w:rsidR="00B70FB4" w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, 2mM glutamine, and 100 U/ml penicillin and streptomycin. </w:t></w:r><w:r w:rsidR="00A436AE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Cell lines were kindly provided by the individuals thanked in the acknowledgments.  </w:t></w:r><w:bookmarkStart w:id="0" w:name="_GoBack"/><w:bookmarkEnd w:id="0"/><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>All cell lines were maintained in a humidified environment at 37˚C and 5% CO</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="subscript"/></w:rPr><w:t>2</w:t></w:r><w:r w:rsidRPr="003E7D29"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  Cell counting was performed using the Cellometer Auto T4 system (Nexcelom).  </w:t></w:r></w:p><w:p w14:paraId="78F40BCC" w14:textId="77777777" w:rsidR="006865BE" w:rsidRDefault="006865BE" w:rsidP="004F71D1"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="457596EE" w14:textId="4B2C122F" w:rsidR="006865BE" w:rsidRPr="006865BE" w:rsidRDefault="006865BE" w:rsidP="004F71D1"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Plasmid construction</w:t></w:r></w:p><w:p w14:paraId="062D7DC2" w14:textId="43C75278" w:rsidR="00417741" w:rsidRDefault="00417741" w:rsidP="004F71D1"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Guide RNAs </w:t></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">targeting protein domains in MELK, PCNA, and RPA3 were designed </w:t></w:r><w:r w:rsidR="00E84929"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>with assistance from</w:t></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A84A6E" w:rsidRPr="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Osama El Demerdash</w:t></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (</w:t></w:r><w:r w:rsidR="003A4901"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>manuscript in preparation).</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00601BD9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00652074"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Oligonucleotides were ordered from IDT and then </w:t></w:r><w:r w:rsidR="007D287E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cloned into the LRG 2.1 vector [</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">a gift from Jun-Wei Shi (University of Pennsylvania) and Chris Vakoc (Cold Spring Harbor </w:t></w:r><w:r w:rsidR="00A97641"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Laboratory)</w:t></w:r><w:r w:rsidR="00E1560B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>]</w:t></w:r><w:r w:rsidR="00A97641"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">using </w:t></w:r><w:r w:rsidR="009347F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">a </w:t></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>BsmBI</w:t></w:r><w:r w:rsidR="009347F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> digestion </w:t></w:r><w:r w:rsidR="009347F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"l6mhf9nkh","properties":{"formattedCitation":"(57)","plainCitation":"(57)"},"citationItems":[{"id":324,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/2VRVBBMD"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/2VRVBBMD"],"itemData":{"id":324,"type":"article-journal","title":"Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells","container-title":"Science","page":"84-87","volume":"343","issue":"6166","source":"science.sciencemag.org","abstract":"Improving Whole-Genome Screens\nImproved methods are needed for the knockout of individual genes in genome-scale functional screens. Wang et al. (p. 80, published online 12 December) and Shalem et al. (p. 84, published online 12 December) used the bacterial CRISPR/Cas9 system to power-screen protocols that avoid several of the pitfalls associated with small interfering RNA (siRNA) screens. Genome editing by these methods completely disrupts target genes, thus avoiding weak signals that can occur when transcript abundance is partially decreased by siRNA. Furthermore, gene targeting by the CRISPR system is more precise and appears to produce substantially fewer off-target effects than existing methods.\nThe simplicity of programming the CRISPR (clustered regularly interspaced short palindromic repeats)–associated nuclease Cas9 to modify specific genomic loci suggests a new way to interrogate gene function on a genome-wide scale. We show that lentiviral delivery of a genome-scale CRISPR-Cas9 knockout (GeCKO) library targeting 18,080 genes with 64,751 unique guide sequences enables both negative and positive selection screening in human cells. First, we used the GeCKO library to identify genes essential for cell viability in cancer and pluripotent stem cells. Next, in a melanoma model, we screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic RAF inhibitor. Our highest-ranking candidates include previously validated genes NF1 and MED12, as well as novel hits NF2, CUL3, TADA2B, and TADA1. We observe a high level of consistency between independent guide RNAs targeting the same gene and a high rate of hit confirmation, demonstrating the promise of genome-scale screening with Cas9.\nGenome-editing technology allows improved positive or negative selection screens.\nGenome-editing technology allows improved positive or negative selection screens.","DOI":"10.1126/science.1247005","ISSN":"0036-8075, 1095-9203","note":"PMID: 24336571","language":"en","author":[{"family":"Shalem","given":"Ophir"},{"family":"Sanjana","given":"Neville E."},{"family":"Hartenian","given":"Ella"},{"family":"Shi","given":"Xi"},{"family":"Scott","given":"David A."},{"family":"Mikkelsen","given":"Tarjei S."},{"family":"Heckl","given":"Dirk"},{"family":"Ebert","given":"Benjamin L."},{"family":"Root","given":"David E."},{"family":"Doench","given":"John G."},{"family":"Zhang","given":"Feng"}],"issued":{"date-parts":[["2014",1,3]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="009347F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(57)</w:t></w:r><w:r w:rsidR="009347F0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00803FC0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Plasmids were amplified in Stbl3 E. coli (ThermoFischer; </w:t></w:r><w:r w:rsidR="00803FC0" w:rsidRPr="00803FC0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>C737303</w:t></w:r><w:r w:rsidR="00803FC0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="006F754D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> prepared using the Mix &amp; Go transformation kit (Zymo Research; </w:t></w:r><w:r w:rsidR="006F754D" w:rsidRPr="006F754D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>T3001</w:t></w:r><w:r w:rsidR="006F754D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>)</w:t></w:r><w:r w:rsidR="00803FC0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00E1560B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00A84A6E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="197A7F59" w14:textId="77777777" w:rsidR="00324CA8" w:rsidRPr="004F71D1" w:rsidRDefault="00324CA8" w:rsidP="004F71D1"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="4C39311F" w14:textId="222CB5B9" w:rsidR="00291A76" w:rsidRPr="00291A76" w:rsidRDefault="007E5983" w:rsidP="00291A76"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Plasmid t</w:t></w:r><w:r w:rsidR="00291A76"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ransfection and </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>t</w:t></w:r><w:r w:rsidR="00291A76" w:rsidRPr="00291A76"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ransduction</w:t></w:r></w:p><w:p w14:paraId="1E01D98C" w14:textId="4792141A" w:rsidR="00243027" w:rsidRDefault="00291A76" w:rsidP="00243027"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>HEK293T</w:t></w:r><w:r w:rsidRPr="00291A76"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cells</w:t></w:r><w:r w:rsidR="00E521EA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidRPr="00291A76"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">were transfected </w:t></w:r><w:r w:rsidR="00502DCA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>using the calcium-phosphate method</w:t></w:r><w:r w:rsidR="00912C62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00912C62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"60udv6crq","properties":{"formattedCitation":"(58)","plainCitation":"(58)"},"citationItems":[{"id":314,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/48C7Z86W"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/48C7Z86W"],"itemData":{"id":314,"type":"article-journal","title":"Calcium Phosphate Transfection of 3T3 Fibroblasts","container-title":"Cold Spring Harbor Protocols","page":"pdb.prot5372","volume":"2010","issue":"2","source":"cshprotocols.cshlp.org","abstract":"INTRODUCTION\nMixing DNA with calcium chloride in a phosphate buffer results in the formation of a DNA/calcium phosphate precipitate which, when layered onto cultured cells, is taken up by endocytosis. The method is used widely for transfecting fibroblasts and other adherent cell types and can be performed easily with reagent-grade chemicals. This protocol describes the calcium phosphate transfection of murine 3T3 fibroblasts. Briefly, cells are grown on 60- or 100-mm tissue culture dishes and passaged 1 d prior to transfection, such that they are ~50% confluent at the time of transfection. This allows the cells to be transfected when most are not in direct contact with other cells. It also allows the cells to reach 100% confluence ~48 h post-transfection, when most transiently transfected cells are harvested. A precipitate containing DNA and calcium phosphate is formed by gradually mixing a phosphate-containing buffer with a solution of DNA and calcium chloride. The mixture is then layered onto a plate containing the adherent cultured cells and growth medium. After the cells have been exposed to the precipitate for a defined period of time, the medium containing the precipitate is removed and fresh medium is added to prevent toxicity. The procedure is suitable for performing both transient and stable transfection experiments.","DOI":"10.1101/pdb.prot5372","ISSN":"1940-3402, 1559-6095","note":"PMID: 20150135","journalAbbreviation":"Cold Spring Harb Protoc","language":"en","author":[{"family":"Smale","given":"Stephen T."}],"issued":{"date-parts":[["2010",2,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00912C62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(58)</w:t></w:r><w:r w:rsidR="00912C62"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00502DCA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Supernatant was harvested 48 to 72 hours post-</w:t></w:r><w:r w:rsidRPr="00291A76"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>transfection</w:t></w:r><w:r w:rsidR="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, filtered through a 0.45</w:t></w:r><w:r w:rsidR="00243027" w:rsidRPr="00243027"><w:rPr><w:rFonts w:ascii="Helvetica" w:eastAsia="Times New Roman" w:hAnsi="Helvetica" w:cs="Times New Roman"/><w:iCs/><w:color w:val="252525"/><w:sz w:val="21"/><w:szCs w:val="21"/><w:shd w:val="clear" w:color="auto" w:fill="FFFFFF"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00243027" w:rsidRPr="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μm</w:t></w:r><w:r w:rsidR="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> syringe, and then</w:t></w:r><w:r w:rsidR="00A94474"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> frozen at -80</w:t></w:r><w:r w:rsidR="00A94474" w:rsidRPr="00A94474"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>°</w:t></w:r><w:r w:rsidR="00A94474"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> C for later use or applied directly to cells </w:t></w:r><w:r w:rsidR="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">with </w:t></w:r><w:r w:rsidR="00276440"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>4</w:t></w:r><w:r w:rsidR="00276440" w:rsidRPr="00243027"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μ</w:t></w:r><w:r w:rsidR="00276440"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>g/mL polybrene.</w:t></w:r><w:r w:rsidR="00C17212"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The culture media </w:t></w:r><w:r w:rsidR="00DD64A3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">on target plates </w:t></w:r><w:r w:rsidR="00C17212"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>was chang</w:t></w:r><w:r w:rsidR="00F31970"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ed 24 hours post-transduction. </w:t></w:r></w:p><w:p w14:paraId="282BC069" w14:textId="77777777" w:rsidR="00072CD2" w:rsidRDefault="00072CD2" w:rsidP="00243027"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="318143B4" w14:textId="28C32E6A" w:rsidR="00072CD2" w:rsidRDefault="00072CD2" w:rsidP="00243027"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Proliferation analysis</w:t></w:r></w:p><w:p w14:paraId="470F15C6" w14:textId="4312DC10" w:rsidR="00072CD2" w:rsidRPr="00072CD2" w:rsidRDefault="000D4375" w:rsidP="00243027"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>To measure cell proliferation, 100,000 cells of each strain were plated on a 6 well plate and then allowed to grow for 72 hours.  Cells were then trypsinized, counted, and</w:t></w:r><w:r w:rsidR="00086B85"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 100,000 cells were</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> re</w:t></w:r><w:r w:rsidR="00086B85"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-plated in fresh media</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00FC5937"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cells were passaged five times, </w:t></w:r><w:r w:rsidR="00086B85"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and cumulative population doublings and doubling times were calculated </w:t></w:r><w:r w:rsidR="00562652"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>at each passage</w:t></w:r><w:r w:rsidR="00086B85"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r></w:p><w:p w14:paraId="716A55BF" w14:textId="77777777" w:rsidR="00F9065E" w:rsidRDefault="00F9065E" w:rsidP="00243027"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="17688204" w14:textId="1B597E30" w:rsidR="00F9065E" w:rsidRDefault="00F9065E" w:rsidP="00243027"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:iCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Soft agar assays</w:t></w:r></w:p><w:p w14:paraId="329E2D82" w14:textId="3B5B528F" w:rsidR="00F9065E" w:rsidRDefault="00754E59" w:rsidP="00F9065E"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>S</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>olution</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1.0%</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and 0.7%</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Difco Agar Noble</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in sterile water </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>were</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> autoclaved and then allowed to equilibrate at</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 42˚C</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or 37.5</w:t></w:r><w:r w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>˚C</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, respectively</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  The </w:t></w:r><w:r w:rsidR="00181ECB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">1% </w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>agar solution</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> was</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> then</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> mix</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ed 1:1 with 2ml of the appropriate </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>media</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, </w:t></w:r><w:r w:rsidR="008609A3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>supplemented with</w:t></w:r><w:r w:rsidR="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 2X the concentration of serum</w:t></w:r><w:r w:rsidR="003C1C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, glutamine, and </w:t></w:r><w:r w:rsidR="003C1C32" w:rsidRPr="003C1C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>penicillin</w:t></w:r><w:r w:rsidR="003C1C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">/streptomycin.  </w:t></w:r><w:r w:rsidR="00132550"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">1 mL </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">of this mixture was then plated in one well of a 6 well plate and </w:t></w:r><w:r w:rsidR="00132550"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>allowed to</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> solidify at room temperature for 30 minutes, resulting in a 0.5% agar base layer. </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="008609A3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cells of interest</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> were then trypsinized and re-suspended in their appropriate media. </w:t></w:r><w:r w:rsidR="00D37918"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>20,000</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cells were </w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>diluted in</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 1ml of 2X med</w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ia</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">then </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">mixed with 1ml of </w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>the 0.7% agar solution</w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 500</w:t></w:r><w:r w:rsidR="00BC3932" w:rsidRPr="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μ</w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">l </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">of this mixture was then plated on the solidified base layer, resulting in 5,000 cells in a 0.375% agar suspension. </w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> The agar was allowed to solidify a</w:t></w:r><w:r w:rsidR="00104E2D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>t room temperature for one hour before being transferred to an incubator.</w:t></w:r><w:r w:rsidR="006700BD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00104E2D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Fresh 1X media was added to the surface of </w:t></w:r><w:r w:rsidR="00F00936"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">each well </w:t></w:r><w:r w:rsidR="00F9065E" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>24 hours after plating</w:t></w:r><w:r w:rsidR="00F00936"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and then were re-fed every 3 days.  After </w:t></w:r><w:r w:rsidR="005020B1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>21</w:t></w:r><w:r w:rsidR="00F00936"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> days of growth, colonies were </w:t></w:r><w:r w:rsidR="009251D2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>scored under 1</w:t></w:r><w:r w:rsidR="001C24CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">0x magnification. </w:t></w:r><w:r w:rsidR="00846767" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">All </w:t></w:r><w:r w:rsidR="001C24CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>experiments</w:t></w:r><w:r w:rsidR="00846767" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> were </w:t></w:r><w:r w:rsidR="003E1035"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>plated in triplicate and performed twice.</w:t></w:r><w:r w:rsidR="00846767" w:rsidRPr="00F9065E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="1E8F96BD" w14:textId="77777777" w:rsidR="003B0F0D" w:rsidRDefault="003B0F0D" w:rsidP="007944D5"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="74E306B9" w14:textId="0DDDEE62" w:rsidR="003B0F0D" w:rsidRPr="003B0F0D" w:rsidRDefault="003B0F0D" w:rsidP="003B0F0D"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Western blot analysis</w:t></w:r></w:p><w:p w14:paraId="57001DA8" w14:textId="5B22EDF3" w:rsidR="00331A41" w:rsidRDefault="003B0F0D" w:rsidP="003B0F0D"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cells were </w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>lysed with RIPA buffer [</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>25 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X 100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, protease inhibitor cocktail (Roche), phosphatase inhibitor cocktail (Roche)</w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>]</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Lysates were </w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>quantified</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> using the Pierce BCA Kit (Thermo Scientific)</w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>e</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>q</w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ual a</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>mount</w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>s</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of protein </w:t></w:r><w:r w:rsidR="00FF0566"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">were </w:t></w:r><w:r w:rsidR="00D11383"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>denatured and loaded onto a 8</w:t></w:r><w:r w:rsidRPr="003B0F0D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">% SDS-PAGE gel. The protein was transferred onto a polyvinylidene difluoride membrane using the Trans-Blot Turbo Transfer System (Bio-Rad). </w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>The membrane was blocked in 5% non-fat milk-TBST</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and then incubated with </w:t></w:r><w:r w:rsidR="009C467A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>a</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nti-MELK</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(abcam; </w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ab108529)</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">at a </w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1:3000</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> dilution, </w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>or</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> blocked in</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 10% BSA-TBST and then i</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ncubated with </w:t></w:r><w:r w:rsidR="009C467A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>a</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nti-MELK (Cell Signal; 2274S)</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">at </w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">a </w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1:1000</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> dilution.  Anti-alpha-tubulin (Sigma-Aldrich; T6199) was used as a loading control at a 1:3000 dilution.  All primary antibody incubations were performed overnight at 4°C.  Following incubation, the membranes were washed and then incubated in either a</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nti-rabbit</w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> secondary</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (abcam; </w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ab6721) at 1:50000 for MELK or a</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nti-mouse</w:t></w:r><w:r w:rsidR="007063AC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> secondary</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (Bio-Rad; </w:t></w:r><w:r w:rsidR="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1706516) at 1:10000 for Tubulin</w:t></w:r><w:r w:rsidR="00223756" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> for 1 hour at room temperature.</w:t></w:r></w:p><w:p w14:paraId="6173B151" w14:textId="77777777" w:rsidR="00223756" w:rsidRDefault="00223756" w:rsidP="003B0F0D"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="3A7E9843" w14:textId="25A42133" w:rsidR="00331A41" w:rsidRDefault="00331A41" w:rsidP="003B0F0D"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Analysis of CRISPR-mediated mutagenesis</w:t></w:r></w:p><w:p w14:paraId="03035653" w14:textId="354B0219" w:rsidR="00480B7E" w:rsidRDefault="00480B7E" w:rsidP="003B0F0D"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00480B7E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Genomic DNA was extracted </w:t></w:r><w:r w:rsidR="004A6BFD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">from transduced cell lines </w:t></w:r><w:r w:rsidR="00520991"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>using the QIAmp DNA M</w:t></w:r><w:r w:rsidRPr="00480B7E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ini kit (</w:t></w:r><w:r w:rsidR="00A73B79"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Qiagen; </w:t></w:r><w:r w:rsidRPr="00480B7E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cat. No. </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">51304).  Loci targeted by guide RNAs were amplified using the primers listed in </w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 2</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and then sequenced </w:t></w:r><w:r w:rsidR="00AB2913"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">using the forward and reverse primers </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>at the Cold Spring Harbor Laboratory sequencing facility.</w:t></w:r><w:r w:rsidR="00142EDB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Sequence traces were analyzed using TIDE </w:t></w:r><w:r w:rsidR="00142EDB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"2k73671k5k","properties":{"formattedCitation":"(35)","plainCitation":"(35)"},"citationItems":[{"id":152,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/H5NWVFJS"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/H5NWVFJS"],"itemData":{"id":152,"type":"article-journal","title":"Easy quantitative assessment of genome editing by sequence trace decomposition","container-title":"Nucleic Acids Research","page":"e168-e168","volume":"42","issue":"22","source":"nar.oxfordjournals.org","abstract":"The efficacy and the mutation spectrum of genome editing methods can vary substantially depending on the targeted sequence. A simple, quick assay to accurately characterize and quantify the induced mutations is therefore needed. Here we present TIDE, a method for this purpose that requires only a pair of PCR reactions and two standard capillary sequencing runs. The sequence traces are then analyzed by a specially developed decomposition algorithm that identifies the major induced mutations in the projected editing site and accurately determines their frequency in a cell population. This method is cost-effective and quick, and it provides much more detailed information than current enzyme-based assays. An interactive web tool for automated decomposition of the sequence traces is available. TIDE greatly facilitates the testing and rational design of genome editing strategies.","DOI":"10.1093/nar/gku936","ISSN":"0305-1048, 1362-4962","note":"PMID: 25300484","journalAbbreviation":"Nucl. Acids Res.","language":"en","author":[{"family":"Brinkman","given":"Eva K."},{"family":"Chen","given":"Tao"},{"family":"Amendola","given":"Mario"},{"family":"van Steensel","given":"Bas"}],"issued":{"date-parts":[["2014",12,16]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00142EDB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(35)</w:t></w:r><w:r w:rsidR="00142EDB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00142EDB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.   </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="1CA3DC65" w14:textId="77777777" w:rsidR="0040799C" w:rsidRPr="0040799C" w:rsidRDefault="0040799C" w:rsidP="0040799C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="31D96858" w14:textId="67218271" w:rsidR="0040799C" w:rsidRPr="0040799C" w:rsidRDefault="0040799C" w:rsidP="0040799C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Analysis of OTS</w:t></w:r><w:r w:rsidR="00D100B0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>SP</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>167 sensitivity</w:t></w:r></w:p><w:p w14:paraId="3B701B8A" w14:textId="20953C7A" w:rsidR="00CE1A75" w:rsidRDefault="00F05A7F" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>For every cell li</w:t></w:r><w:r w:rsidR="002364CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ne of interest, 10,000 cells </w:t></w:r><w:r w:rsidR="00524B24"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">were plated in </w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>100</w:t></w:r><w:r w:rsidR="00BC3932" w:rsidRPr="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μ</w:t></w:r><w:r w:rsidR="002364CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">l of media </w:t></w:r><w:r w:rsidR="00564975"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">in </w:t></w:r><w:r w:rsidR="00524B24"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>an 8 x 4</w:t></w:r><w:r w:rsidR="00BC5834"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">matrix on a </w:t></w:r><w:r w:rsidR="00B17BBC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">flat-bottomed </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">96-well plate. </w:t></w:r><w:r w:rsidR="00C221D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A75972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cells were allowed to attach for 24 hours, at which point the media in every </w:t></w:r><w:r w:rsidR="00C221D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>well was</w:t></w:r><w:r w:rsidR="00A75972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> changed.  500nM of OTSSP167 (</w:t></w:r><w:r w:rsidR="00A75972" w:rsidRPr="00A75972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MedChem Express</w:t></w:r><w:r w:rsidR="00A75972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, Cat. No. </w:t></w:r><w:r w:rsidR="00A75972" w:rsidRPr="00A75972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>HY-15512A</w:t></w:r><w:r w:rsidR="00A75972"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) </w:t></w:r><w:r w:rsidR="00A50FB8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>was added to one row of cells, and then 6 3-fold serial dilutions were performed.</w:t></w:r><w:r w:rsidR="00ED6188"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  After 72 hours of growth in the presence of the drug, </w:t></w:r><w:r w:rsidR="004E1622"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cells were trypsinized and counted using a </w:t></w:r><w:r w:rsidR="00D736F9" w:rsidRPr="00D736F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MacsQuant Analyzer 10 (Milltenyi Biotec).  </w:t></w:r><w:r w:rsidR="00742D93"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>The fraction of cells</w:t></w:r><w:r w:rsidR="00AF1B46"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> recovered</w:t></w:r><w:r w:rsidR="00742D93"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> at every</w:t></w:r><w:r w:rsidR="00AF1B46"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> drug</w:t></w:r><w:r w:rsidR="00742D93"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> concentration, relative to a row of untreated cells, was determined.  </w:t></w:r><w:r w:rsidR="004F250D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>GI50</w:t></w:r><w:r w:rsidR="00D100B0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> values were calculated using a four-parameter </w:t></w:r><w:r w:rsidR="00724B3A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>inhibition</w:t></w:r><w:r w:rsidR="00D100B0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> vs. concentration model in Prism</w:t></w:r><w:r w:rsidR="007C1768"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 7 (Graphpad)</w:t></w:r><w:r w:rsidR="00D100B0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00CB0A01"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Sensitivity experiments in Figure 4H </w:t></w:r><w:r w:rsidR="006839BE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and Figure 3-figure supplement 1</w:t></w:r><w:r w:rsidR="00B20971"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> were performed 2-3 times</w:t></w:r><w:r w:rsidR="00B720DA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> each</w:t></w:r><w:r w:rsidR="00B20971"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, while sensitivity experiments in Figure 3</w:t></w:r><w:r w:rsidR="00A71E9A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and Figure 4-figure supplement 1</w:t></w:r><w:r w:rsidR="00B20971"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> were performed once.  </w:t></w:r><w:r w:rsidR="00D100B0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="04C01BBC" w14:textId="77777777" w:rsidR="00CE1A75" w:rsidRDefault="00CE1A75" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="1D841E38" w14:textId="77777777" w:rsidR="00F67238" w:rsidRDefault="00CE1A75" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>GFP dropout screening</w:t></w:r></w:p><w:p w14:paraId="3689832B" w14:textId="1DA519BD" w:rsidR="0024212F" w:rsidRDefault="008B1F1E" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cells were transduced on day 0 with</w:t></w:r><w:r w:rsidR="00DF295F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> sgRNA</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> lentiviral supernatant, which was then replaced with fresh media on day 1.  On day 3, the baseline percentage of GFP+ cells was measured using a </w:t></w:r><w:r w:rsidRPr="00D736F9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MacsQuant Analyzer 10 (Milltenyi Biotec</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>).  Cells were then passaged every 3 or 4 days, according to their growth rate and confluence, and the percentage of GFP+ cells was measured at every split.  Dropout values represent the fold decrease in GFP+ cells at each passage, relative to the GFP+ percentage on day 3.</w:t></w:r><w:r w:rsidR="00B720DA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  In preliminary experiments with A375 and MDA-MB-231, replicate dropout assays were highly reproducible across independent replicates.  For that reason, GFP dropout experiments </w:t></w:r><w:r w:rsidR="00ED6B3E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>in the</w:t></w:r><w:r w:rsidR="00B720DA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 13 tested cell lines were performed once.    </w:t></w:r><w:r w:rsidR="000A63CC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="62E05B50" w14:textId="77777777" w:rsidR="0024212F" w:rsidRDefault="0024212F" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="541BFE2D" w14:textId="77777777" w:rsidR="0024212F" w:rsidRDefault="0024212F" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>DNA staining</w:t></w:r></w:p><w:p w14:paraId="1CF7EF3C" w14:textId="3552B427" w:rsidR="00A75972" w:rsidRDefault="0024212F" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>10,000</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00B92464"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(A375, Cal51) </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">or </w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>20,000</w:t></w:r><w:r w:rsidR="00B92464"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> (MDA-MB-231)</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cells</w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of interest were plated in 250</w:t></w:r><w:r w:rsidR="00BC3932" w:rsidRPr="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μ</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">l of media in a flat-bottomed </w:t></w:r><w:r w:rsidR="00B92464"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>24</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">-well plate and allowed to attach for 24 hours. </w:t></w:r><w:r w:rsidR="00DE7FB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Then the media was replaced, and</w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> OTS</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">167 </w:t></w:r><w:r w:rsidR="00DE7FB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>or Cytochalasin B (</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Cayman Chemical Company, Cat</w:t></w:r><w:r w:rsidR="00DE7FB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>. No. 11328</w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) were added</w:t></w:r><w:r w:rsidR="00DE7FB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> to </w:t></w:r><w:r w:rsidR="006A2E2F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>control</w:t></w:r><w:r w:rsidR="00DE7FB0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> wells</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>. Following a</w:t></w:r><w:r w:rsidR="00785C3C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>n additional</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> 24-hour </w:t></w:r><w:r w:rsidR="006A2E2F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>period of growth</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>,</w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> c</w:t></w:r><w:r w:rsidR="00785C3C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ells were </w:t></w:r><w:r w:rsidR="00AE6C5F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>stained</w:t></w:r><w:r w:rsidR="00785C3C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> with 2.5</w:t></w:r><w:r w:rsidR="00785C3C" w:rsidRPr="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>μ</w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>g/</w:t></w:r><w:r w:rsidR="0033717D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>m</w:t></w:r><w:r w:rsidR="006A2E2F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>l of Hoechst d</w:t></w:r><w:r w:rsidRPr="0024212F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ye (Thermo Fisher, Cat. No. H3569) for 30 minutes and imaged </w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>using appropriate filters.</w:t></w:r><w:r w:rsidR="007E2AF2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  DNA staining experiments were performed twice.  </w:t></w:r><w:r w:rsidR="00BC3932"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="6B2DA755" w14:textId="77777777" w:rsidR="00E1560B" w:rsidRDefault="00E1560B" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="34621B97" w14:textId="77777777" w:rsidR="00E1560B" w:rsidRDefault="00E1560B" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Acknowledgments</w:t></w:r></w:p><w:p w14:paraId="50F6FD92" w14:textId="36F71394" w:rsidR="001E33F4" w:rsidRDefault="00E1560B" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:tab/></w:r><w:r w:rsidR="00430637"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We thank </w:t></w:r><w:r w:rsidR="008611CF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Chris Vakoc and Junw</w:t></w:r><w:r w:rsidR="002F5AE2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ei Shi for providing Cas9 and guide RNA expression plasmids.  We thank Chris Vakoc</w:t></w:r><w:r w:rsidR="00D51213"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, Camila dos </w:t></w:r><w:r w:rsidR="0014532C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Santos, </w:t></w:r><w:r w:rsidR="00E019A2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and</w:t></w:r><w:r w:rsidR="0014532C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="003C1C32"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Ken Chang for providing </w:t></w:r><w:r w:rsidR="002F5AE2"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cell lines.  </w:t></w:r><w:r w:rsidR="00B056B6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We thank Allison Leonard for technical assistance with lentiviral production.  </w:t></w:r><w:r w:rsidR="00042EE8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">We thank </w:t></w:r><w:r w:rsidR="00430637" w:rsidRPr="00430637"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Osama El Demerdash</w:t></w:r><w:r w:rsidR="00430637"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> for assistance designing </w:t></w:r><w:r w:rsidR="00042EE8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">domain-targeted </w:t></w:r><w:r w:rsidR="00430637"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>guide RNAs.</w:t></w:r><w:r w:rsidR="00A217F1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00A217F1" w:rsidRPr="00A217F1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>This work was performed with assistance from CSHL Shared Resources, including the CSHL Flow Cytometry Shared Resource, which are supported by the Cancer Cen</w:t></w:r><w:r w:rsidR="00E84929"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ter Support Grant 5P30CA045508.</w:t></w:r><w:r w:rsidR="00042EE8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Research in the Sheltzer Lab is supported by an NIH Early Independence Award (</w:t></w:r><w:r w:rsidR="00042EE8" w:rsidRPr="00042EE8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>1DP5OD021385</w:t></w:r><w:r w:rsidR="00042EE8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">).     </w:t></w:r><w:r w:rsidR="00430637"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00417741"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="005206EE"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="001E33F4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="6B6AFDB6" w14:textId="1F28B368" w:rsidR="00FB7A45" w:rsidRDefault="00FB7A45"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br w:type="page"/></w:r></w:p><w:p w14:paraId="77775C78" w14:textId="39235092" w:rsidR="001A540E" w:rsidRPr="00ED295E" w:rsidRDefault="00FB7A45" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00ED295E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>References</w:t></w:r></w:p><w:p w14:paraId="4A245ED8" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="001A540E" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00ED295E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_BIBL {"custom":[]} CSL_BIBLIOGRAPHY </w:instrText></w:r><w:r w:rsidRPr="00ED295E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00D8363A" w:rsidRPr="00D8363A"><w:t xml:space="preserve">1. </w:t></w:r><w:r w:rsidR="00D8363A" w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Sørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. </w:t></w:r><w:r w:rsidR="00D8363A" w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Proc Natl Acad Sci</w:t></w:r><w:r w:rsidR="00D8363A" w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 98(19):10869–10874.</w:t></w:r></w:p><w:p w14:paraId="70575623" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">2. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Badve S, et al. (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Mod Pathol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 24(2):157–167.</w:t></w:r></w:p><w:p w14:paraId="61907C77" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">3. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-Like Breast Cancer: A Critical Review. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Clin Oncol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 26(15):2568–2581.</w:t></w:r></w:p><w:p w14:paraId="7F03D5E4" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">4. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Luo J, Solimini NL, Elledge SJ (2009) Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cell</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 136(5):823–837.</w:t></w:r></w:p><w:p w14:paraId="513184E9" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">5. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Weinstein IB (2002) Addiction to Oncogenes--the Achilles Heal of Cancer. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Science</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 297(5578):63–64.</w:t></w:r></w:p><w:p w14:paraId="73C4CCDC" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">6. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Boettcher M, McManus MT (2015) Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Mol Cell</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 58(4):575–585.</w:t></w:r></w:p><w:p w14:paraId="5FF41B8A" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">7. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Jackson AL, et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nat Biotechnol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 21(6):635–637.</w:t></w:r></w:p><w:p w14:paraId="32D174A5" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">8. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Jackson AL, et al. (2006) Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>RNA</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 12(7):1179–1187.</w:t></w:r></w:p><w:p w14:paraId="2874ACEB" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">9. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Singh S, Narang AS, Mahato RI (2011) Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Pharm Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 28(12):2996–3015.</w:t></w:r></w:p><w:p w14:paraId="1F1A7815" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">10. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Heyer BS, Warsowe J, Solter D, Knowles BB, Ackerman SL (1997) New member of the Snf1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Mol Reprod Dev</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 47(2):148–156.</w:t></w:r></w:p><w:p w14:paraId="557D86C2" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">11. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Jung H, Seong H-A, Ha H (2008) Murine Protein Serine/Threonine Kinase 38 Activates Apoptosis Signal-regulating Kinase 1 via Thr838 Phosphorylation. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Biol Chem</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 283(50):34541–34553.</w:t></w:r></w:p><w:p w14:paraId="4BA7A51B" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">12. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Vulsteke V, et al. (2004) Inhibition of Spliceosome Assembly by the Cell Cycle-regulated Protein Kinase MELK and Involvement of Splicing Factor NIPP1. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Biol Chem</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 279(10):8642–8647.</w:t></w:r></w:p><w:p w14:paraId="7975D479" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">13. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Nakano I, et al. (2005) Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Cell Biol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 170(3):413–427.</w:t></w:r></w:p><w:p w14:paraId="386513BA" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">14. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Gray D, et al. (2005) Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cancer Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 65(21):9751–9761.</w:t></w:r></w:p><w:p w14:paraId="18B2A475" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">15. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Lin M-L, Park J-H, Nishidate T, Nakamura Y, Katagiri T (2007) Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Breast Cancer Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 9:R17.</w:t></w:r></w:p><w:p w14:paraId="185BE6D6" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">16. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Kuner R, et al. (2012) The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Mol Med</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 91(2):237–248.</w:t></w:r></w:p><w:p w14:paraId="18B35A6A" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">17. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Du T, et al. (2014) Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Mol Cancer</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 13:100.</w:t></w:r></w:p><w:p w14:paraId="33A0509A" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">18. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Kig C, et al. (2013) Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Biol Chem</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 288(33):24200–24212.</w:t></w:r></w:p><w:p w14:paraId="2840F159" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">19. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Speers C, et al. (2016) Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Clin Cancer Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t>:clincanres.2711.2015.</w:t></w:r></w:p><w:p w14:paraId="5E77AF28" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">20. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Alachkar H, et al. (2014) Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Oncotarget</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 5(23):12371–12382.</w:t></w:r></w:p><w:p w14:paraId="30878AD7" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">21. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Marie SKN, et al. (2008) Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Int J Cancer</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 122(4):807–815.</w:t></w:r></w:p><w:p w14:paraId="5AE636DE" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">22. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Nakano I, et al. (2008) Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Neurosci Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 86(1):48–60.</w:t></w:r></w:p><w:p w14:paraId="4CD3B78B" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">23. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Hebbard L, et al. (2010) MELK is Upregulated and Required in Mammary Tumor Initiating Cells In Vivo. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cancer Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 70(21):8863–8873.</w:t></w:r></w:p><w:p w14:paraId="7135219D" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">24. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Wang Y, et al. (2014) MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>eLife</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 3:e01763.</w:t></w:r></w:p><w:p w14:paraId="1E57873D" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">25. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Choi S, Ku J-L (2011) Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Biochem Biophys Res Commun</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 412(2):207–213.</w:t></w:r></w:p><w:p w14:paraId="1EEBE4BC" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">26. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Xia H, et al. (2016) MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cancer Lett</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 383(1):85–93.</w:t></w:r></w:p><w:p w14:paraId="5AB2D544" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">27. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Gu C, et al. (2013) Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Stem Cells Dayt Ohio</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 31(5):870–881.</w:t></w:r></w:p><w:p w14:paraId="19AC6ACC" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">28. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Beke L, et al. (2015) MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Biosci Rep</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 35(6). doi:10.1042/BSR20150194.</w:t></w:r></w:p><w:p w14:paraId="0689C677" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">29. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Touré BB, et al. (2016) Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>J Med Chem</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 59(10):4711–4723.</w:t></w:r></w:p><w:p w14:paraId="6E8F791A" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">30. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Johnson CN, et al. (2015) Fragment-Based Discovery of Type I Inhibitors of Maternal Embryonic Leucine Zipper Kinase. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>ACS Med Chem Lett</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 6(1):25–30.</w:t></w:r></w:p><w:p w14:paraId="1125CB4A" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">31. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Johnson CN, et al. (2015) Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>ACS Med Chem Lett</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 6(1):31–36.</w:t></w:r></w:p><w:p w14:paraId="71F49EA3" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">32. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Chung S, et al. (2012) Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Oncotarget</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 3(12):1629–1640.</w:t></w:r></w:p><w:p w14:paraId="5076BB5D" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">33. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Sheltzer JM (2013) A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally-unstable cancer cells and informs clinical prognosis. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cancer Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 73(21):6401–6412.</w:t></w:r></w:p><w:p w14:paraId="75FECB34" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">34. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Ryu B, Kim DS, DeLuca AM, Alani RM (2007) Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>PLoS ONE</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 2(7). doi:10.1371/journal.pone.0000594.</w:t></w:r></w:p><w:p w14:paraId="4AC683B9" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">35. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Brinkman EK, Chen T, Amendola M, van Steensel B (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nucleic Acids Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 42(22):e168–e168.</w:t></w:r></w:p><w:p w14:paraId="3CB83789" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">36. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Shi J, et al. (2015) Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nat Biotechnol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 33(6):661–667.</w:t></w:r></w:p><w:p w14:paraId="023748C2" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">37. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Aguirre AJ, et al. (2016) Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cancer Discov</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t>:CD-16-0154.</w:t></w:r></w:p><w:p w14:paraId="1DEEE09E" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">38. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Campbell J, et al. (2016) Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cell Rep</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 14(10):2490–2501.</w:t></w:r></w:p><w:p w14:paraId="702BD255" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">39. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Hart T, et al. (2015) High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cell</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 163(6):1515–1526.</w:t></w:r></w:p><w:p w14:paraId="5C30FBEA" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">40. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Marcotte R, et al. (2012) Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cancer Discov</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 2(2):172–189.</w:t></w:r></w:p><w:p w14:paraId="5E3D35B8" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">41. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J (2014) Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Mol Syst Biol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 10(7):n/a-n/a.</w:t></w:r></w:p><w:p w14:paraId="6D42BB64" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">42. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Tzelepis K, et al. (2016) A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cell Rep</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 17(4):1193–1205.</w:t></w:r></w:p><w:p w14:paraId="341BEC95" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">43. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Mohr SE, Smith JA, Shamu CE, Neumüller RA, Perrimon N (2014) RNAi screening comes of age: improved techniques and complementary approaches. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nat Rev Mol Cell Biol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 15(9):591–600.</w:t></w:r></w:p><w:p w14:paraId="2E4FD058" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">44. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Silva JM, et al. (2008) Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Science</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 319(5863):617–620.</w:t></w:r></w:p><w:p w14:paraId="46F88CFF" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">45. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Marcotte R, et al. (2016) Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cell</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 164(1–2):293–309.</w:t></w:r></w:p><w:p w14:paraId="4845E1FC" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">46. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Cowley GS, et al. (2014) Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Sci Data</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 1:140035.</w:t></w:r></w:p><w:p w14:paraId="3BFB6819" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">47. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Ji W, et al. (2016) OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>PLOS ONE</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 11(4):e0153518.</w:t></w:r></w:p><w:p w14:paraId="36D561F9" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">48. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Cao L-S, et al. (2013) Structural Basis for the Regulation of Maternal Embryonic Leucine Zipper Kinase. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>PLOS ONE</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 8(7):e70031.</w:t></w:r></w:p><w:p w14:paraId="331C4D99" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">49. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Cho Y-S, Kang Y, Kim K, Cha Y, Cho H-S (2014) The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Biochem Biophys Res Commun</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 447(1):7–11.</w:t></w:r></w:p><w:p w14:paraId="5FD9ACA3" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">50. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ (2012) A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nat Cell Biol</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 14(3):318–328.</w:t></w:r></w:p><w:p w14:paraId="3CC0E30C" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">51. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Hübner NC, et al. (2010) Re-examination of siRNA specificity questions role of PICH and Tao1 in the spindle checkpoint and identifies Mad2 as a sensitive target for small RNAs. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Chromosoma</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 119(2):149–165.</w:t></w:r></w:p><w:p w14:paraId="4ED32A89" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">52. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Sigoillot FD, et al. (2012) A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nat Methods</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 9(4):363–366.</w:t></w:r></w:p><w:p w14:paraId="1613A82F" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">53. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Badouel C, Chartrain I, Blot J, Tassan J-P (2010) Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Exp Cell Res</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 316(13):2166–2173.</w:t></w:r></w:p><w:p w14:paraId="0B27C175" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">54. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Nat Rev Cancer</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 10(2):130–137.</w:t></w:r></w:p><w:p w14:paraId="0F3569B1" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">55. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Gil M, Yang Y, Lee Y, Choi I, Ha H (1997) Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Gene</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 195(2):295–301.</w:t></w:r></w:p><w:p w14:paraId="0F246A05" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">56. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Malumbres M, Barbacid M (2007) Cell cycle kinases in cancer. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Curr Opin Genet Dev</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 17(1):60–65.</w:t></w:r></w:p><w:p w14:paraId="0303F692" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">57. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Shalem O, et al. (2014) Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Science</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 343(6166):84–87.</w:t></w:r></w:p><w:p w14:paraId="4A16EDB8" w14:textId="77777777" w:rsidR="00D8363A" w:rsidRPr="00D8363A" w:rsidRDefault="00D8363A" w:rsidP="00D8363A"><w:pPr><w:pStyle w:val="Bibliography"/></w:pPr><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve">58. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:tab/><w:t xml:space="preserve">Smale ST (2010) Calcium Phosphate Transfection of 3T3 Fibroblasts. </w:t></w:r><w:r w:rsidRPr="00D8363A"><w:rPr><w:i/><w:iCs/></w:rPr><w:t>Cold Spring Harb Protoc</w:t></w:r><w:r w:rsidRPr="00D8363A"><w:t xml:space="preserve"> 2010(2):pdb.prot5372.</w:t></w:r></w:p><w:p w14:paraId="02941C71" w14:textId="2B1CD684" w:rsidR="00F60106" w:rsidRDefault="001A540E" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00ED295E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r></w:p><w:p w14:paraId="531B3F66" w14:textId="77777777" w:rsidR="00F60106" w:rsidRDefault="00F60106"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br w:type="page"/></w:r></w:p><w:p w14:paraId="5273ECE3" w14:textId="55819D73" w:rsidR="001172B3" w:rsidRDefault="001172B3" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure Legend</w:t></w:r></w:p><w:p w14:paraId="15711851" w14:textId="0A2E8070" w:rsidR="00ED7EF6" w:rsidRDefault="001172B3" w:rsidP="00A75972"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00ED7EF6"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Figure 1. </w:t></w:r><w:r w:rsidR="006B406B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Mutation of the MELK kinase domain does not affect cancer cell proliferation or anchorage-independent growth</w:t></w:r></w:p><w:p w14:paraId="17DF4041" w14:textId="0B153250" w:rsidR="005519C0" w:rsidRDefault="005D5254" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="005519C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(A) Domain structure of MELK and locations of the </w:t></w:r><w:r w:rsidR="00400729"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>sequences</w:t></w:r><w:r w:rsidR="005519C0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> targeted by 7 MELK gRNAs.</w:t></w:r></w:p><w:p w14:paraId="20483E23" w14:textId="4333D446" w:rsidR="00012A49" w:rsidRDefault="00012A49" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(B) Genomic DNA was purified from the indicated population of MDA-MB-231 cells and the targeted loci were amplified by PCR.  </w:t></w:r><w:r w:rsidR="00AA0BF4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Percent</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> indel formation was estimated using TIDE analysis.  The highlighted region indicates 20 nucleotides or 15 nucleotides of the sequence recognized by the guide RNA.</w:t></w:r><w:r w:rsidR="008D70D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Other sequenc</w:t></w:r><w:r w:rsidR="005308AD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">e traces are presented in </w:t></w:r><w:r w:rsidR="00070F4B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 1-figure supplements 1-</w:t></w:r><w:r w:rsidR="005308AD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>3</w:t></w:r><w:r w:rsidR="008D70D1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">    </w:t></w:r></w:p><w:p w14:paraId="6D685284" w14:textId="6967F346" w:rsidR="001865BD" w:rsidRDefault="001865BD" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(C</w:t></w:r><w:r w:rsidR="004010E0"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Western blot analysis of </w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">GFP+ </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MDA-MB-231 </w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cells using the Abcam</w:t></w:r><w:r w:rsidR="00BC208D" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t> </w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ab108529 MELK antibody</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Alpha-tubulin </w:t></w:r><w:r w:rsidR="00D8363A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>levels were analyzed</w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> as a loading control.</w:t></w:r></w:p><w:p w14:paraId="4718043D" w14:textId="426E354B" w:rsidR="00044111" w:rsidRDefault="001865BD" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(D</w:t></w:r><w:r w:rsidR="00C0607C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-F</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) </w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Proliferation </w:t></w:r><w:r w:rsidR="00044111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and doubling time analysis of </w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>A375</w:t></w:r><w:r w:rsidR="00044111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, Cal51, and MDA-MB-231</w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell lines transduced with </w:t></w:r><w:r w:rsidR="00044111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">3 </w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Rosa26 gRNAs </w:t></w:r><w:r w:rsidR="00044111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>or</w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> with </w:t></w:r><w:r w:rsidR="00044111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">7 </w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK</w:t></w:r><w:r w:rsidR="00044111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> gRNAs</w:t></w:r><w:r w:rsidR="00D54A4D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r></w:p><w:p w14:paraId="18FF4DD3" w14:textId="145EB990" w:rsidR="00C0607C" w:rsidRDefault="00C0607C" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(G) </w:t></w:r><w:r w:rsidR="00E83CAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Images of colonies </w:t></w:r><w:r w:rsidR="005D5254"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">from the indicated Cal51 strains </w:t></w:r><w:r w:rsidR="00E83CAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>grown in soft agar</w:t></w:r><w:r w:rsidR="005D5254"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="00E83CAA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="6142AE27" w14:textId="73CCB34D" w:rsidR="00AA20BF" w:rsidRDefault="00E83CAA" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(H</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-I</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) Quantification of anchorage-independent growth in Cal51</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> or A375</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cel</w:t></w:r><w:r w:rsidR="00481CAB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ls transduced with the indicated</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> gRNA.</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00BF7C30"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">For each assay, colonies were counted in at least 15 fields under a 10x objective.  </w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Boxes represent the 25</w:t></w:r><w:r w:rsidR="00AA20BF" w:rsidRPr="00146807"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>th</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, 50</w:t></w:r><w:r w:rsidR="00AA20BF" w:rsidRPr="00146807"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>th</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, and 75</w:t></w:r><w:r w:rsidR="00AA20BF" w:rsidRPr="00146807"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>th</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> percentiles of colonies per field, while the whiskers represent the 10</w:t></w:r><w:r w:rsidR="00AA20BF" w:rsidRPr="00146807"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>th</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and 90</w:t></w:r><w:r w:rsidR="00AA20BF" w:rsidRPr="00146807"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/><w:vertAlign w:val="superscript"/></w:rPr><w:t>th</w:t></w:r><w:r w:rsidR="00AA20BF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> percentiles.  </w:t></w:r></w:p><w:p w14:paraId="10962E21" w14:textId="7F677777" w:rsidR="00486111" w:rsidRPr="00044111" w:rsidRDefault="00D54A4D" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="40372E89" w14:textId="23ACE64A" w:rsidR="005C7F45" w:rsidRDefault="00876ECE" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 2</w:t></w:r><w:r w:rsidR="00486111"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r><w:r w:rsidR="008D1022"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Guide RNAs targeting MELK fail to </w:t></w:r><w:r w:rsidR="00A84E78"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>drop out</w:t></w:r><w:r w:rsidR="008D1022"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in triple-n</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>egative breast cancer cell line competition experiments</w:t></w:r><w:r w:rsidR="00A84E78"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r></w:p><w:p w14:paraId="2FFEAC1F" w14:textId="29214CFB" w:rsidR="00F3493B" w:rsidRDefault="005C7F45" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(A) </w:t></w:r><w:r w:rsidR="008A293E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>The fold change in the percentage of GFP+ cells, relative to the percentage of GFP+ cel</w:t></w:r><w:r w:rsidR="00C91092"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">ls at passage 1, is displayed </w:t></w:r><w:r w:rsidR="006F23C8"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>for 7 triple-negative breast cancer cell lines.</w:t></w:r><w:r w:rsidR="00C91092"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="28E41F6B" w14:textId="0E6A8A70" w:rsidR="001B618D" w:rsidRDefault="00F3493B" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(B) </w:t></w:r><w:r w:rsidR="00AD07CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>A table summarizing the results present</w:t></w:r><w:r w:rsidR="00E140E5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ed</w:t></w:r><w:r w:rsidR="00AD07CD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in (A) is displayed.</w:t></w:r></w:p><w:p w14:paraId="529609D6" w14:textId="77777777" w:rsidR="001B618D" w:rsidRDefault="001B618D" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="408500F6" w14:textId="1DAA99D9" w:rsidR="00F6257B" w:rsidRDefault="005B2232" w:rsidP="00F6257B"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 3</w:t></w:r><w:r w:rsidR="00F6257B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. Mutating MELK does not affect OTS167 sensitivity. </w:t></w:r></w:p><w:p w14:paraId="76D76A98" w14:textId="36A926FB" w:rsidR="00010A15" w:rsidRDefault="00010A15" w:rsidP="00F6257B"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(A) Summary of GI50 values from OTS167 treatment of A375 cells harboring guide RNAs targeting Rosa26 or MELK.</w:t></w:r></w:p><w:p w14:paraId="34FF0680" w14:textId="516CAAF0" w:rsidR="00010A15" w:rsidRDefault="00010A15" w:rsidP="00F6257B"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(B) </w:t></w:r><w:r w:rsidR="008276AD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>7 point dose-response curves of OTS167 in the indicated A375 cell lines.</w:t></w:r></w:p><w:p w14:paraId="24AF3141" w14:textId="583DAEED" w:rsidR="008276AD" w:rsidRDefault="008276AD" w:rsidP="00F6257B"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(C) Summary of GI50 values from OTS167 treatment of Cal51 cells harboring guide RNAs targeting Rosa26 or MELK.</w:t></w:r></w:p><w:p w14:paraId="3260EBEB" w14:textId="75FDE24B" w:rsidR="008276AD" w:rsidRDefault="008276AD" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(D) 7 point dose-response curves of OTS167 in the indicated Cal51 cell lines.</w:t></w:r></w:p><w:p w14:paraId="612CBE4F" w14:textId="0DE33E0B" w:rsidR="00A370CC" w:rsidRDefault="00A370CC" w:rsidP="00A370CC"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(E) Summary of GI50 values from OTS167 treatment of MDA-MB-231 cells harboring guide RNAs targeting Rosa26 or MELK.</w:t></w:r></w:p><w:p w14:paraId="0C8DB7AA" w14:textId="7C5226F9" w:rsidR="00A370CC" w:rsidRDefault="00A370CC" w:rsidP="00A370CC"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(F) 7 point dose-response curves of OTS167 in the indicated </w:t></w:r><w:r w:rsidR="00FD29C9"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MDA-MB-231</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> cell lines.</w:t></w:r></w:p><w:p w14:paraId="6289F299" w14:textId="77777777" w:rsidR="00A370CC" w:rsidRDefault="00A370CC" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="44CAA3D2" w14:textId="01122D98" w:rsidR="001565FA" w:rsidRDefault="001565FA" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Figure 4. MELK-knockout cell lines proliferate at normal rates and remain sensitive to OTS167.  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br/><w:t xml:space="preserve">(A) Schematic of </w:t></w:r><w:r w:rsidR="0073507A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>exons in the</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00A03DF4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MDA-MB-231 </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK-KO g1/g6 knockout line.  Half-arrows indicate positions of either cut-site or deletion-spanning primers used to screen </w:t></w:r><w:r w:rsidR="00890A41"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">these </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>colonies.</w:t></w:r><w:r w:rsidR="00890A41"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Primer sequences are presented in </w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 2</w:t></w:r><w:r w:rsidR="00890A41"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r></w:p><w:p w14:paraId="647CE3D1" w14:textId="714C8AD8" w:rsidR="00C53382" w:rsidRDefault="001565FA" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(B) </w:t></w:r><w:r w:rsidR="00C53382"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">PCR validation of 3 independent MELK-KO clones.  Note that amplification of the MELK-KO g3/g5 DNA with deletion-spanning primers yielded deletion products of </w:t></w:r><w:r w:rsidR="00DA6B2D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">at least </w:t></w:r><w:r w:rsidR="00C53382"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>two distinct sizes.</w:t></w:r></w:p><w:p w14:paraId="2FCAEEC3" w14:textId="0EBE9E00" w:rsidR="006A66B5" w:rsidRDefault="00C53382" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(C) </w:t></w:r><w:r w:rsidR="000976C7"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Sanger sequence validation of 3 independent MELK-KO clones.  </w:t></w:r><w:r w:rsidR="00C7795E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>While MELK-KO g1/g6 and g1/g5 harbor a single homozygous deletion, MELK-KO g3/g5 h</w:t></w:r><w:r w:rsidR="006A66B5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">arbors </w:t></w:r><w:r w:rsidR="00903D15"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">at least </w:t></w:r><w:r w:rsidR="006A66B5"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>two distinct deletions.</w:t></w:r></w:p><w:p w14:paraId="2C22BEDB" w14:textId="0D1BE42A" w:rsidR="00F17ABF" w:rsidRDefault="006A66B5" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(D) </w:t></w:r><w:r w:rsidR="00F17ABF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Western blot analysis of MELK-KO clones using an antibody that recognizes a region in</w:t></w:r><w:r w:rsidR="00ED1D3E"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> the N-terminal kinase domain (A</w:t></w:r><w:r w:rsidR="00F17ABF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>bcam</w:t></w:r><w:r w:rsidR="00F17ABF" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t> </w:t></w:r><w:r w:rsidR="00F17ABF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ab108529).</w:t></w:r></w:p><w:p w14:paraId="31550F9F" w14:textId="77777777" w:rsidR="008F21FA" w:rsidRDefault="00F17ABF" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(E) Western blot analysis of MELK-KO clones using an antibody that recognizes a region in the C-terminal domain (Cell Signal</w:t></w:r><w:r w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t> 2274S)</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r></w:p><w:p w14:paraId="022BC8C1" w14:textId="77777777" w:rsidR="00A03DF4" w:rsidRDefault="008F21FA" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(F) </w:t></w:r><w:r w:rsidR="00A03DF4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Proliferation analysis and doubling time measurements of MELK-KO cell lines.  </w:t></w:r></w:p><w:p w14:paraId="6F122ECC" w14:textId="77777777" w:rsidR="007C1B86" w:rsidRDefault="00A03DF4" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(G)</w:t></w:r><w:r w:rsidR="003F1B74"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Representative images of Rosa26 gRNA or MELK-KO clones </w:t></w:r><w:r w:rsidR="007C1B86"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">either untreated or treated with 100nM OTS167 and then stained with Hoechst dye.  </w:t></w:r></w:p><w:p w14:paraId="42C5A5D5" w14:textId="77777777" w:rsidR="006F1B0C" w:rsidRDefault="007C1B86" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(H) The indicated cell lines were either left untreated or were treated with the cytokinesis inhibitor </w:t></w:r><w:r w:rsidR="00564BC4" w:rsidRPr="00564BC4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cytochalasin </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>B or with OTS167.</w:t></w:r><w:r w:rsidR="003456A3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  Cells were then stained with Hoechst dye.</w:t></w:r><w:r w:rsidR="00564BC4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  For each experiment, at least 200 cells were counted. </w:t></w:r></w:p><w:p w14:paraId="11F83B22" w14:textId="397EB7CF" w:rsidR="006F1B0C" w:rsidRDefault="006F1B0C" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(I) Summary of GI50 values from OT</w:t></w:r><w:r w:rsidR="00082072"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>S167 treatment of either MDA-MB-</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">231 Rosa26 gRNA or MELK-KO clones. </w:t></w:r></w:p><w:p w14:paraId="76EE8729" w14:textId="22D04A64" w:rsidR="001565FA" w:rsidRPr="001565FA" w:rsidRDefault="006F1B0C" w:rsidP="008276AD"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(J) 7 point dose-response curves of OTS167 in the indicated cell lines.   </w:t></w:r><w:r w:rsidR="007C1B86"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">     </w:t></w:r><w:r w:rsidR="00A03DF4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00F17ABF"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00C53382"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">   </w:t></w:r><w:r w:rsidR="001565FA"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="2C3D236E" w14:textId="77777777" w:rsidR="00F6257B" w:rsidRDefault="00F6257B" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="67783C51" w14:textId="77777777" w:rsidR="00FF4B20" w:rsidRDefault="00FF4B20" w:rsidP="00236B71"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="7788CB75" w14:textId="77777777" w:rsidR="008C6A00" w:rsidRDefault="008C6A00" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="55F22DC8" w14:textId="46D3293F" w:rsidR="008C6A00" w:rsidRDefault="008C6A00"><w:pPr><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:br w:type="page"/></w:r></w:p><w:p w14:paraId="2DE23CB1" w14:textId="1D03E700" w:rsidR="008C6A00" w:rsidRDefault="008C6A00" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplemental Figure Legends</w:t></w:r></w:p><w:p w14:paraId="5B3F0DDE" w14:textId="157E69CB" w:rsidR="008C6A00" w:rsidRDefault="008C6A00" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 1</w:t></w:r><w:r w:rsidR="00C424B1"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-figure supplement 1</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. Mutation of MELK using 7 different guide RNAs in the A375 melanoma cell line. </w:t></w:r></w:p><w:p w14:paraId="12F425A4" w14:textId="7B7B7A50" w:rsidR="0081239A" w:rsidRPr="0081239A" w:rsidRDefault="00AE15EF" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Following sorting of GFP+ populations, genomic DNA was purified from each cell line and the targeted loci were amplified by PCR.</w:t></w:r><w:r w:rsidR="00294E0C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The amplified fragments were sequenced using the forward </w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>and reverse PCR primers (Supplementary File 2</w:t></w:r><w:r w:rsidR="00294E0C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>), and i</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ndel formation was estimated using TIDE analysis.</w:t></w:r><w:r w:rsidR="00294E0C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The highlighted region indicates 20 nucleotides or 15 nucleotides of the sequence recognized by the guide RNA.  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="39C1AD50" w14:textId="77777777" w:rsidR="008C6A00" w:rsidRDefault="008C6A00" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="5FED40BE" w14:textId="61345DE9" w:rsidR="008C6A00" w:rsidRDefault="00C424B1" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 1-figure supplement 2</w:t></w:r><w:r w:rsidR="008C6A00"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. Mutation of MELK using 7 different guide RNAs in the Cal51 triple-negative breast cancer cell line. </w:t></w:r></w:p><w:p w14:paraId="3F93B19D" w14:textId="5B573BB6" w:rsidR="006104A0" w:rsidRPr="0081239A" w:rsidRDefault="006104A0" w:rsidP="006104A0"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Following sorting of GFP+ populations, genomic DNA was purified from each cell line and the targeted loci were amplified by PCR.  The amplified fragments were sequenced using the forward and reverse PCR primers (</w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 2</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>), and indel formation was estimated using TIDE analysis.  The highlighted region indicates 20 nucleotides or 15 nucleotides of the sequence recognized by the guide RNA.</w:t></w:r><w:r w:rsidR="00C46AA4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The heterogeneity in sequence reads </w:t></w:r><w:r w:rsidR="00BB3744"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">at MELK g1 and MELK g3 </w:t></w:r><w:r w:rsidR="00C46AA4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>in the Rosa</w:t></w:r><w:r w:rsidR="00382A77"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>26</w:t></w:r><w:r w:rsidR="00C46AA4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> gRNA line</w:t></w:r><w:r w:rsidR="00BB3744"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00F4767A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>was</w:t></w:r><w:r w:rsidR="00BB3744"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> observed in multiple samples, and likely represent polymorphisms present in the Cal51 population.  </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">    </w:t></w:r></w:p><w:p w14:paraId="2E5A5771" w14:textId="77777777" w:rsidR="008C6A00" w:rsidRDefault="008C6A00" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="72BF9AE8" w14:textId="1D1FB02B" w:rsidR="005C2ED4" w:rsidRDefault="00C424B1" w:rsidP="005C2ED4"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 1-figure supplement 3</w:t></w:r><w:r w:rsidR="005C2ED4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. Mutation of MELK using 7 different guide RNAs in the MDA-MB-231 triple-negative breast cancer cell line. </w:t></w:r></w:p><w:p w14:paraId="2011BA64" w14:textId="12EF01B6" w:rsidR="006104A0" w:rsidRDefault="006104A0" w:rsidP="006104A0"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Following sorting of GFP+ populations, genomic DNA was purified from each cell line and the targeted loci were amplified by PCR.  The amplified fragments were sequenced using the forward a</w:t></w:r><w:r w:rsidR="00A65930"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>nd reverse PCR primers (</w:t></w:r><w:r w:rsidR="00C16C2B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 2</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">), and indel formation was estimated using TIDE analysis.  The highlighted region indicates 20 nucleotides or 15 nucleotides of the sequence recognized by the guide RNA.    </w:t></w:r></w:p><w:p w14:paraId="5291D58A" w14:textId="15E866B6" w:rsidR="00BA7262" w:rsidRDefault="00BA7262" w:rsidP="00BA7262"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 1-figure supplement 4. Western blot analysis of MELK-disrupted cell populations.</w:t></w:r><w:r w:rsidR="00774641"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="00774641"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Following sorting of GFP+ populations, </w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>whole-cell lysate was collected and analyzed for MELK expression using the Abcam</w:t></w:r><w:r w:rsidR="00BC208D" w:rsidRPr="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> ab108529</w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> antibody.  Alpha-tubulin was </w:t></w:r><w:r w:rsidR="00175DFD"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>analyzed</w:t></w:r><w:r w:rsidR="00BC208D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> as a loading control. </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="051E340D" w14:textId="77777777" w:rsidR="005C2ED4" w:rsidRDefault="005C2ED4" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="461562DD" w14:textId="0D565B57" w:rsidR="008804BC" w:rsidRDefault="00C424B1" w:rsidP="008804BC"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 2-figure supplement 1</w:t></w:r><w:r w:rsidR="008804BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  Guide RNAs targeting MELK fail to drop out in several cancer cell lines.  </w:t></w:r></w:p><w:p w14:paraId="3D7E804B" w14:textId="1E2E9DD2" w:rsidR="008804BC" w:rsidRDefault="008804BC" w:rsidP="008804BC"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(A) The fold change in the percentage of GFP+ cells, relative to the percentage of GFP+ cells </w:t></w:r><w:r w:rsidR="0046400C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>at passage 1, is displayed for 6</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> additional cancer cell lines.</w:t></w:r></w:p><w:p w14:paraId="390C8614" w14:textId="1A7BC051" w:rsidR="008804BC" w:rsidRDefault="008804BC" w:rsidP="008804BC"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(B) A table summarizing the results present</w:t></w:r><w:r w:rsidR="004D47ED"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ed</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> in (A) is displayed.</w:t></w:r></w:p><w:p w14:paraId="3598E852" w14:textId="77777777" w:rsidR="008804BC" w:rsidRDefault="008804BC" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="5D1A4948" w14:textId="46F6AFD5" w:rsidR="008C6A00" w:rsidRDefault="00C424B1" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 2-figure supplement 2</w:t></w:r><w:r w:rsidR="008C6A00"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.  Unbiased screens do not identify MELK as a cancer dependency.</w:t></w:r></w:p><w:p w14:paraId="547A4910" w14:textId="5AEBE747" w:rsidR="008C6A00" w:rsidRDefault="008C6A00" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Gene essentiality data were examined from a kinome-wide siRNA screen </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"1vuvp9j4ba","properties":{"formattedCitation":"(38)","plainCitation":"(38)"},"citationItems":[{"id":278,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/7HS8TASR"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/7HS8TASR"],"itemData":{"id":278,"type":"article-journal","title":"Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines","container-title":"Cell Reports","page":"2490-2501","volume":"14","issue":"10","source":"ScienceDirect","abstract":"Summary\nOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase genetic dependencies in 117 cancer cell lines from ten cancer types. By integrating the siRNA screen data with molecular profiling data, including exome sequencing data, we show how vulnerabilities/genetic dependencies that are associated with mutations in specific cancer driver genes can be identified. By integrating additional data sets into this analysis, including protein-protein interaction data, we also demonstrate that the genetic dependencies associated with many cancer driver genes form dense connections on functional interaction networks. We demonstrate the utility of this resource by using it to predict the drug sensitivity of genetically or histologically defined subsets of tumor cell lines, including an increased sensitivity of osteosarcoma cell lines to FGFR inhibitors and SMAD4 mutant tumor cells to mitotic inhibitors.","DOI":"10.1016/j.celrep.2016.02.023","ISSN":"2211-1247","journalAbbreviation":"Cell Reports","author":[{"family":"Campbell","given":"James"},{"family":"Ryan","given":"Colm J."},{"family":"Brough","given":"Rachel"},{"family":"Bajrami","given":"Ilirjana"},{"family":"Pemberton","given":"Helen N."},{"family":"Chong","given":"Irene Y."},{"family":"Costa-Cabral","given":"Sara"},{"family":"Frankum","given":"Jessica"},{"family":"Gulati","given":"Aditi"},{"family":"Holme","given":"Harriet"},{"family":"Miller","given":"Rowan"},{"family":"Postel-Vinay","given":"Sophie"},{"family":"Rafiq","given":"Rumana"},{"family":"Wei","given":"Wenbin"},{"family":"Williamson","given":"Chris T."},{"family":"Quigley","given":"David A."},{"family":"Tym","given":"Joe"},{"family":"Al-Lazikani","given":"Bissan"},{"family":"Fenton","given":"Timothy"},{"family":"Natrajan","given":"Rachael"},{"family":"Strauss","given":"Sandra J."},{"family":"Ashworth","given":"Alan"},{"family":"Lord","given":"Christopher J."}],"issued":{"date-parts":[["2016",3,15]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(38)</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, a genome-wide shRNA screen </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"67cct2dbo","properties":{"formattedCitation":"(40, 41)","plainCitation":"(40, 41)"},"citationItems":[{"id":285,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/WA5ZFQQP"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/WA5ZFQQP"],"itemData":{"id":285,"type":"article-journal","title":"Measuring error rates in genomic perturbation screens: gold standards for human functional genomics","container-title":"Molecular Systems Biology","page":"n/a-n/a","volume":"10","issue":"7","source":"Wiley Online Library","abstract":"Technological advancement has opened the door to systematic genetics in mammalian cells. Genome-scale loss-of-function screens can assay fitness defects induced by partial gene knockdown, using RNA interference, or complete gene knockout, using new CRISPR techniques. These screens can reveal the basic blueprint required for cellular proliferation. Moreover, comparing healthy to cancerous tissue can uncover genes that are essential only in the tumor; these genes are targets for the development of specific anticancer therapies. Unfortunately, progress in this field has been hampered by off-target effects of perturbation reagents and poorly quantified error rates in large-scale screens. To improve the quality of information derived from these screens, and to provide a framework for understanding the capabilities and limitations of CRISPR technology, we derive gold-standard reference sets of essential and nonessential genes, and provide a Bayesian classifier of gene essentiality that outperforms current methods on both RNAi and CRISPR screens. Our results indicate that CRISPR technology is more sensitive than RNAi and that both techniques have nontrivial false discovery rates that can be mitigated by rigorous analytical methods.","DOI":"10.15252/msb.20145216","ISSN":"1744-4292","shortTitle":"Measuring error rates in genomic perturbation screens","journalAbbreviation":"Mol Syst Biol","language":"en","author":[{"family":"Hart","given":"Traver"},{"family":"Brown","given":"Kevin R"},{"family":"Sircoulomb","given":"Fabrice"},{"family":"Rottapel","given":"Robert"},{"family":"Moffat","given":"Jason"}],"issued":{"date-parts":[["2014",7,1]]}}},{"id":288,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/VDW47NXE"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/VDW47NXE"],"itemData":{"id":288,"type":"article-journal","title":"Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells","container-title":"Cancer Discovery","page":"172-189","volume":"2","issue":"2","source":"cancerdiscovery.aacrjournals.org","abstract":"Genomic analyses are yielding a host of new information on the multiple genetic abnormalities associated with specific types of cancer. A comprehensive description of cancer-associated genetic abnormalities can improve our ability to classify tumors into clinically relevant subgroups and, on occasion, identify mutant genes that drive the cancer phenotype (“drivers”). More often, though, the functional significance of cancer-associated mutations is difficult to discern. Genome-wide pooled short hairpin RNA (shRNA) screens enable global identification of the genes essential for cancer cell survival and proliferation, providing a “functional genomic” map of human cancer to complement genomic studies. Using a lentiviral shRNA library targeting </w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Bradley Hand Bold" w:hAnsi="Bradley Hand Bold" w:cs="Bradley Hand Bold"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText>∼</w:instrText></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve">16,000 genes and a newly developed, dynamic scoring approach, we identified essential gene profiles in 72 breast, pancreatic, and ovarian cancer cell lines. Integrating our results with current and future genomic data should facilitate the systematic identification of drivers, unanticipated synthetic lethal relationships, and functional vulnerabilities of these tumor types.\nSignificance: This study presents a resource of genome-scale, pooled shRNA screens for 72 breast, pancreatic, and ovarian cancer cell lines that will serve as a functional complement to genomics data, facilitate construction of essential gene profiles, help uncover synthetic lethal relationships, and identify uncharacterized genetic vulnerabilities in these tumor types. Cancer Discovery; 2(2); 172–89. © 2011 AACR.\nThis article is highlighted in the In This Issue feature, p. 95.","DOI":"10.1158/2159-8290.CD-11-0224","ISSN":"2159-8274, 2159-8290","note":"PMID: 22585861","journalAbbreviation":"Cancer Discov","language":"en","author":[{"family":"Marcotte","given":"Richard"},{"family":"Brown","given":"Kevin R."},{"family":"Suarez","given":"Fernando"},{"family":"Sayad","given":"Azin"},{"family":"Karamboulas","given":"Konstantina"},{"family":"Krzyzanowski","given":"Paul M."},{"family":"Sircoulomb","given":"Fabrice"},{"family":"Medrano","given":"Mauricio"},{"family":"Fedyshyn","given":"Yaroslav"},{"family":"Koh","given":"Judice L. Y."},{"family":"Dyk","given":"Dewald","dropping-particle":"van"},{"family":"Fedyshyn","given":"Bohdana"},{"family":"Luhova","given":"Marianna"},{"family":"Brito","given":"Glauber C."},{"family":"Vizeacoumar","given":"Franco J."},{"family":"Vizeacoumar","given":"Frederick S."},{"family":"Datti","given":"Alessandro"},{"family":"Kasimer","given":"Dahlia"},{"family":"Buzina","given":"Alla"},{"family":"Mero","given":"Patricia"},{"family":"Misquitta","given":"Christine"},{"family":"Normand","given":"Josee"},{"family":"Haider","given":"Maliha"},{"family":"Ketela","given":"Troy"},{"family":"Wrana","given":"Jeffrey L."},{"family":"Rottapel","given":"Robert"},{"family":"Neel","given":"Benjamin G."},{"family":"Moffat","given":"Jason"}],"issued":{"date-parts":[["2012",2,1]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(40, 41)</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r w:rsidR="00755647"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">, and two genome-wide CRISPR screens </w:t></w:r><w:r w:rsidR="00755647"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="begin"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:instrText xml:space="preserve"> ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"299jhsbuv1","properties":{"formattedCitation":"(39, 42)","plainCitation":"(39, 42)"},"citationItems":[{"id":281,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/278T2M9U"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/278T2M9U"],"itemData":{"id":281,"type":"article-journal","title":"High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities","container-title":"Cell","page":"1515-1526","volume":"163","issue":"6","source":"www.cell.com","abstract":"The ability to perturb genes in human cells is crucial for elucidating gene function and holds great potential for finding therapeutic targets for diseases such as cancer. To extend the catalog of human core and context-dependent fitness genes, we have developed a high-complexity second-generation genome-scale CRISPR-Cas9 gRNA library and applied it to fitness screens in five human cell lines. Using an improved Bayesian analytical approach, we consistently discover 5-fold more fitness genes than were previously observed. We present a list of 1,580 human core fitness genes and describe their general properties. Moreover, we demonstrate that context-dependent fitness genes accurately recapitulate pathway-specific genetic vulnerabilities induced by known oncogenes and reveal cell-type-specific dependencies for specific receptor tyrosine kinases, even in oncogenic KRAS backgrounds. Thus, rigorous identification of human cell line fitness genes using a high-complexity CRISPR-Cas9 library affords a high-resolution view of the genetic vulnerabilities of a cell.","DOI":"10.1016/j.cell.2015.11.015","ISSN":"0092-8674, 1097-4172","note":"PMID: 26627737","journalAbbreviation":"Cell","language":"English","author":[{"family":"Hart","given":"Traver"},{"family":"Chandrashekhar","given":"Megha"},{"family":"Aregger","given":"Michael"},{"family":"Steinhart","given":"Zachary"},{"family":"Brown","given":"Kevin R."},{"family":"MacLeod","given":"Graham"},{"family":"Mis","given":"Monika"},{"family":"Zimmermann","given":"Michal"},{"family":"Fradet-Turcotte","given":"Amelie"},{"family":"Sun","given":"Song"},{"family":"Mero","given":"Patricia"},{"family":"Dirks","given":"Peter"},{"family":"Sidhu","given":"Sachdev"},{"family":"Roth","given":"Frederick P."},{"family":"Rissland","given":"Olivia S."},{"family":"Durocher","given":"Daniel"},{"family":"Angers","given":"Stephane"},{"family":"Moffat","given":"Jason"}],"issued":{"date-parts":[["2015",12,3]]}}},{"id":355,"uris":["http://zotero.org/users/local/sk3Vw0aK/items/TXZAS2MW"],"uri":["http://zotero.org/users/local/sk3Vw0aK/items/TXZAS2MW"],"itemData":{"id":355,"type":"article-journal","title":"A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia","container-title":"Cell Reports","page":"1193-1205","volume":"17","issue":"4","source":"www.cell.com","DOI":"10.1016/j.celrep.2016.09.079","ISSN":"2211-1247","journalAbbreviation":"Cell Reports","language":"English","author":[{"family":"Tzelepis","given":"Konstantinos"},{"family":"Koike-Yusa","given":"Hiroko"},{"family":"De Braekeleer","given":"Etienne"},{"family":"Li","given":"Yilong"},{"family":"Metzakopian","given":"Emmanouil"},{"family":"Dovey","given":"Oliver M."},{"family":"Mupo","given":"Annalisa"},{"family":"Grinkevich","given":"Vera"},{"family":"Li","given":"Meng"},{"family":"Mazan","given":"Milena"},{"family":"Gozdecka","given":"Malgorzata"},{"family":"Ohnishi","given":"Shuhei"},{"family":"Cooper","given":"Jonathan"},{"family":"Patel","given":"Miten"},{"family":"McKerrell","given":"Thomas"},{"family":"Chen","given":"Bin"},{"family":"Domingues","given":"Ana Filipa"},{"family":"Gallipoli","given":"Paolo"},{"family":"Teichmann","given":"Sarah"},{"family":"Ponstingl","given":"Hannes"},{"family":"McDermott","given":"Ultan"},{"family":"Saez-Rodriguez","given":"Julio"},{"family":"Huntly","given":"Brian J. P."},{"family":"Iorio","given":"Francesco"},{"family":"Pina","given":"Cristina"},{"family":"Vassiliou","given":"George S."},{"family":"Yusa","given":"Kosuke"}],"issued":{"date-parts":[["2016",10,18]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} </w:instrText></w:r><w:r w:rsidR="00755647"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="separate"/></w:r><w:r w:rsidR="00E7021A"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:noProof/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(39, 42)</w:t></w:r><w:r w:rsidR="00755647"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:fldChar w:fldCharType="end"/></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  In the kinome-wide screen, a gene with a Z score &lt; -2 was considered essential.  In the </w:t></w:r><w:r w:rsidR="00755647"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Hart et al. </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>genome-wide CRISPR screen, a gene with a Bayes Factor &gt; 5 was considered essential.  In the genome-wide shRNA screen</w:t></w:r><w:r w:rsidR="00755647"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and the Tzelepis et al. CRISPR screen</w:t></w:r><w:r w:rsidR="00246836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>, a threshold of P</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> &lt; .01 was </w:t></w:r><w:r w:rsidR="00246836"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>used to identify essential genes.</w:t></w:r></w:p><w:p w14:paraId="58ADA5E6" w14:textId="77777777" w:rsidR="0046400C" w:rsidRDefault="0046400C" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="6FA22C8D" w14:textId="22BD0041" w:rsidR="0046400C" w:rsidRDefault="00C424B1" w:rsidP="0046400C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 3-figure supplement 1</w:t></w:r><w:r w:rsidR="0046400C"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>. Receptor-positive breast cancer cell lines are sensitive to OTS167.</w:t></w:r></w:p><w:p w14:paraId="3B9409A5" w14:textId="77777777" w:rsidR="0046400C" w:rsidRDefault="0046400C" w:rsidP="0046400C"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(A) Summary of GI50 values from OTS167 treatment of various breast cancer cell lines.</w:t></w:r></w:p><w:p w14:paraId="18C24372" w14:textId="64A527BE" w:rsidR="0046400C" w:rsidRDefault="0046400C" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(B and C) 7 point dose-response curves of OTS167 in the indicated cell lines. </w:t></w:r><w:r w:rsidR="004E12FB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Note that the summary values in (A) represent averages from 2 or 3 replicate experiments per cell line, while individual replicate experiments are displayed in (B) and (C).  </w:t></w:r></w:p><w:p w14:paraId="75E56B19" w14:textId="77777777" w:rsidR="008804BC" w:rsidRDefault="008804BC" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="7D4A8867" w14:textId="0D9D6C93" w:rsidR="008804BC" w:rsidRDefault="00604DDE" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 3-figure supplement 2</w:t></w:r><w:r w:rsidR="008804BC"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. OTS167 treatment, but not </w:t></w:r><w:r w:rsidR="006F21B3"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">MELK mutation, causes the accumulation of multinucleate cells. </w:t></w:r></w:p><w:p w14:paraId="28FC720F" w14:textId="079DA070" w:rsidR="00E86FA4" w:rsidRDefault="004D47ED" w:rsidP="008C6A00"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(A - C</w:t></w:r><w:r w:rsidR="00B87E7B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) Cells </w:t></w:r><w:r w:rsidR="00D93EEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">were either </w:t></w:r><w:r w:rsidR="00987F7D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>untreated or treated with the indicated drug</w:t></w:r><w:r w:rsidR="00D93EEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> for 24 hours.</w:t></w:r><w:r w:rsidR="00987F7D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r><w:r w:rsidR="00D93EEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Subsequently, cells </w:t></w:r><w:r w:rsidR="00B87E7B"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>were stained with Hoechst dye</w:t></w:r><w:r w:rsidR="0006110D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> and </w:t></w:r><w:r w:rsidR="00D93EEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">at least 200 </w:t></w:r><w:r w:rsidR="007D1D97"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>cells</w:t></w:r><w:r w:rsidR="00D93EEB"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> for each condition were examined.   </w:t></w:r></w:p><w:p w14:paraId="5FA69037" w14:textId="7CF89AEF" w:rsidR="0034211D" w:rsidRDefault="004D47ED" w:rsidP="00191A94"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(D</w:t></w:r><w:r w:rsidR="00E86FA4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) Representative images of C</w:t></w:r><w:r w:rsidR="00191A94"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>al51 cells stained with Hoechst.</w:t></w:r></w:p><w:p w14:paraId="46F42ECB" w14:textId="77777777" w:rsidR="008E1434" w:rsidRDefault="008E1434" w:rsidP="00191A94"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="353EB081" w14:textId="3B1CDBCC" w:rsidR="008E1434" w:rsidRDefault="008E1434" w:rsidP="00155602"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Figure 4</w:t></w:r><w:r w:rsidR="002C3021"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>-figure supplement 1</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">. </w:t></w:r><w:r w:rsidR="002C3021"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Generation and analysis of Cal51 MELK-KO cell lines.</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r></w:p><w:p w14:paraId="4106060D" w14:textId="3C05C650" w:rsidR="008E1434" w:rsidRDefault="00155602" w:rsidP="008E1434"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(A</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Sanger sequencing</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> of 3 independent </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cal51 </w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>MELK-KO clones</w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> transduced with single gRNAs targeting the MELK kinase domain.</w:t></w:r><w:r w:rsidR="008F6E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  The </w:t></w:r><w:r w:rsidR="00431F47"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>highlighted regions</w:t></w:r><w:r w:rsidR="008F6E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> indicate bases </w:t></w:r><w:r w:rsidR="008B4923"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>recognized</w:t></w:r><w:r w:rsidR="008F6E1D"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> by the gRNA.</w:t></w:r></w:p><w:p w14:paraId="1F22FB9D" w14:textId="65AE354B" w:rsidR="008E1434" w:rsidRDefault="00155602" w:rsidP="008E1434"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(B</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) Western blot analysis of MELK-KO clones using an antibody that recognizes a region in the N-terminal kinase domain (Abcam</w:t></w:r><w:r w:rsidR="008E1434" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t> </w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>ab108529).</w:t></w:r></w:p><w:p w14:paraId="1C1B762D" w14:textId="099AF6B0" w:rsidR="008E1434" w:rsidRDefault="00155602" w:rsidP="008E1434"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(C</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) Western blot analysis of MELK-KO clones using an antibody that recognizes a region in the C-terminal domain (Cell Signal</w:t></w:r><w:r w:rsidR="008E1434" w:rsidRPr="00223756"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t> 2274S)</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">.  </w:t></w:r></w:p><w:p w14:paraId="64916267" w14:textId="3F89B6C7" w:rsidR="008E1434" w:rsidRDefault="00155602" w:rsidP="008E1434"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(D</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) Proliferation analysis and doubling time measurements of MELK-KO cell lines.  </w:t></w:r></w:p><w:p w14:paraId="34375502" w14:textId="0C3603AF" w:rsidR="008E1434" w:rsidRDefault="005E1774" w:rsidP="008E1434"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(E</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">) Summary of GI50 values from OTS167 treatment of either </w:t></w:r><w:r w:rsidR="00571B58"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Cal51 </w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Rosa26 gRNA or MELK-KO clones. </w:t></w:r></w:p><w:p w14:paraId="0F3805ED" w14:textId="77777777" w:rsidR="005E1774" w:rsidRDefault="005E1774" w:rsidP="008E1434"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>(F</w:t></w:r><w:r w:rsidR="008E1434"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>) 7 point dose-response curves of OTS167 in the indicated cell lines.</w:t></w:r></w:p><w:p w14:paraId="2F60AB59" w14:textId="77777777" w:rsidR="005E1774" w:rsidRDefault="005E1774" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(G) Representative images of Rosa26 gRNA or MELK-KO clones either untreated or treated with 100nM OTS167 and then stained with Hoechst dye.  </w:t></w:r></w:p><w:p w14:paraId="2A9A4D13" w14:textId="77777777" w:rsidR="005E1774" w:rsidRDefault="005E1774" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">(H) The indicated cell lines were either left untreated or were treated with the cytokinesis inhibitor </w:t></w:r><w:r w:rsidRPr="00564BC4"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">cytochalasin </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">B or with OTS167.  Cells were then stained with Hoechst dye.  For each experiment, at least 200 cells were counted. </w:t></w:r></w:p><w:p w14:paraId="01328DE0" w14:textId="77777777" w:rsidR="009F5AB1" w:rsidRDefault="009F5AB1" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="01EF620D" w14:textId="77777777" w:rsidR="008D0B4F" w:rsidRDefault="009F5AB1" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="008D0B4F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>Supplementary File 1.</w:t></w:r><w:r w:rsidR="008D0B4F" w:rsidRPr="008D0B4F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> Guide RNA sequences</w:t></w:r><w:r w:rsidR="008D0B4F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>.</w:t></w:r></w:p><w:p w14:paraId="0B797311" w14:textId="2C95582E" w:rsidR="009F5AB1" w:rsidRPr="008D0B4F" w:rsidRDefault="008D0B4F" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">The sequences of every guide RNA </w:t></w:r><w:r w:rsidR="00014D07"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">and the protein domain targeted by the guide RNAs are displayed. </w:t></w:r><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">  </w:t></w:r><w:r w:rsidR="009F5AB1" w:rsidRPr="008D0B4F"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="4D3FF87E" w14:textId="77777777" w:rsidR="009F5AB1" w:rsidRDefault="009F5AB1" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr></w:p><w:p w14:paraId="0DC5D171" w14:textId="77777777" w:rsidR="00CB0433" w:rsidRDefault="009F5AB1" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r w:rsidRPr="00CB0433"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">Supplementary File 2. </w:t></w:r><w:r w:rsidR="00CB0433" w:rsidRPr="00CB0433"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t>PCR primers to amplify MELK gRNA cut sites and deletions.</w:t></w:r></w:p><w:p w14:paraId="13591FD9" w14:textId="1C1C5860" w:rsidR="009F5AB1" w:rsidRPr="00CB0433" w:rsidRDefault="00D07BE4" w:rsidP="005E1774"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">The sequences of PCR primers used in this manuscript are displayed.  </w:t></w:r><w:r w:rsidR="009F5AB1" w:rsidRPr="00CB0433"><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve"> </w:t></w:r></w:p><w:p w14:paraId="1E9C4EAB" w14:textId="5539B45B" w:rsidR="0034211D" w:rsidRPr="00B448D6" w:rsidRDefault="008E1434" w:rsidP="00191A94"><w:pPr><w:pStyle w:val="NoSpacing"/><w:spacing w:line="480" w:lineRule="auto"/><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:b/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr></w:pPr><w:r><w:rPr><w:rFonts w:ascii="Arial" w:hAnsi="Arial" w:cs="Arial"/><w:bCs/><w:sz w:val="22"/><w:szCs w:val="22"/></w:rPr><w:t xml:space="preserve">               </w:t></w:r></w:p><w:sectPr w:rsidR="0034211D" w:rsidRPr="00B448D6" w:rsidSect="00191A94"><w:footerReference w:type="even" r:id="rId7"/><w:footerReference w:type="default" r:id="rId8"/><w:pgSz w:w="12240" w:h="15840"/><w:pgMar w:top="1440" w:right="1440" w:bottom="1440" w:left="1440" w:header="720" w:footer="720" w:gutter="0"/><w:cols w:space="720"/><w:docGrid w:linePitch="360"/></w:sectPr></w:body></w:document>